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Abstract 
This PhD project developed the femoral 3-in-1 nerve block to provide safe, 
effective regional analgesia to the 60,000 patients admitted annually to UK 
hospitals with a fractured neck of femur. The hospital mortality for patients 
with a fractured hip in a large UK study was 14.3% with cardiac aetiologies 
predominating in the first 2 days (Bottle & Aylin 2006).  In contrast to the 
marked improvements in mortality for elective surgery, the overall mortality 
from emergency surgery and in particular surgery for fractured neck of femur 
patients has remained unchanged (Roberts & Goldacre 2003).  Development of 
the femoral 3-in-1 nerve block for fractured neck of femur patients will provide 
analgesia but may also improve outcome.  A relationship between effective pain 
analgesia and improved cardiac morbidity and reduced mortality in patients with 
a fractured neck of femur was demonstrated by Matot et al using epidural 
analgesia in 2001 but this is not the current clinical standard in the UK (Matot et 
al. 2003).  The femoral 3-in-1 nerve block (also called the fascia iliacus block or 
anterior psoas compartment block) offered a viable solution to provide analgesia 
to patients with a fractured neck of femur prior to surgical fixation.  The 
femoral 3-in-1 nerve block is technically undemanding and requires a minimum 
of extra training and resources.  In contrast to epidural analgesia which requires 
extensive training of practitioners and continuous cardio-respiratory monitoring 
of patients and an increased level of nursing care, ultrasound guided nerve 
blocks have been associated with an increased success rate, need less local 
anaesthetic and have shorter onset times than traditional techniques (Marhofer 
et al. 1997;Marhofer et al. 1998).  Ultrasound guidance may increase the nerve 
block success rate and lower complication rates but it is associated with the 
extra cost of the ultrasound machine, disposables and staff training.  In contrast, 
needle guidance using loss of resistance for a femoral 3-in-1 block is technically 
simple and cheap but is potentially inaccurate and, as a result, may be less 
effective.  Anaesthetists currently utilise the femoral 3-in-1 nerve block to 
provide effective pain after surgical fixation of the femur but these techniques 
use large doses of local anaesthetic.  Further information on dosing based on 
efficacy and duration of action will allow a reduction in dose and hence an 
improvement in safety of the femoral 3-in-1 nerve block. 
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The information needed to develop the femoral 3-in-1 nerve block to provide 
analgesia for patients with a fractured neck of femur was provided by 
undertaking one prospective observer-blinded muticentre randomised controlled 
study, a clinical trial of an investigational medicinal product and a cadaveric 
dissection study.  A multicentre randomised controlled study compared the 
efficacy of using ultrasound, nerve stimulator and loss of resistance techniques 
to guide the needle for a femoral 3-in-1 nerve block in elective primary total hip 
arthroplasty patients.  This initial study recruited patients scheduled for a 
similar operation to fracture neck of femur patients (elective primary total hip 
arthroplasty) as it was impossible to recruit and assess a large number (>100) 
elderly, frail emergency patients.  The use of the nerve stimulator is the current 
gold standard for elective femoral 3-in-1 nerve blocks but if used on patients 
with a fractured neck of femur it will cause unnecessary discomfort in a limb 
with an unfixed fracture.  In order to determine the comparative efficacy of 
ultrasound, nerve stimulator and loss of resistance techniques, we performed 
femoral 3-in-1 nerve blocks on 180 patients scheduled for elective primary total 
hip arthroplasty.  The efficacy of these three techniques was measured by 
assessing femoral nerve sensory and motor response at 30 minutes after the 
femoral 3-in-1 nerve block.  The use of ultrasound and nerve stimulator (US+NS) 
for the femoral 3-in-1 femoral nerve block for elective total hip replacement 
was statistically significantly more effective than loss of resistance (LOR-59.5%, 
US+NS-80.3%, p=0.0159 (p≤0.025)) with a number needed to treat of 5.  There 
was no statistically significant difference in the effectiveness of using the nerve 
stimulator(NS) and ultrasound(US) to guide the insertion of a femoral 3-in-1 
nerve block (NS-77.5, US-83.1%, p=0.527 (p≤0.025).  Since the use of nerve 
stimulator would result in significant unnecessary discomfort in patients with an 
unfixed fracture it was concluded that ultrasound was the optimal technique to 
guide femoral 3-in-1 nerve blocks for analgesia in patients with a fractured neck 
of femur. 
 
The dosing and safety of the femoral 3-in-1 nerve block was determined in 
patients with a fractured neck of femur.  Levobupivacaine dosing was estimated 
by a Dixon’s up/down sequential methodology.  Femoral 3-in-1 nerve blocks 
were performed and the concentration of levobupivacaine was increased or 
decreased (using a fixed volume) for an ineffective or effective nerve block 
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respectively, as a result the concentration tended towards the EC50 (effective 
concentration in 50% of patients).  The EC50 and the EC95 (effective 
concentration in 95% of patients) for 30 ml of levobupivacaine was estimated 
using a binary probit regression model; in which the probability of an effective 
nerve block was modelled against the concentration of levobupivacaine. 
 
The second part of this clinical trial assessed the pharmacokinetics (to ensure 
that serum levels were within the safe range) and pharmacodynamics (to assess 
duration of analgesia).  The estimated EC95 concentration of levobupivacaine for 
the femoral 3-in-1 nerve block was 30mls of 0.036% with 95% confidence interval 
of 0.0332% to 0.0383%.  The EC95 concentration of levobupivacaine gave a mean 
duration of analgesia of 166 minutes with a standard error of the mean of 35 
minutes and peak median plasma level of 52 ng/ml 30 minutes after the femoral 
3-in-1 nerve block.  The measured plasma levobupivacaine concentrations were 
below the threshold (2100ng/ml) associated with toxicity. 
 
The clinical anatomy of the femoral 3-in-1 nerve block was determined by 
dissection.  We investigated the distribution of 30 ml of black 10% latex injected 
lateral to the femoral nerve under the fascia iliacus membrane in two 
unembalmed adult cadavers.  In all four dissections the lateral cutaneous and 
femoral nerves were stained at the inguinal ligament and the latex travelled 
distally in the adductor canal into the popliteal fossa to stain the sciatic nerve 
and its terminal branches. 
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1 The development of a safe and effective method 
of providing analgesia to patients with a broken 
hip 
1.1 Introduction 
This chapter will outline the disease burden represented by patients with a 
fractured neck of femur, discuss the aetiology of the mortality associated with 
this disease and briefly look at the potential for improving the outcome.  The 
clinical evidence for improved outcomes associated with the use of regional 
analgesia in patient groups other than those with a fractured neck of femur will 
also be discussed.  The term fractured neck of femur will be used inclusively 
throughout this thesis to include all types of proximal femoral fracture, 
((extracapsular).subtrochnetric, intratrochentric fractures and intracapsular 
(fractured surgical neck of femur fracture). 
1.1.1 Burden of disease caused by fractured neck of femur 
Fractured neck of femur or proximal femoral fracture is a significant cause of 
morbidity and mortality in the developed world.  Johnell et al calculated that 
hip fracture was associated with 1.75 million disability adjusted life years 
(DALYS) which represented 1.4% of the total disease burden calculated in DALYS 
for women in established market economies in 1990 (Johnell & Kanis 2004).  
Disability adjusted life years (DALYS) are a sum of years lost due to premature 
mortality and disability directly related to hip fracture for the number of years 
that patient survives multiplied by a disability factor between 0 (no disability) to 
1 (death).  The disability weight has been estimated for hip fracture by expert 
panels at 0.272 for each year of illness (Murray & Lopez 1997).  Fractured neck 
of femur represents a greater burden of disease in established market economies 
for women than cirrhosis of the liver (1.1%), stomach cancer (0.9%) or ovarian 
cancer (0.9%) (Johnell & Kanis 2004).  Fractured neck of femur was found to be 
significantly more common in the women, with a male to female ratio of 1 to 
2.71 worldwide with a ratio of 1 to 4 in the established market economies of 
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Western Europe, North America, Japan and Australia (Gullberg, Johnell, & Kanis 
1997).  Gullberg et al estimated that worldwide the total number of hip 
fractures in men and women in 1990 was 338,000 and 917,000 respectively, a 
total of 1.26 million (Gullberg, Johnell, & Kanis 1997).  Gullberg also estimated 
the incidence of hip fractures will double to 2.6 million by the year 2025, and 
4.5 million by the year 2050 with a 95% confidence interval of between 7.3 and 
21.3 million if we assume no change in the age and sex specific incidence. 
1.1.2 Prognosis, historical perspective and operative/ 
non-operative management 
The prognosis for patients with a fractured neck of femur in the UK is poor with 
an overall 1 year mortality of approximately 25% (Heikkinen, Parker, & Jalovaara 
2001) and a hospital mortality of 14.3% for patients admitted from home (Bottle 
& Aylin 2006).  The one year mortality improved significantly since Beals 
reported a 50% 1 year mortality in a surgically managed cohort of patients 
recruited between 1956 and 1961 (Beals 1972).  Subsequently, Roberts et al 
retrospectively analysed the mortality rates for 32590 English patients with a 
fractured neck of femur between 1968 and 1998 (Roberts & Goldacre 2003) and 
concluded that although mortality rates had reduced between 1968 and 1983, no 
significant fall in mortality was observed in the next 15 years. 
 
Holmberg found that while following up 3002 patients with a intracapsular 
femoral neck fracture admitted during a 3-year period in the Stockholm area 
that those admitted from institutional care had a 3 to 4 times higher long-term 
mortality than those admitted from home (Holmberg et al. 1986). After 6 years, 
54% of the patients admitted from home were alive compared with only 16% of 
those admitted from institutions.  Several other studies have concluded that 
prognosis was and is associated with the age, morbidity and preoperative 
functional status of the patient and no single surgical, medical or anaesthetic 
intervention has yet impacted significantly on the overall morality of these 
patients (Bannister et al. 1990;Holmberg et al. 1986;Jensen, Johansen, & Morch 
1977).  This may be due to the multifactorial nature of the patients’ co-
morbidities and the single factorial nature of many clinical trials looking for 
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improved outcomes.  In 2005 Foss et al suggested that only 25%-60% of the 
mortality observed in an unselected population may be susceptible to 
intervention (Foss & Kehlet 2005). 
 
In a review of 50235 fractured neck of femur patients over 7 years in Ontario 
Canada non-operative management of fractured neck of femur was associated 
with significantly higher 30 day mortality (18%) compared to operative 
management (11%) (Jain, Basinski, & Kreder 2003) .  In this study by Jain et al 
89.4% of all patients were treated operatively and the odds ratio for 30 day 
mortality when non-operative management was compared with operative 
management was 1.7, with a 95% confidence interval (CI): 1.6 to 1.8.  Jain et al 
also examined a series of 62 elderly patients within their 5235 patient cohort 
with severe co-morbidity treated non-operatively, 41 had bed rest and traction, 
while 21 were mobilised early.  They found no statistically significant difference 
in mortality between operatively treated patients (29%) and patients treated 
non-operatively with immediate mobilization (19%) but they found that non-
operative treatment and bed rest was 2.5 times more likely to be associated 
with mortality compared to operative treatment with early mobilisation (95% CI: 
1.1 to 5.5) (Jain, Basinski, & Kreder 2003).  These results should be interpreted 
with caution due the possibility of bias from the small cohort of non-operatively 
treated patients analysed but it does suggest that early mobilisation may 
improve outcome even in patients with severe co-morbidity. 
1.1.3 Prognosis and delay in definitive surgical management 
Delayed mobilisation caused by delays in definitive surgical fracture fixation was 
also associated with an increased risk of mortality.  Bottle et al examined a 
retrospective cohort of 129522 patients from 151 Trusts in England and Wales 
between April 2001 and March 2004 and found an independent association 
between delayed operative treatment and an increased risk of death in hospital 
(Bottle & Aylin 2006).  For all deaths in hospital, the odds ratio for more than 
one days delay relative to one day or less was 1.27 (95% CI: 1.23 to 1.32) after 
adjustment for co morbidity.  It is interesting to note that if the death rates in 
patients with at most one days delay had been repeated throughout all 151 
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trusts in this study, there would have been an average of 581 (95% CI: 478 to 
683) fewer deaths per year (9.4% of the total deaths per year).  The association 
between delay in surgical treatment and increased mortality was also shown by 
Moran et al (Moran et al. 2005).  Moran et al conducted a prospective 
observational study examining the mortality rates for 2660 patients in 
Nottingham, UK and concluded that if patients who were fit for surgery were 
delayed more than four days it was associated with a significant increase in 
mortality at 30 days (risk ratio=2.4; p<0.001) and 1 year (risk ratio 2.25; 
p<0.001). 
1.1.4 Prognosis and aetiology for fractured neck of femur 
patients 
The aetiology of this poor prognosis is multifactorial; a review of multiple post 
mortem studies suggested that the principal cause of death was 
bronchopneumonia in 46% of patients, cardiac failure and myocardial infarction 
in 23% of patients and pulmonary embolism in 14% of patients (Perez et al. 
1995).  Mortality from bronchopneumonia and pulmonary embolism were 
significantly reduced but cardiac failure was not altered in those patients who 
had surgical fixation of the fracture within 24 hours (Perez et al. 1995).  Todd et 
al and Jain et al found an association between the use of thromboprophylaxis 
and reduced death from fatal pulmonary embolism (Jain, Basinski, & Kreder 
2003;Todd et al. 1995).  The positive impact of early mobilisation on outcome 
may be as a result of reduced infectious and thromboembolic respiratory 
complications.  Currently, best practice aims to minimise the delay to surgical 
fixation of proximal neck of femur fractures and encourage early mobilisation 
(Scottish Intercollegiate Guidelines Network (SIGN)-Guideline 111). 
1.1.5 Could improved analgesia from regional analgesia and 
anaesthesia result in better outcomes for patients? 
The SIGN guidelines on proximal hip fractures have been widely implemented 
but the outcome for fractured neck of femur patients remains poor (Scottish 
Intercollegiate Guidelines Network (SIGN)-Guideline 111).  The possibility that 
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regional analgesia could improve the poor outcome associated with fracture 
neck of femur may be considered.  The trials which deal with regional 
anaesthesia and analgesia and outcome in patients with a fractured neck of 
femur and these will be discussed in Chapter 2.  The remainder of this chapter 
will deal with the impact on outcome associated with regional anaesthesia and 
analgesia in the general surgery and cardiac patient populations. 
 
The Cochrane review by Nishimori used meta-analysis to assess the risks and 
benefits of postoperative epidural analgesia compared with postoperative 
systemic opioid based pain relief for adult patients scheduled for elective 
abdominal aortic surgery (Nishimori, Ballantyne, & Low 2006). Nishimori et al 
looked at published trial data on OVID MEDLINE between 1966 to July 2004 and 
on EMBASE between 1980 and June 2004.  They found 13 studies which met their 
quality control criteria which had recruited a total of 1224 patients; 597 patients 
received epidural analgesia and 627 received systemic opiate based analgesia.  
The epidural analgesia group showed significantly lower pain visual analogue 
scale (VAS) scores on movement for up to three days postoperatively; on 
postoperative day one, weighted mean difference was -1.78 (95% CI: -2.32 to -
1.25), day two weighted mean difference was -1.63 (95% CI: -2.16 to -1.10), and 
day three weighted mean difference was -1.37 (95% CI: -2.24 to -0.51).  The 
duration of postoperative tracheal intubation and mechanical ventilation was 
also reduced by 48% in patients receiving epidural analgesia Risk ratio (RR)=0.52 
(95% CI: 0.41-0.72), p<0.048).  The statistically significant results of the 
Cochrane review by Nishimori are shown in Table 1-1.  The Cochrane review 
showed that epidural analgesia was associated with a reduction in all 
cardiovascular complications, including acute myocardial infraction.  Epidural 
analgesia was also associated with reduced respiratory, gastrointestinal and 
renal complications in the 2008 Cochrane review. 
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Table 1-1:  Summary of statistically significant results from the 2008 Cochrane review of 
epidural analgesia compared with opiate based analgesia 
 RR (95% CI) NNT (95% CI) 
All Cardiovascular complications 0.74 (0.56-0.97) 14 (7-100) 
Myocardial infarctions 0.52 (0.29-0.93) 25 (14-100) 
Acute respiratory complications 0.63 (0.51-0.79) 9 (6-17) 
Gastrointestinal complications 0.37 (0.15-0.92) 50 (20-∞) 
Renal insufficiency 0.64 (0.46-0.90) 14 (8-50) 
RR-Risk ratio, NNT-number needed to treat, CI-confidence interval 
 
Nishimori did not find any evidence regarding the effect of postoperative 
epidural analgesia on mortality (Peto odds ratio: 0.86, 95% CI: 0.48-1.55). 
In contrast, Yeager et al found an improved mortality in those patients assigned 
to receive epidural analgesia compared with those who received opiate based 
analgesia in a mixed population of high risk patients (Yeager et al. 1987).  
Yeager recorded 16% mortality in the control group which received opiate based 
analgesia postoperatively and 0% mortality in the epidural analgesia group.  This 
study was stopped after recruiting only 53 patients; 28 patients received 
standard anaesthetic and epidural analgesia and 25 patients received standard 
anaesthetic and analgesic techniques based on opiates without epidural 
anaesthesia.  The study has been widely criticised due to the small number of 
patients recruited and the early termination.  However, surgical "risk" was 
evaluated preoperatively and found to be comparable in both groups.  When 
compared to control patients, patients who received epidural analgesia had a 
reduction in the overall postoperative complication rates (p= 0.002) and in the 
incidence of both cardiovascular failure (p= 0.007) and major infectious 
complications (p= 0.007). Urinary cortisol excretion, a marker of the stress 
response, was significantly diminished during the first 24 postoperative hours in 
the group receiving epidural analgesia and anaesthesia (p= 0.025). The 
significant survival benefits observed therefore were consistent with the other 
endpoints measured. 
 
Chapter 1 
 
Page 25 of 287 
The MASTER trial was the largest prospective clinical trial conducted comparing 
postoperative epidural analgesia and systemic opiate based postoperative 
analgesia (Rigg et al. 2002).  The MASTER trial did not find a statistically 
significant difference in 30 day mortality between those patients assigned to 
receive postoperative epidural analgesia and those assigned to receive systemic 
opiate analysed on an intention to treat basis.  The MASTER trial was conducted 
over 6 years in 6 counties and 25 hospitals and recruited a total of 955 patients.  
The MASTER trial recruited patients undergoing major abdominal, non 
laparoscopic surgery with significant comorbidity and an estimated baseline 30 
day mortality of 5%.  It was calculated that a minimum of 814 patients were 
required for the MASTER trial to have a power of 80% to find a 10% relative risk 
reduction in the primary outcome (30 day mortality), with a two sided alpha 
error=0.05.  Compliance with the protocol was a significant issue, with protocol 
violations in 42.5% (192 of 447 patients) of those assigned to the epidural 
analgesia group.  In the epidural group 190 patients had their epidural catheters 
removed at less than 72 hours, in 26 patients the epidural catheter was 
accidentally removed in theatre and in 43 patients the catheter was removed 
due to inadequate analgesia and in the remaining 121 patients the catheter was 
removed without reason less than 72 hours after surgery.  Therefore, it is 
arguable that the intention to treat analysis was not appropriate as 42.5% of 
patients allocated to receive epidural analgesia did not receive 72 hours of 
epidural analgesia.  The MASTER trial did show a reduction in the incidence of 
respiratory failure in the postoperative period requiring prolonged ventilation 
(p=0.02, NNT=15).  Rigg et al did note a non significant decrease of 3.6% in the 
incidence of death or major complication in the group of patients treated with 
epidural analgesia. It is worth considering that if the true 30 day morality 
benefit was a 3.6% reduction in relative risk then to adequately power this trial 
6000 patients would be needed.  The possibility that the MASTER trial represents 
a false negative must be considered. 
 
In contrast, the meta analysis of Rodgers et al included 141 trials with a total of 
9559 patients on or before 1 January 1997 found overall mortality was reduced 
by about a third in patients allocated to intraoperative neuraxial blockade with 
or without concomitant use of general anaesthesia compared to only general 
anaesthesia (103 deaths/4871 patients versus 144/4688 patients, odds ratio = 
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0.70 [95% CI: 0.54 to 0.90, p=0.006]) (Rodgers et al. 2000).  Neuraxial blockade 
reduced the odds of deep vein thrombosis by 44%, pulmonary embolism by 55%, 
transfusion requirements by 50%, pneumonia by 39%, and respiratory depression 
by 59% (all p<0.001).  There were also reductions in myocardial infarction and 
renal failure but this result was less reliable as the number of patients in this 
subgroup was small.  These effects appeared consistent with different types of 
surgical patients; however, only the orthopaedic subgroup of patients had 
enough patients to be able to show a positive mortality benefit.  Rodgers et al 
concluded that the size of the effect of neuraxial block would be 1 less death 
per 100 patients treated. This very small effect may be the reason that previous 
studies examining mortality effects of neuraxial blockade have failed to find any 
mortality benefit.  
 
Beattie et al performed a meta analysis to determine whether postoperative 
epidural analgesia continued for more than 24 hours after surgery reduced 
postoperative myocardial infarction or in hospital death in high risk cardiac 
patients (Beattie, Badner, & Choi 2001).  A total of 11 trials and 1173 patients 
were included in the meta analysis and patients had aortic surgery (in five 
trials), peripheral vascular surgery (in two trials), mixed vascular surgery (in one 
trial) abdominal surgery (in two trials) or mixed high risk surgery (in one trial).  
Postoperative epidural analgesia resulted in better analgesia for the first 
24 hours after surgery and this effect was statistically significant in three out of 
the four studies.  The pain scores were lower in the epidural group in the fourth 
study but the effect was not statistically significant.  The frequency of in-
hospital death was 3.3%, with no statistically significant difference between 
epidural and non epidural groups but a lower death rate in the epidural group 
(event rate difference:-1.3% [95% CI: -3.8% to 1.2%, p=0.091]).  The rate of 
postoperative myocardial infarction was 6.3%, with lower event rates in the 
epidural group (event rate difference: -3.8% [95% CI: -7.4% to -0.2%, p=0.049).  
Subgroup analysis of postoperative thoracic epidural analgesia showed a 
significant reduction in postoperative myocardial infarction in the epidural group 
(event rate difference:-5.3% [95% CI: -9.9% to -0.7%, p=0.04]).  Three trials 
reported the incidence of postoperative ischemia which was monitored using 
Holter monitoring; the incidence was reduced in the group receiving 24 hours of 
epidural analgesia but did not reach statistical significance (event rate 
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difference: -7.5%; p=0.19).  Two studies found an improvement in coagulation 
variables in the group receiving epidural analgesia.  In summary, this meta 
analysis was conducted by using both the fixed effects and random effects 
model, calculating both an odds ratio and a rate difference and the analysis did 
show a consistent reduction in postoperative myocardial infarction rate despite 
the analytical method used with the subset analysis suggesting that thoracic 
epidural analgesia was significantly more beneficial than lumbar epidural 
analgesia. 
 
A recent publication which addressed the impact of epidural analgesia and 
anaesthesia on outcome was a retrospective cohort study of 259037 patients, 
aged 40 years or older, who underwent selected elective intermediate-to-high 
risk non-cardiac surgical procedures between April 1 1994, and March 31 2004, in 
Ontario, Canada (Wijeysundera et al. 2008).  A propensity-score method was 
used to construct a matched-pairs cohort that reduced important baseline 
differences between patients who received epidural anaesthesia or analgesia 
and those that did not to determine the association of epidural anaesthesia and 
analgesia with 30-day mortality within these matched-pairs.  A total of 259037 
patients were included in the data base, 56556 (22%) received epidural 
anaesthesia, 44094 patients that received an epidural were matched with 
44094 patients who did not receive an epidural analgesia and anaesthesia was 
associated with a small reduction in 30-day mortality (1·7% vs 2·0%; relative risk 
0·89 [95% CI: 0·81–0·98, p=0·02]).  Epidural anaesthesia and analgesia was 
associated with a small improvement in 30-day survival, but this effect should be 
interpreted cautiously as the estimate had borderline significance and it 
corresponded to a number needed to treat of 477. This study did not provide 
compelling evidence that epidural anaesthesia and analgesia improved 
postoperative survival but it did support the safety of perioperative epidural 
anaesthesia when used for indications other than improving survival such as 
improved postoperative pain relief and preventing postoperative pulmonary and 
cardiac complications.  The evidence suggests that major postoperative 
pulmonary and respiratory complications are reduced by providing epidural 
anaesthesia and it would seem logical to review the evidence of improved 
outcome in cardiac surgery as this patients group should see a particularly large 
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benefit as cardiac and respiratory comorbidity are almost universal in this 
patient group and the surgical insult is significant. 
1.1.6 The use of regional analgesia to improve outcomes in 
cardiac surgery 
The evidence for a positive outcome for the use of regional analgesia in the form 
of thoracic epidural analgesia in cardiac surgery is currently limited to a single 
randomised controlled trial (Scott et al. 2001).  Scott et al 2001 showed outcome 
benefits in 420 cardiac surgery patients.  It is notable that in this cohort of 420 
patients anaesthesia was maintained using a target controlled infusion of 
propofol and alfentanil and that they continued the epidural infusion of 
bupivacaine and clonidine for four days postoperatively. The improvements in 
outcome noted by this study were substantial and the reduction in the incidence 
of lower respiratory infections was particularly striking.  The incidence of lower 
respiratory tract infection was 31 in 206 patients (15.3%) in those patients 
receiving thoracic epidural analgesia compared with 59 of 202 patients (29%) in 
the general anaesthesia patient group (p=0.0007), odds ratio 2.33 (1.43-3.79), 
which after adjustment for baseline covariates was 2.06 (1.22-3.47) (p=0.0065).  
Patients were extubated significantly earlier using standardised extubation 
criteria in the thoracic epidural analgesia group, with only 11 of 202 patients in 
the general anaesthesia group compared with 51 of 206 in the thoracic epidural 
analgesia group extubated within the first four hours postoperatively.  
The incidence of new supraventricular arrhythmias that required treatment in 
patients receiving thoracic epidural analgesia was significantly reduced 
compared with those receiving general anaesthesia (45 of 202 [22.3%] vs 21 of 
206 [10.2%], p=0.0012, odds ratio 2.53 [1.44-4.42], which after adjustment for 
baseline covariates was 2.56 [1.41-4.66], p=0.002).  There was no difference in 
the incidence of bradycardia, ventricular arrhythmia, conduction defects, or 
myocardial infarction between the two groups.  Myocardial infarction occurred 
in eight patients in the general anaesthesia group and six patients in the thoracic 
epidural analgesia group, and the overall incidence in the study was 4%.  There 
was a significant reduction in the incidence of acute renal failure in patients 
receiving thoracic epidural analgesia (general anaesthesia = 14 of 202, thoracic 
epidural analgesia = 4 of 206; p=0.016) and also in the incidence of 
postoperative confusion (general anaesthesia = 11 of 202, thoracic epidural 
Chapter 1 
 
Page 29 of 287 
analgesia = 3 of 206; p=0.031). The incidence of cerebrovascular accidents was 
less in patients receiving thoracic epidural analgesia (general anaesthesia = 6 of 
202, thoracic epidural analgesia = 2 of 206), however the overall number was 
small and the difference was not statistically significant (p=0.17). 
 
Liu conducted  a meta analysis on thoracic epidural analgesia (Liu, Block, & Wu 
2004) in cardiac surgery which analysed the results of 15 trials which recruited a 
total of 1178 patients (Table 1-2).  The meta-analysis did show significant 
benefits of thoracic epidural compared to opiate based analgesia.  Liu estimated 
that 30000 patients would be needed to detect a difference in mortality in 
cardiac patients with thoracic epidural analgesia. 
Table 1-2: The benefits of thoracic epidural analgesia in cardiac patients 
 Peto odds ratio 95% confidence interval p value 
Reduction in arrhythmias 0.52 0.29 to 0.93 0.03 
Reduced pulmonary complications 
(pneumonia and atelecasis) 
0.41 0.27 to 0.60 <0.00001 
Pain scores at rest -7.8 -15 to -0.6 0.03 
Pain scores during activity -11.6 -19.7 to -3.5 0.005 
Opiate requirements -11 -15 to -7 <0.00001 
 
Fillinger et al did not see any benefits of thoracic epidural anaesthesia in cardiac 
surgery but the study included a total of 60 patients (Fillinger et al. 2002).  
Thiopentone was used for induction and propofol was used for maintenance of 
anaesthesia, normothermic cardiopulmonary bypass was used and patients were 
not cooled to 28 degrees as in the study by Scott et al.  The thoracic epidural 
was sited at the T3-T10 interspaces in contrast to Scott et al who used the T3-T5 
interspaces.  Fentanyl not clonidine was used in combination with bupivacaine in 
the epidural catheters infusion.  Fillinger did also not record any differences in 
pain scores and it is therefore possible to conclude that the epidurals were not 
providing any analgesic or sympatholyic effect. 
 
Hansdottir et al conducted a trial of epidural thoracic analgesia in cardiac 
patients examining length of stay and quality of analgesia (Hansdottir et al. 
2006).  They found no difference between the quality of analgesia but they only 
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randomised a total of 97 patients.  A non-statistically significant reduction in the 
number of episodes of confusion (p=0.1) and lower respiratory tract infections 
(p=0.086) but no reduction in arrhythmias was observed.  This may be due to the 
use of β-blockers intra-operatively and in the immediate postoperative period.  
They concluded that epidural analgesia may have a role in those patients with 
significant morbidity (unstable angina and obesity) at high risk of adverse cardio 
respiratory problems. 
1.2 Summary of Chapter 1 
Fractured neck of femur is a significant cause of morbidity and mortality in the 
developed world, the aetiology of these deaths is mainly cardiac and respiratory 
complications. The patients suffer high rates of morbidity and mortality and 
despite many studies the current most effective treatments are rapid 
mobilisation by surgical fixation of the fracture or early mobilisation in 
association with non operative management.  The use of regional anaesthetic 
techniques in all types of surgical patient has shown benefit; however, the 
impact on mortality has diminished as improvements in surgical and anaesthetic 
techniques resulted in a significant reduction in the overall mortality.  The 
mortality from high risk elective surgery is now less than 5%; therefore, it is very 
difficult to show a reduction in mortality as the study would need to recruit 
thousands of patients.  To quantify benefit, secondary outcome measures (i.e. 
lower respiratory tract infection, the need for ventilation and renal support) 
have been used to assess the effect of regional analgesia.  In contrast to the 
marked improvements in the previous 30 years in elective surgery, the overall 
mortality from emergency surgery and in particular surgery for fractured neck of 
femur patients has remained unchanged.  Regional analgesia and anaesthesia 
offers the potential of reduced complications in patient populations with 
significant cardiac and respiratory co-morbidity.  It is therefore possible that 
effective regional analgesia could improve morbidity and mortality in patients 
with a fractured neck of femur and may impact positively on their morbidity and 
mortality
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2 Review of analgesia for patients with a fractured 
neck of femur 
2.1 Introduction 
This chapter will examine the analgesic regimes that have been used in patients 
with a fractured neck of femur and the evidence for their effectiveness.  Three 
analgesic regimes have been commonly used in this population, parenteral 
opiates, lumbar epidural analgesia and femoral 3-in-1 nerve block.  In order to 
avoid confusion it should be noted that the femoral 3-in-1 nerve block has also 
been called the femoral nerve block, anterior psoas compartment block and the 
fascia iliacus block depending on the method of guiding the needle and the 
chosen end point.  It is the opinion of this worker that these are the same nerve 
block as all the descriptions result in local anaesthetic being injected below the 
fascia iliacus membrane close to the femoral nerve, therefore the term femoral 
3-in-1 nerve block will be use throughout this thesis. 
2.1.1 Parenteral opiate based analgesia for fractured neck of 
femur patients 
Evidence from a prospective observational study by Morrison et al suggested that 
the beneficial effects of improved analgesia may also be observed in fractured 
neck of femur patients receiving opiate based analgesia (Morrison et al. 2003).  
Four hundred and eleven consecutive cognitively intact patients admitted with a 
diagnosis of fractured neck of femur to four hospitals in New York were enrolled 
in a prospective cohort study.  Patients were interviewed daily using 
standardised pain assessments.  Morrison et al used multiple logistic regression 
and ordinary least squares linear regression to examine the association of post-
operative pain on immediate post-operative outcomes (duration of stay, physical 
therapy sessions missed or shortened, ambulation following surgery, and post-
operative complications) and outcomes six months following fracture 
(locomotion, mortality, return to the community, residual pain).  The study 
found that patients with higher pain scores at rest had a statistically 
significantly increased length of hospital stay (p=0.03), were more likely to have 
physical therapy sessions missed or shortened (p=0.002), were less likely to be 
ambulating by post-operative day three (p=0.001), took longer to ambulate past 
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a bedside chair (p=0.01), and had lower locomotion scores at six months 
(p=0.02).  Pain at rest was not significantly associated with post-operative 
complications, nursing home placement, survival at six months, or residual pain 
at six months. 
 
A further prospective observational study by Morrison et al found an association 
between inadequate analgesia and the development of delirium in patients with 
a fractured neck of femur (Morrison et al. 2003).  This study enrolled 541 
patients at four hospitals in New York with a diagnosis of traumatic hip fracture 
without delirium.  Delirium was identified prospectively by patient interview 
supplemented by medical record review.  Multiple logistic regression techniques 
were used to identify risk factors.  Eighty-seven of 541 patients (16%) became 
delirious.  Among all subjects, risk factors for delirium were cognitive 
impairment (relative risk [RR], 3.6, [95% CI: 1.8 to 7.2]), abnormal blood 
pressure (RR=2.3, [95% CI: 1.2 to 4.7]), and heart failure (RR=2.9, [95% CI: 1.6 to 
5.3]).  Patients who received less than 10 mg of parenteral morphine sulphate 
equivalents per day were more likely to develop delirium than patients who 
received more analgesia (RR=5.4, [95% CI: 2.4 to 12.3]).  Patients who received 
meperidine were at increased risk of developing delirium as compared with 
patients who received other opioid analgesics (RR=2.4, [95% CI: 1.3 to 4.5]).  In 
cognitively intact patients, severe pain significantly increased the risk of 
delirium (RR=9.0, [95% CI: 1.8 to 45.2).  Cognitively intact patients with under 
treated pain were nine times more likely to develop delirium than patients 
whose pain was adequately treated.  Under treated pain and inadequate 
analgesia appear to be risk factors for delirium in frail older adults.  The use of 
opiate based analgesia is recommended (in SIGN guideline 111) as part of the 
early management of patients with a fractured neck of femur.  The work of 
Morrison et al demonstrated that the use of adequate amounts of opiate 
analgesia was associated with improved cognitive function but it did not 
demonstrate any reduction in other cardio-respiratory outcomes or mortality. 
2.1.2 Lumbar epidural analgesia for a fractured neck of femur 
patients 
In 2000 Scheinin et al published a prospective clinical trial comparing epidural 
and parental opiate based analgesia in 77 patients scheduled for surgical repair 
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of a traumatic hip fracture (Scheini et al. 2000). Patients were randomised to 
conventional analgesic regimen of intramuscular oxycodone (opiate group) or 
continuous epidural infusion of bupivacaine and fentanyl (epidural group).  The 
analgesic regimens were started preoperatively.  The patient’s hip fractured was 
fixed under spinal anaesthesia and the analgesic regimes were continued three 
days postoperatively.  The electro cardiogram (ECG) was continuously recorded 
using Holter monitors.  Ischaemic episodes were defined as an ST segment 
depression of ≥0.1 mV or elevation of ≥0.2 mV lasting ≥1 minute. Nocturnal 
arterial oxygen saturation (SaO2) was recorded perioperatively, and pain was 
assessed every morning using a pain visual analogue scale (VAS) scores.  Fifty-
nine patients (30 in the opiate group and 29 in the epidural group) of the total 
77 patients were evaluated by Holter monitors.  Thirteen patients (43%) in the 
opiate group and 12 patients (41%) in the epidural group had ischaemic episodes 
(p=1.0).  However, significantly more patients in the opiate group had ischaemic 
episodes during the surgery (8 vs 0 patients in the epidural group, p=0.005). The 
median (interquartile range) total ischaemic burden (i.e. integral of ST-change 
vs. time) in patients with ischaemic episodes was ten times larger in the opiate 
group (340 [342] mm·min) compared with the epidural group (30 [36] mm·min) 
(p=0.002). The vast majority of the total ischaemic time was postoperatively 
with almost 80% of the total ischaemic burden during this time period.  There 
were no significant differences between the groups in average heart rates or in 
heart rates at the start of ischaemic episodes or in maximal heart rates during 
the attacks.  Average nocturnal SaO2 was similar in the two groups and there 
were no differences in the number of hypoxaemic (SaO2<90%) episodes.  
Preoperatively there were no differences in pain VAS scores, but postoperative 
and average perioperative pain VAS scores for pain were almost 40% lower in the 
epidural group (p=0.006).  The reduced pain scores observed postoperatively 
may have resulted in reduced sympathetic activation and produced fewer 
imbalances between coronary artery oxygen supply and myocardial oxygen 
demand.  However it is not possible to explain the reduction in ischaemic 
episodes in the epidural group intra-operatively based on differential 
sympathetic activation.  Spinal anaesthesia was used intra-operatively for all 
patients in this study and no patients required conversion to general anaesthesia 
or supplemental regional analgesia intra-operatively and therefore all patients 
had a dense sympathetic block.  Preoperative epidural infusion of bupivacaine 
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and fentanyl may have resulted in myocardial preconditioning that prevented 
ischaemic episode in the epidural group.  The tentative conclusion from this 
small study was that continuous epidural bupivacaine and fentanyl analgesic 
regimen, started preoperatively, reduced the amount of myocardial ischaemia in 
elderly patients with hip fracture.  This study was well conducted and although 
the number of patients recruited was small it appears methodologically sound.  
However ischaemic episodes were not verified by measuring the cardiac enzyme 
profile.  
 
In 2003 Matot et al also published a study which randomised patients with a 
fractured neck of femur to conventional intramuscular opiate based analgesia or 
epidural analgesia using both local anaesthetic and opiate in the infusion (Matot 
et al. 2003).  The effect of early administration of epidural analgesia during the 
pre-surgical period, on preoperative cardiac events was evaluated in a 
prospective randomised study in 68 patients with hip fractures who either had 
known coronary artery disease or were at high risk for coronary artery disease.  
On admission to the emergency room, patients were assigned to receive either a 
standard analgesic regimen (intramuscular meperidine, control group, n=34) or 
continuous epidural infusion of local anaesthetic and opioid (epidural group, 
n=34).  Matot et al found that preoperative adverse cardiac events were 
significantly more prevalent in the control group compared with the epidural 
group (7 of 34 vs. 0 of 34; p=0.01). The adverse cardiac events recorded 
included fatal myocardial infarction in three patients, fatal congestive heart 
failure in one patient, nonfatal congestive heart failure in one patient, and new 
onset atrial fibrillation in two patients. The incidence of intra-operative and 
postoperative adverse cardiac events was similar for the two groups.  The data 
from this study indicated that compared with standard opiate based analgesia, 
early administration of continuous epidural analgesia was associated with a 
lower incidence of preoperative adverse cardiac events in elderly patients with 
hip fracture who have, or are at risk of, coronary artery disease.  It is interesting 
to note that this effect does not appear to be related to a reduction in resting 
pain scores as the control groups also received adequate analgesia based on the 
pain scores at rest preoperatively.  The results of this study should be treated 
with caution as the significant difference in the incidence of preoperative 
cardiac events prompted termination of the study after the planned interim 
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analysis.  The possibility of bias in the study was increased by the unblinded 
methodology utilised; however, the cardiac end points chosen were objective in 
nature.  It is notable that at one hour after analgesia and before surgery, the 
pain scores on movement were statistically significantly lower (p<0.05) in the 
patients with lumbar epidural analgesia. 
 
The previous two studies using lumbar epidural analgesia studies were published 
in 2000 and 2003; however, the majority of UK hospitals do not use lumbar 
epidurals to provide analgesia patients with a fractured neck of femur despite 
the compelling evidence in these studies.  The reason for this lack of 
implementation is likely to be financial.  In 2003, the average hospital cost for a 
patient over 60 years of age undergoing surgery for a hip fracture was 
retrospectively estimated at £12163.  There were 6369 hip fracture patients in 
2008 in Scotland the estimated annual hospital cost for NHS Scotland was around 
£77 million in 2008.  The extra cost of implementing lumbar epidural analgesia 
(increased medical and nursing staff and mandatory constant cardiorespiratory 
monitoring) for the commonest orthopaedic emergency would be prohibitive. 
2.1.3 Femoral 3-in-1 nerve blocks for analgesia of fractured neck 
of femur patients 
The femoral 3-in-1 nerve block can provide effective analgesia to fractured neck 
of femur patients prior to definitive surgical fixation.  The remainder of this 
chapter will present the clinical anatomy, sonoanatomy, history, methods of 
insertion, adverse events and benefits associated with the femoral 3-in-1 nerve 
block. This chapter will also discuss the clinical evidence for and against the 
utilisation of this nerve block. 
2.2 Summary of clinical anatomy 
The lumbar plexus is formed from the anterior primary rami of lumbar nerve 
roots L1-L4 in the body of the psoas muscle approximately one centimetre deep 
to the transverse processes of the respective lumbar vertebra.  The branches 
emerge from the medial (obturator nerve), anterior surface (gentitofemoral 
nerve) and the lateral border (ilioinguinal, iliohypogastric, lateral cutaneous 
nerve of thigh and the femoral nerve from above downwards) of the psoas 
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muscle to supply the skin of the groin, upper leg and the muscles of the hip and 
knee joint (see Figure 2-1). 
 
The femoral nerve is formed in the body of the psoas muscle from the posterior 
divisions of the anterior primary rami of L2-4.  Inferiorly it lies on the surface of 
a groove between iliacus muscle laterally and psoas muscle medially.  It is 
covered by the iliacus facia which also covers the lateral cutaneous nerve of the 
thigh and separates both nerves from the femoral artery and vein (see Figure 2-
2). The femoral nerve passes under the inguinal ligament and divides into an 
anterior and posterior division and its terminal branches.  The anterior division 
supplies muscular branches to the sartorius and pectineus muscles and cutaneous 
branches to the intermediate and medial cutaneous nerves of the thigh.  The 
posterior division supplies the quadriceps muscles and forms the saphenous 
nerve which supplies the skin on the medial side of the foot and leg. 
 
The lateral cutaneous nerve of the thigh is formed from the anterior primary 
rami of L2 and L3 travel inferiorly and laterally on the body of the iliacus muscle 
covered by the iliacus fascia to lie on top of the sartorius muscle.  It then 
pierces the lateral end of the inguinal ligament and divides into anterior and 
posterior divisions to supply an extensive area of skin on the lateral aspect of 
the leg from the lower lateral quadrant of the buttock to the lateral aspect of 
the hip and knee joints. 
 
The obturator nerve is formed from the anterior primary rami of L2, L3 and L4.  
It emerges from the medial border of the psoas muscle and travels inferiorly to 
cross the pelvic brim and lie anterior to the sacroiliac joint and posterior to the 
common iliac vessels.  It leaves the pelvis and passes into the thigh by passing 
through the obturator foramen and dividing into anterior and posterior divisions.  
The anterior division emerges over the top of the obturator externus muscle and 
passes between the obturator longus muscle anteriorly and the adductor brevis 
muscle posteriorly to supply both these muscles and the gracilis muscle.  It gives 
an articular branch to the hip joint and supplies a variable branch to the skin 
overlying the subsartorial canal (see Figure 2-3).  The posterior division passes 
through the obturator externus muscle supplying it and passes between the 
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adductor brevis muscle and adductor magnus muscle supplying the adductor part 
of adductor magus and terminates with articular branches to the knee joint. 
 
Figure 2-1: The Lumbar plexus 
 
The Lumbar plexus  Adapted from Snell Clinical Anatomy For Medical Students, 
3rd edition by Little, Brown and Company publishing, page 263. 
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Figure 2-2:.The femoral vein artery and nerve and the lateral cutaneous nerve with 
superficial structure removed. 
 
Adapted from Last’s Anatomy Regional And Applied, 4th edition Churchill 
publishing page 193 
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Figure2-3: The obturator nerve in the anterior thigh: 
 
Adapted from Snell Clinical Anatomy For Medical Students, 3rd edition by Little 
Brown and company publishing page 585. 
Chapter 2 
 
Page 40 of 287 
2.2.1 The sonoanatomy of 3-in-1 femoral nerve block 
The ultrasound probe should be positioned parallel to the inguinal ligament at 
that level or just below it and moved medially and lateral until the common 
femoral artery is imaged in cross section proximal to the profunda femoris 
branch.  The position of the ultrasound probe and the ultrasound image of the 
femoral nerve, artery and vein are shown in Figure 2-4 and Figure 2-5 
respectively.  
Figure 2-4: The position of the ultrasound probe to generate the image below of the femoral 
artery vein and nerve. 
 
Image from personal collection of Dr Malcolm Watson 
Figure 2-5: The femoral nerve is usually seen lateral to the femoral artery as a triangular 
speckled structure. 
 
Image from personal collection of Dr Malcolm Watson 
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2.2.2 History 
Winnie et al first described the femoral 3-in-1 block in 1973 in a paper which 
was entitled the ‘inguinal perivascular technique for lumbar plexus anaesthesia, 
the “3-in-1 Block”(Winnie, Ramamurthy, & Durrani 1973).  In this paper, Winnie 
et al described the anatomy of the femoral 3-in-1 nerve block, and claimed that 
a single injection would consistently block the femoral, obturator and lateral 
cutaneous nerves due to the presence of a fascia sheath enveloping all three 
nerves and rostral spread of local anaesthetic.  The existence of the fascia 
sheath and the ability to block all three nerves, consistently, with a single 
injection has been widely disputed.  The omission of the obturator nerve block 
has been demonstrated by a number of investigators.  The first clinical trial to 
demonstrate this was published by Parkinson et al in 1989 (Parkinson et al. 
1989).  Two case reports pre-dated this by Sharrock (Sharrock 1980) and 
Lonsdale (Lonsdale 1988) in which they descried inadvertent femoral nerve block 
with no motor (adductors muscle weakness) evidence of an obturator nerve 
block while attempting to block the lateral cutaneous nerve in 1980 and 1988 
respectively.  The most widely quoted evidence for ‘obturator escape’ was 
provided by Lang et al in 1993.  Lang et al demonstrated that sensation in the 
medial part of the upper thigh was supplied by the femoral nerve in a majority 
of cases, and that determination of obturator nerve block could only be done by 
measuring adductor power (Lang et al. 1993).  Bouaziz et al confirmed this 
finding by selectively blocking the obturator nerve and then performing a 
femoral 3-in-1 nerve block using a nerve stimulator (Bouaziz et al. 2002).  
Bouaziz et al found that in 57% of patients the obturator nerve had no cutaneous 
sensory innervation and in the remaining 23% had an area of hypoesthesia 
(partial innervation) on the inferior medial aspect of the thigh and that only 20% 
of patients had a cutaneous sensory distribution. 
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2.3 Methods used to site the femoral 3-in-1 nerve block 
2.3.1 The use of nerve stimulators for femoral 3-in-1 nerve blocks 
Greenblatt et al 1962 produced the first description of the percutaneous use of a 
nerve stimulator in a method which would be recognisable to anaesthetists today 
(Greenblatt & Denson 1962).  However the technique and principles of nerve 
localisation using electrical stimulation were first described by Pearson in 1955 
(Pearson 1955) and Sarnoff in 1951 (Sarnoff & Sarnoff 1951). 
 
Nerve stimulator is the current gold standard in regional anaesthesia to detect 
proximity of the needle tip to the nerve.  Fanelli et al conducted a prospective 
multicentre observational study in Italy of 3996 patients of which 2175 had 
combined femoral and sciatic nerve blocks guided with a nerve stimulator for a 
lower limb surgery (Fanelli et al. 1999).  Fanelli reported a failure rate of only 
153 (7%), which was defined as the use of general anaesthesia to complete the 
surgical procedure.  It is interesting to note that 635 (29%) of these patients 
when questioned afterwards would refuse the same anaesthetic technique if 
they were scheduled to have further similar surgery.  Fanelli et al thought that 
this was the result of the transient discomfort during the block placement due 
the combined effects of nerve stimulation and multiple needle advancements.  
It is interesting to postulate that it could have been due to the discomfort of an 
incomplete nerve block during surgery which would have been treated initially 
with wound infiltration and supplementary block by the surgeon.  The 
observational design of this study could have allowed observer bias.  It is 
therefore reasonable to conclude that the true block failure rate for combined 
sciatic and femoral nerve blocks using a nerve stimulator was likely to have been 
higher than the 7% reported by Fanelli et al.  A study by Marhofer et al 
estimated the success rate of a nerve stimulator guided femoral 3-in-1 nerve 
block as 85% (Marhofer et al. 1997). 
2.3.2 Loss of resistance for femoral 3-in-1 nerve blocks 
The loss of resistance technique was a development of the inguinal perivascualar 
technique of Winnie’s original description.  It utilised the presence of a loss of 
resistance to the advancement of a blunt tipped needle to the fascia lata and 
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fascia iliacus membranous layers (covering the branches of the lumbar plexus 
anteriorly).  The first description of this technique in the literature was by Khoo 
et al in 1983 (Khoo & Brown 1983) but this method was first used in a clinical 
trial published in 1989 by Dalens et al (Dalens, Vanneuville, & Tanguy 1989).  
Dalens et al claimed a 90% success rate with a loss of resistance technique in the 
first published series using quality of analgesia as the primary end point in a 
paediatric patient population.  The technique utilised by Dalens did not require 
a nerve stimulator or special needles and used a blunt ‘Tuohy’ tipped needle to 
detect loss of resistance to advancement.  Dalens et al also claimed to 
consistently block the obturator, femoral and lateral nerves using this 
technique.  Capedvila et al was the first to use the loss of resistance technique 
in an adult population (Capdevila et al. 1998). In contrast to Dalens, but in 
common with the studies using the femoral 3-in-1 technique of Winnie (Lang 
1998), Capdevila et al was unable to demonstrate consistent motor blockade of 
the obturator nerve but was able to demonstrate reliable blockade of the 
femoral and lateral cutaneous nerves.  Morau et al concluded that the loss of 
resistance technique was at least as effective in providing post operative 
analgesia in a cohort of 44 adults scheduled for elective anterior cruciate repair 
or femoral osteotomy as the femoral 3-in-1 nerve block guided by a nerve 
stimulator and was quicker cheaper and required less equipment. 
 
The simplicity and effectiveness of the loss of resistance technique has lead to it 
being used successfully in the pre-hospital trauma setting for fractured shaft of 
femur (Lopez et al. 2003) and in accident and emergency departments to 
provide pain relief for fractured neck of femur patients (Monzon, Iserson, & 
Vazquez 2007). 
2.3.3 The use of ultrasound for the femoral 3-in-1 nerve block 
Thirty years ago, Winnie and colleagues succeeded in blocking the femoral, 
obturator and lateral cutaneous femoral nerves with a single inguinal 
perivascular injection.  This approach came to be known as the ‘femoral 3-in-1 
nerve block’.  Despite the use of nerve stimulation and the loss of resistance the 
femoral 3-in-1 nerve block has a failure rate of approximately to 20% (Tierney et 
al. 1987).  It is possible that the use of ultrasound could reduce the failure rate 
of the femoral 3-in-1 nerve block. 
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The femoral 3-in-1 nerve block is ideally suited to the use of ultrasound guidance 
with a high frequency (10 MHz or more) linear probe because of the relatively 
superficial position of the femoral nerve distal to the inguinal ligament, lateral 
to the femoral artery, and below the fascia iliacus membrane.  The Vienna group 
demonstrated that ultrasound guidance significantly improved the puncture-to-
onset interval and the quality of sensory block in all three nerves while avoiding 
complications such as arterial puncture (Marhofer et al. 1997).  The use of 
ultrasound monitoring has allowed repositioning of the needle in the event of 
misdistribution of local anaesthetic above the fascia iliacus membrane.  The 
work of Marhofer et al also demonstrated that less local anaesthetic was 
required for a femoral 3-in-1 nerve block with ultrasound guidance in 
comparison to the use of a nerve stimulation (Marhofer et al. 1998). 
2.3.4 Adverse events related to femoral 3-in-1 nerve block 
The largest study of the complications associated with regional anaesthesia was 
a survey of 158083 regional anaesthetic procedures performed by 487 
anaesthesiologists over a 10 month period in France (Auroy et al. 2002).  10309 
femoral 3-in-1 nerve blocks were performed during this study; no deaths, cardiac 
arrests, episodes of respiratory failure or seizures were reported and only three 
peripheral neuropathies were reported all of which had completely recovered by 
three weeks.  The study estimated that the true incidence of deaths, cardiac 
arrests, episodes of respiratory failure or seizures associated with the femoral 
nerve block using loss of resistance and nerve stimulation was a 95% CI: 0 - 
2.9/10000 nerve blocks.  The recorded incidence of transient neurological 
complications was 2.9/10000 (95% CI: 0 to 7.8/10000 nerve blocks.  Fanelli et al 
reported a 2% incidence (45 nerve blocks) of transient neurological complications 
in his observational study of 2175 combined femoral 3-in-1 and sciatic nerve 
blocks in Italy and all but one of these complications had resolved completely by 
the 12 week follow up (Fanelli et al. 1999).  The very high incidence of 
neurological complication in Fanelli’s study may be partly explained by the use 
of a multiple injection technique, high tourniquet pressures (>400 mmHg) and 
the combined reporting of adverse events from both the sciatic nerve block and 
the femoral nerve blocks.  In the study by Auroy (Auroy et al. 2002) the popliteal 
approach to the sciatic nerve was associated with a neurological complication 
Chapter 2 
 
Page 45 of 287 
incidence of 31/10000 (95% CI: 0 to 84.0/10000 nerve blocks), however Fanelli 
et al used the classic subgulteal approach of Labat which was associated with 
very low neurological complication incidence of 3/10000 (95% CI: 0 to 8.2/10000 
nerve blocks). 
 
Neurological complications are the category of adverse events most frequently 
attributed to a peripheral nerve blockade but several factors have been 
highlighted in the development of neurological complications.  These factors 
include neurotoxicity of local anaesthetics and malpostioning during surgery, 
tourniquet inflation pressure (Fanelli et al. 1999)and Blumenthal et al 
(Blumenthal et al. 2006) suggested that pre-existing subclinical polyneuropathy 
may be a risk factor for the development of neurological complications.  
 
The aggregate incidence of transient neurological adverse events associated with 
a femoral 3-in-1 nerve block in meta-analysis of 4 trials by Brull et al was 
34/10000 (95% CI: 0.04 to 2.81%) (Brull et al. 2007).  The femoral 3-in-1 nerve 
blocks were inserted using various techniques (nerve stimulator, loss of 
resistance and elicitation of paraesthesia).  Brull reported only one incidence of 
permanent neurological injury associated with a femoral nerve block after 13378 
(incidence 7.5/100000) femoral 3-in-1 nerve blocks.  The vast majority of 
neurological complications reported have been transient but Cuvillon et al 
reported one femoral paraesthesia without motor weakness which had only 
partially resolved at one year follow up in 211 patients who had femoral nerve 
block using a nerve stimulator and catheter insertion (Cuvillon et al. 2001). 
 
In comparison, in the meta analysis by Brull the incidence of neurological 
complications caused by brachial plexus block using the interscalene approach 
(2.84/100 [95% CI: 1.33 to 5.98]) and the axillary approach (1.48/100 [95% CI: 
0.52 to 4.11]) and the sciatic nerve (0.41/100 (95% CI: 0.02 to 9.96]) was in 
excess of the cumulative incidence in the femoral nerve group (0.34/100 [95% 
CI: 0.04 to 2.81]) (Brull et al. 2007).  In summary, several studies have 
confirmed that femoral nerve block has one of the lowest incidences of adverse 
events both in terms of cardiac and respiratory complications and peripheral 
neuropathies.  
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2.3.5 The use of ultrasound to increase success rate and 
decreased adverse events 
The systematic review by Abrahams et al did find that ultrasound guided blocks 
were associated with fewer vascular punctures (RR(risk ratio)=0.16 [95% CI: 0.05 
to 0.47]) compared to those blocks performed with a nerve stimulator they did 
not find any statistically significant difference in paraesthesia during block or 
persistent neurological symptoms after the block’s resolution (Abrahams et al. 
2009).  However, the total number of patients included in the meta analysis was 
only 946.  Four studies containing a total of 240 patients reported vascular 
puncture and only two studies reporting neurological symptoms and these 
studies contained a total of 206 patients.  The systematic review may be 
criticised on the basis that one of the studies included by Sauter et al (Sauter et 
al. 2008) contained a worryingly high rate of vascular punctures in the nerve 
stimulator treatment group (i.e. 13 vascular punctures in 40 patients and 
therefore provided 56.4% of the weighting of the final result).  However, all the 
studies included favoured the use of ultrasound over nerve stimulator to reduce 
vascular puncture.  If the incidence of serious neurological symptoms following 
the resolution of the block is assumed to be 1/10000 (averaging the values found 
by Auroy et al for the supraclavicular (0/10000 [95% CI: 0.0 to 15.9]) block and 
axillary block (1.8/10000, [95% CI: 0.0 to 6.3]) then it is unlikely that any 
conclusion could be drawn from this meta analysis for neurological complications 
as they where only reported in two of the studies containing a total of 206 
patients. 
2.3.6 Comparison of methods; ultrasound, nerve stimulator, loss 
of resistance 
The success of a peripheral nerve block can be measured in many different 
ways, loss of sensory and motor function, postoperative pain scores, analgesia 
consumption postoperatively or by the need for supplementary regional or 
general anaesthesia to complete the scheduled surgical procedure.  In 1997, 
Marhofer et al used sensory and motor testing to define success and published a 
series of patients with a 95% success rate using sensory testing as the primary 
end point in patients with a fractured neck of femur and 85% success rate using 
a nerve stimulator guided technique (Marhofer et al. 1997).  The 1997 Marhofer 
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et al study recruited forty patients American Association of Anesthesiologists 
(ASA) physical status II or III) undergoing hip fixation or replacement 
hemiarthroplasty after suffering a fractured neck of femur.  Patients were 
randomised to receive 20 ml bupivacaine 0.5% administered using ultrasound 
(US) guidance or with nerve stimulator (NS) guidance.  The quality and the onset 
of the sensory block was assessed by using the pinprick test in the central 
sensory region of each of the three nerves and compared with the same area on 
the contra lateral leg every 10 minutes for one hour.  The rating was performed 
using a scale from 100% (uncompromised sensation) to 0% (no sensory sensation).  
The onset of sensory blockade was significantly quicker in the US Group 
compared with NS Group (US 16 ± 14 min, NS 27 ± 16 min; P<0.05). The quality 
of the sensory block after injection of the local anaesthetic was also significantly 
better in US Group compared with NS Group (US 15% ± 10% of initial value, NS 
27% ± 14% of initial value; P<0.05).  A successful femoral nerve block was 
achieved in 95% of the patients in the US group and in 85% of the patients in the 
NS group.  In the US group, visualisation of the cannula tip, the femoral nerve, 
the major vessels, and the local anaesthetic spread was possible in 85% of 
patients.  Incidental arterial puncture (n=3) was observed only in the NS group.  
Marhofer et al concluded that a US guided approach for femoral 3-in-1 nerve 
block reduced the onset time, improved the quality of the sensory block and 
minimised the risks associated with this regional anaesthetic technique.  
Although this study included a small number of patients it did show an improved 
sensory block and a reduced onset of block time associated with the use of 
ultrasound.  The use of nerve stimulators in patients with an unfixed proximal 
femoral fracture would be unlikely to gain ethical approval if repeated today but 
otherwise the study appeared to be methodologically sound. 
 
Marhofer published a further study in 1998 which supported his original 
conclusions that ultrasound guidance improved sensory blockade, increased the 
success rate and could also allow reduction in local anaesthetic dosing (Marhofer 
et al. 1998).  Sixty patients with a fractured neck of femur were recruited and 
randomly assigned to three groups of 20.  Group A received a femoral nerve 
block with ultrasound and 20 ml of 0.5% bupivacaine, group B and group C 
received a femoral nerve block using a nerve stimulator with 20 and 30 ml of 
bupivacaine respectively.  The overall success of the blocks defined by sensory 
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testing as in the previous study was 95% in the ultrasound group and 80% in the 
two nerve stimulator groups (p>0.01).  The onset time for group A was 13mins ± 
6mins, group B was 27±12mins and group C was 26±13mins.  The onset of the 
femoral 3-in-1 nerve block was significantly shorter (p<.01) when group A (which 
used ultrasound) was compared to both to groups B and C (which both used 
nerve stimulator) to guide the femoral 3-in-1 nerve block. 
 
Dalens et al published a 90% success rate with femoral 3-in-1 nerve block using 
the loss of resistance technique in but the majority of workers have achieved a 
lower rate of success. (Dalens, Vanneuville, & Tanguy 1989).  However Morau et 
al claimed a 100% success rate in two small groups of patients; 22 patients in the 
3-in-1 group using a nerve stimulator and 22 patients in the loss of resistance 
group (Morau et al. 2003).  The results of a study by Dolan et al suggested that 
the femoral 3-in-1 nerve block was significantly less successful if loss of 
resistance was used to guide the needle placement in comparison with 
ultrasound guidance (47% success with loss of resistance in comparison to 85% 
with ultrasound)(Dolan et al. 2008). 
 
A systematic review and meta-analysis by Abrahams et al showed that the use of 
ultrasound in comparison with using nerve stimulators to guide the needle was 
associated with fewer block failures (risk ratio=0.41 [95% CI: 0.26 to 0.66; 
p<0.001]) (Abrahams et al. 2009).  Abrahams et al defined block failure as 
necessitating the use of additional general or spinal anaesthesia to complete the 
planned surgical procedure as all the blocks were used to provide surgical 
anaesthesia.  The systematic review and meta analysis by Abrahams does suggest 
that the use of ultrasound is superior to the use of a nerve stimulator.  It should 
also be noted that of the nine studies included in this part of this meta analysis 
only one used a combined femoral nerve and only sciatic nerve block for lower 
limb surgery.  The strength of this conclusion is further weakened by the fact 
that the largest study recruited only 126 patients with 4 out of nine studies 
recruiting less than 40 patients. 
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2.3.7 The use of the femoral nerve block and hip fracture to 
reduce pain scores and morphine consumption 
In 1995 Haddad et al randomised 50 patients with a fractured neck of femur to 
opiate analgesia or femoral 3-in-1 nerve block using a controlled prospective 
unblinded methodology (Haddad & Williams 1995).  Paraesthesia was elicited by 
a needle inserted perpendicular to the skin one centimetre lateral to the 
femoral artery and 0.3 ml/Kg of 0.25% bupivacaine was injected.  The pain 
visual analogue scores (VAS) were then recorded at 15 minutes, two hours and 
eight hours and complication rate and systemic analgesia required during the 
subsequent 24 hours were recorded.  A statistically significant reduction in mean 
pain VAS score, was noted between the group of 24 patients with a femoral 3-in-
1 nerve block and the 21 patients in the control group at 15 minutes (4.8 mm, 
range 1-8 mm; 6.8 mm, range 3-10 mm, p<0.05) and two hours (3.7 mm, range 
1-8 mm; 5.7 mm range 2-9 mm p<0.05) respectively post femoral 3-in-1 nerve 
blockade.  A reduction in respiratory complications in femoral 3-in-1 nerve block 
group (two incidences versus nine incidences) was recorded.  However Haddad 
et al failed to define the nature or severity of the respiratory complications or 
the number of the affected patients.  No difference was noted in the incidence 
of urinary tract, wound infection, skin break down, cardiac complications or 
proven deep vein thrombosis.  A statistically significant reduction in the number 
of doses of parental opiate given in the first 24 hours after the femoral nerve 
block was also recorded (35 doses versus 12 doses; p<0.05).  However Haddad et 
al provided no details of the doses of analgesia given, nature of the opiate 
analgesia or the prescribing procedures used.  Five patients were recruited to 
this study but their results are not included in the final analysis as this accounts 
for 10% of the total population of the study their removal from the study could 
confound the results and conclusions of this study.  This study was open to bias 
as many of the end points used were subjective.  The failure to define the 
outcome adequately further weakens this study and limits its usefulness. 
 
In 1988 Finlayson et al recruited thirty-six patients with traumatic femoral neck 
fractures attending the accident department during a three month period who 
received femoral 3-in-1 nerve blocks from one of the two authors (Finlayson & 
Underhill 1988). The effect of the block was assessed both subjectively and 
objectively.  Thirty patients reported a ‘worthwhile reduction in pain’ following 
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the procedure and this was supported by objective sensory testing in 29 
patients.  In all six patients who reported no benefit, the block had also failed 
on objective sensory testing. 
 
In 2003 the femoral 3-in-1 nerve block guided by loss of resistance was used in a 
pre-hospital setting to provide analgesia for 27 patients with a femoral shaft 
fracture to allow transport to hospital and hip radiography (Lopez et al. 2003a).  
The block produced a significant reduction in pain (p<0.05 in comparison to the 
pre-block pain score although a simplified verbal scale (SVS) from 0 (no pain) to 
4 (severe pain) was used to assess pain.  The use of a non standard pain score 
detracted from the impact of this study. 
 
In 2007 Monzon et al published a prospective, interventional, and uncontrolled 
study of the utility of the femoral 3-in-1 nerve block in patients with a traumatic 
fractured neck of femur (Monzon, Iserson, & Vazquez 2007).  Sixty three 
sequential adult patients were recruited with traumatic fractured neck of 
femur.  A loss of resistance technique was used to guide needle placement and 
0.3 ml/kg of 0.25% bupivacaine was injected under the fascia iliacus membrane.  
The physician tested the block’s efficacy by assessing cutaneous sensory loss.  
Pain assessments were done using a 10-point Likert Visual Analogue Scale (VAS) 
before, and at 15 minutes, two hours, and eight hours after the block.  Post 
femoral 3-in-1 nerve block pain was reduced in all patients, but not completely 
abolished in any patient.  Pre femoral 3-in-1 nerve block, the pain ranged from 2 
to 10 points (average 8.5) using the pain VAS; at 15 minutes post-injection, it 
ranged from 1 to 7 points (average 2.9); at two hours post-injection, it ranged 
from 2 to 6 points (average 2.3); at eight hours post-injection, it ranged from 4 
to 7 points (average 4.4).  Analgesic requests in the first 24 h after admission 
averaged 1.2 doses (range 1 to 4 doses) of diclofenac 75 mg. There were no 
systemic complications and only two local haematomas.  The confounding 
variables in this study were the inclusion of patients who became confused 
during the study period which could have invalidated the pain VAS assessment in 
these patients, the administration of unrecorded and uncontrolled oral analgesia 
during the study period and the use of different volumes of local anaesthetic in 
patients of different weight.  The study results suggest that a marked reduction 
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in pain VAS score may be possible 15 minutes after the injection of a relatively 
low volume and dose of local anaesthetic. 
 
A Cochrane meta-analysis by Parker et al in 2002 examined the effects of nerve 
blocks (inserted pre-operatively,intra-operatively or post-operatively) as part of 
the treatment for a hip fracture (Parker, Griffiths, & Appadu 2002). Parker et al 
analysed eight randomised or quasi-randomised trials involving 328 patients and 
was published in 2002.  He concluded that nerve blocks resulted in a reduction 
of the quantity of parenteral or oral analgesia administered to control pain from 
the fracture or during surgery and a reduction in reported pain levels.  It was 
not; however, possible to demonstrate any other outcome benefits.  This may 
have been due, in part, to the heterogeneity of methodology of the studies 
included and the relatively small number of patients recruited to the studies. 
2.4 Summary of Chapter 2 
The femoral 3-in-1 nerve block, (femoral nerve, fascia iliacus, or anterior psoas 
compartment block) appears to be a viable solution to provide analgesia to 
patients with a fractured neck of femur prior to definitive surgical fixation.  It 
blocks the majority of the five nerves innervating the hip and since the 
acetabulum is normally undamaged by surgery or trauma it may block the three 
most important nerves (femoral, obturator and lateral cutaneous nerve).  The 
femoral 3-in-1 nerve block is technically simple in contrast to epidural 
anaesthesia and requires little extra monitoring and nursing care.  Ultrasound 
offers the potential of an increased success rate with fewer complications but it 
is associated with the cost of the ultrasound machine and extra of staff training.  
In contrast, the loss of resistance technique is technically simple and cheap but 
potentially inaccurate and associated with a higher complication rates. 
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3 The development of study protocols designed to 
answer the research questions for the project 
3.1 Background 
This project will answer research questions which will allow the development a 
protocol to provide safe, effective regional analgesia to the 60000 to 70000 
patients admitted annually to UK hospitals with a fractured neck of femur 
(Bottle & Aylin 2006).  The hospital mortality for patients with a fractured neck 
of femur in a large UK study was 14.3% with cardiac aetiologies predominating in 
the first 2 days (Bottle & Aylin 2006).  A study has suggested a link with effective 
pain relief and improved cardiac morbidity and reduced mortality in patients 
with a traumatic fractured neck of femur (Matot et al. 2003).  Anaesthetists 
currently utilise the femoral 3-in-1 nerve block to provide effective pain relief 
postoperatively but these techniques use large, potentially toxic doses of local 
anaesthetic.  Ultrasound guided nerve blocks have been associated with an 
increased success rate, lower local anaesthetic doses and shorter onset times 
than traditional techniques (Marhofer et al. 1998).  This will reduce the pain 
experienced by patients with a fractured neck of femur but may also result in 
reduced mortality and morbidity. 
3.2 Research questions 
In order to develop a method of providing pain relief to patients with a fractured 
neck of femur we need to answer the questions below: 
1. Which method do we use to site the local anaesthetic? 
2. Which local anaesthetic should we use? 
3. What is the effective dose of levobupivacaine for a femoral 3-in-1 nerve block 
4. What is the duration of analgesia from the EC95 dose of levobupivacaine? 
5. What is the pharmacokinetic profile of levobupivacaine in the population of patients 
with a fractured neck of femur? 
6. What is the clinical anatomy of the femoral 3-in-1 nerve block? 
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3.2.2 Research question 1: Which method should we use to site 
local anaesthetic for the femoral 3-in-1 nerve block? 
There are currently three methods available to guide the injection of local 
anaesthetic around the femoral nerve; loss of resistance, nerve stimulation and 
ultrasound.  The use of nerve stimulators is the current standard but their use on 
patients with a fractured neck of femur will potentially cause significant 
discomfort.  No clinical study has compared all three techniques for a femoral 3-
in-1 nerve block.  Utilising the data from previous studies we calculated that 180 
patients would need to be recruited to a study to have 80% power to 
discriminate between all three methods (see Chapter six section 6.4.7 for the 
sample size calculation).  The efficacy of a nerve block was determined by 
assessment of the sensory and motor changes associated with the local 
anaesthetic action on nerve fibres.  Indirect measures of success such as 
postoperative pain scores, reduced morphine consumption and the need to 
convert to general anaesthesia have multiple confounding factors.  Primary total 
hip arthroplasty patients were chosen as the patient population for this study 
due to the subjective nature of sensory testing, the inability to use the current 
standard method (nerve stimulator) on unfixed fractures, the large number of 
patients needed (180) and the inability to conduct motor testing on a limb with 
a fracture. 
3.2.1.1 Summary of methodology 
We recruited 180 competent patients scheduled for elective primary total hip 
arthroplasty on three hospitals in Glasgow, Scotland.  A femoral 3-in-1 nerve 
block was performed preoperatively using either ultrasound, loss of resistance or 
nerve stimulator to guide the positioning of the needle tip.  Sensory and motor 
function in the upper leg was assessed to determine the effectiveness of the 
nerve block at 10 minute intervals for 30 minutes.  Spinal anaesthesia was used 
in the vast majority of cases however if the spinal block was considered 
inadequate or the spinal was technically difficult general anaesthesia was used 
at the discretion of the attending consultant anaesthetist.  A primary total hip 
arthroplasty was performed using standard surgical procedures.  Postoperatively, 
all patients received regular paracetamol, patient controlled morphine and 
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titrated doses of morphine as required to provide a pain NRS (numerical rating 
scale) scores <30/100 (mild pain). At six hours and 24 hours postoperatively the 
acute mental test score, total morphine usage and patient satisfaction scores 
were recorded.  We also recorded the day and time the patient was first 
mobilised by physiotherapy and the hospital mortality.  Please see chapter six 
for a description and full discussion of this study. 
3.2.3 Research question 2: Which local anaesthetic should we 
use? 
The choice of local anaesthetic was dictated by two factors namely, duration of 
action and toxicity.  bupivacaine and its stereoisomer levobupivacaine have the 
longest duration of action of any commercially available local anaesthetic agent 
in the UK, with 90% hepatic metabolism and a metabolic half life of 3.5 hours in 
adults (Rossi S 2006).  A single injection of bupivacaine or levobupivacaine will 
provide pain relief (measured by time to first dose of analgesia) for a median of 
approximately 16.5 hours (Urbanek et al. 2003).  Levobupivacaine is the S (-) 
stereoisomer of the racaemic mixture of bupivacaine.  There is convincing 
evidence from in-vitro studies on sodium channels of guinea pig myocytes 
(Valenzuela et al. 1995), from in-vivo animal studies on anaesthetised sheep 
(Chang et al. 2000;Huang et al. 1998) and from human volunteer studies 
(Bardsley et al. 1998) that the probability of an adverse event (Bardsley et al. 
1998) related to the cardiac and CNS toxicity of local anaesthetics can be 
reduced when levobupivacaine is used instead of bupivacaine. 
The vast majority of local anaesthetic dosing is based on administering the 
maximum safe dose were it to be accidentally given intravenously.  This dose is 
2 mg/kg for both levobupivacaine and bupivacaine (Mulroy 2002).  We currently 
have no information from studies that would allow dosing based on the analgesic 
effectiveness of levobupivacaine for the femoral 3-in-1 nerve block.  Sequential 
plasma measurements of levobupivacaine after femoral 3-in-1 nerve block in 
children showed that the concentration increased rapidly from baseline to peak 
after 10 to 45 minutes (Paut et al. 2004).  It is necessary to determine the 
effective dose in patients with a fractured neck of femur as they are usually 
elderly and they are therefore at theoretically greater risk of local anaesthetic 
Chapter 3 
 
Page 55 of 287 
toxicity due to reduced plasma clearance (Knudsen et al. 1997;Paut et al. 2004).  
In contrast, the efficacy of local anaesthetics is greater in peripheral (Paqueron 
et al. 2002) and neuraxial blocks (Bromage 1969;Paqueron et al. 2002;Simon et 
al. 2004) in elderly patients.  The Summary of Product Characteristics updated 
on the eMC: 26/08/2009 for levobupivacaine states in Section 4.4 Special 
warnings and precautions for use ‘The lowest dosage of local anaesthetic that 
results in effective anaesthesia should be used to avoid high plasma levels and 
serious adverse effects.’ 
3.2.4 Research question 3: What is the effective dose of 
levobupivacaine for a femoral 3-in-1 femoral nerve block? 
Several studies have attempted to determine the effective concentration but 
each had methodologically issues which limit the interpretation of the results.  
The currently accepted method is to determine the effective concentration 
(with a fixed volume of local anaesthetic) in 50% of patients (EC50) using a binary 
regression modelling and estimate the EC95 and the 95% confidence intervals for 
both the EC50 and EC95.  This is done by testing the effectiveness of various 
concentrations while the volume remains constant.  The only variable should be 
the concentration of local anaesthetic and hence dose of local anaesthetic 
administered.  Casati et al increased and decreased the volume of local 
anaesthetic for the femoral 3-in-1 nerve block and kept the concentration the 
same.  Therefore the total drug dose and the volume were both altered by each 
change in volume (Casati et al. 2007).  A study by Taboada et al used identical 
methodology to determine the volume of 1.5% mepivacaine for the subgluteal 
and popliteal approach to the sciatic nerve (Taboada et al. 2006) and two 
further studies by Gupta et al and Duggan et al used the same methodology to 
calculate the median effective volume for the supraclavicular block (Duggan et 
al. 2009;Gupta & Hopkins 2008).  In all studies no details on the quality control 
for both the volume and concentration of local anaesthetic was given, no clear 
study end point or justification of sample size was given and no justification of 
the value by which the concentration or the volume was changed (stepping 
value) was given.  The current information available is not adequate to 
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recommend an effective dose of local anaesthetic for peripheral regional 
anaesthesia. 
3.2.3.1 Summary of methodology 
To determine the effective dose of levobupivacaine, patients with a traumatic 
femoral neck of femur fracture were recruited prior to surgical fixation.  All 
patients recruited to the clinical trial received standard anaesthesia and surgical 
fixation of their femoral neck fracture.  Prior to operative fixation of the 
fractured neck of femur an ultrasound guided femoral 3-in-1 nerve block was 
used to anaesthetise the nerves supplying the proximal femur.  At 10 minute 
intervals the sensation to pin prick and cold in the upper leg and pain numerical 
rating scale (NRS) scores were recorded for a total of 30 minutes.  A successful 
femoral 3-in-1 nerve block was defined as ≥20/100 decease in the pain NRS score 
at 30 minutes with a sensory change (to cold or pin prick) in skin supplied by the 
femoral nerve.  The concentration of levobupivacaine was increased or 
decreased if the femoral 3-in-1 nerve block was ineffective or effective 
respectively.  The concentration of levobupivacaine tended towards a 
concentration which was successful in 50% of patients (EC50).  Please see chapter 
four for details of this clinical trial. 
3.2.5 Research question 4: What is the duration of analgesia 
from the EC95 dose of levobupivacaine? 
In the study by Urbank et al the mean duration of analgesia (measured by time 
to first dose of analgesia) for the femoral 3-in-1 nerve block with 20 mls of 0.5% 
levobupivacaine sited using a nerve stimulator in various procedures was a mean 
of 16 hours 41minutes with 95% confidence intervals of (14 hours 4 minutes to 19 
hours 18 minutes) (Urbanek et al. 2003).  The vast majority of patients should 
have surgical fixation of the fractured neck of femur within 24 hours of 
admission within day time working hours (Scottish Intercollegiate Guidelines 
Network (SIGN)-Guideline 111), therefore if the duration of analgesia is longer 
than 24 hours it will prevent early mobilisation of the patient.  In the past, 
delayed surgical management and therefore delayed mobilisation has been 
associated with increased mortality as discussed in chapter one.  Jain et al 
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examined a series of 62 elderly patients within their cohort with severe co-
morbidity treated non-operatively (Jain, Basinski, & Kreder 2003).  They found 
that non-operative treatment with bed rest was 3.8 times more likely to be 
associated with mortality compared to non-operative treatment and operative 
treatment with early mobilisation (95% CI 1.1 to 14).  However, If the duration 
of analgesia provided by the femoral 3-in-1 nerve block is too short it may also 
ameliorate any benefit. 
3.2.4.1 Summary of methodology 
Once the effective concentration to provide analgesia in 95% of patients (EC95) 
had been determined the duration of analgesia by a single 30ml dose of the EC95 
of levobupivacaine was determined.  Patients with a traumatic proximal femoral 
fracture were recruited prior to surgical fixation.  Prior to operative fixation of 
the fractured proximal femur an ultrasound guided femoral 3-in-1 nerve block 
was used to anaesthetise the nerves supplying the proximal femur.  At 10 minute 
intervals the sensation to pin prick and cold in the upper leg and pain verbal 
analogue scores (VAS) were recorded for a total of 30 minutes.  A successful 
femoral nerve block was defined as ≥20/100 decease in the pain NRS score after 
30 minutes associated with a sensory change (to pin prick and cold) in skin 
supplied by the femoral nerve.  If the nerve block was defined as being 
successful then the duration of analgesia was recorded hourly until the pain 
score returned to the starting value.  Please see chapter five for details of this 
clinical trial.  
3.2.6 Research question 5: What is the pharmacokinetic profile 
of levobupivacaine in the population of patients with a 
fractured neck of femur? 
The population of patients that suffer a fractured neck of femur often have 
multiple co-morbidities as shown by the study of Bottle et al (Bottle & Aylin 
2006).  Bottle et al noted that only 29.2% of those patients operated on within 
24 hours of admission had no recorded significant co-morbidity, and this 
decreased to 19.2% in those patients delayed greater than two days.  The 
femoral 3-in-1 nerve block has been associated with rapid absorption which 
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raises the possibility of systemic toxicity (Paut et al. 2004).  The Summary of 
Product Characteristics (SmPC) last updated on the eMC: 26/08/2009 for 
levobupivacaine states in Section 4.2 Physiology and method of administration 
that ‘Debilitated, elderly or acutely ill patients should be given reduced doses of 
levobupivacaine commensurate with their physical status.’ (Abbott Laboratories 
Limited 2010).  The SmPC also states that levobupivacaine should be used in 
reduced dose in those patients with liver impairment or cardiac problems 
(Abbott Laboratories Limited 2010).  It is therefore prudent to characterise the 
pharmokinetic profile of the EC95 concentration of levobupivacaine before 
conducting a large multicentre study by non-anaesthetists outside the operating 
theatre environment. 
3.2.5.1 Summary of methodology 
The blood samples to answer this question were collected using the protocol 
outlined in this section,  The concentration of levobupivacaine used was the EC95 
which was determined from the Up/Down Dixon’s method (Dixon 1965) to 
determine the effective dose of local anaesthetic.  A blood sample was taken 
before the insertion of the EC95 dose of levobupivacaine and at 5, 10, 20, 30 and 
60 minutes post insertion of femoral 3-in-1 nerve block from a cannula.  The 
levobupivacaine blood samples were centrifuged and frozen to -200C 1 hour after 
the first sample was collected for delayed batch analysis.  Please see chapter 
five for details of this clinical trial. 
3.2.7 Research question 6: What is the clinical anatomy of the 
femoral 3-in-1 block? 
The femoral 3-in-1 nerve block is a misnomer as the majority of investigators 
have been unable to consistently anaesthetise the femoral, obturator and lateral 
cutaneous nerves with a single injection (Capdevila et al. 1998;Lang et al. 
1993;Parkinson et al. 1989;Ritter 1995).  A recently published study by Dolan et 
al reignited this debate by demonstrating a motor block of the obturator nerve 
in 44% of cases and a loss of sensation in the medial aspect of the upper thigh in 
60% of ultrasound guided femoral 3-in-1 nerve blocks (Dolan et al. 2008).  We 
undertook pilot research work to determine the maximal spread of 30 ml of 
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black latex dye injected lateral to the femoral nerve under the fascia iliacus 
membrane.  It was hypothesised that the black latex dye may include the 
obturator nerve or its branches as a result of proximal spread or spread across 
the muscular planes in the upper thigh. 
3.2.7.1 Summary of methodology 
In the Anatomy department of Glasgow University two adult female cadavers 
who had donated their bodies to medical science where dissected for this study.  
The two unfixed cadavers had bilateral ultrasound guided femoral 3-in-1 nerve 
blocks with 30 ml of black latex.  They were then fixed and 3 months later 
dissected to determine the maximal extent of the spread of black latex dye.  
The results of this pilot study are discussed in chapter seven. 
3.3 Summary of protocols used in this project 
An initial randomised multicentre trial compared the efficacy of using 
ultrasound, nerve stimulator and loss of resistance techniques to guide the 
needle for femoral 3-in-1 nerve block in patients scheduled for an elective 
primary total hip arthroplasty.  Sensation and movement in the upper leg was 
assessed to determine the effectiveness of the method of guiding the femoral 3-
in-1 nerve block at 10 minutes intervals for 30 minutes. 
The dosing and safety of utilising levobupivacaine to provide femoral 3-in-1 
nerve block was determined in the fractured neck of femur patient population.  
Levobupivacaine dosing was determined using a sequential Dixon’s up/down 
methodology.  Femoral 3-in-1 nerve blocks were performed and the 
concentration of levobupivacaine was increased or decreased for an ineffective 
or effective nerve block respectively until the concentration of levobupivacaine 
was effective in 50% of patients (EC50).  A final clinical trial assessed 
levobupivacaine pharmacokinetics (to ensure that serum levels were within safe 
limits for the estimated EC95 dose of levobupivacaine) and the 
pharmacodynamics (to assess duration of analgesia) using serial blood sampling 
and by monitoring pain NRS scores respectively.  A final pilot dissection study 
was conducted to determine the extent of the spread of a 30 ml volume in the 
space underneath the fascia iliacus membrane and lateral to the femoral nerve.
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4 A dose finding clinical trial for analgesia of a 
broken hip 
4.1 Aim 
To determine the effective concentration of 30 ml of levobupivacaine required 
to produce a reduction in pain numerical rating scale (NRS) score of ≥20 points 
on a 100 point scale in 50% of patients (EC50) and 95% of patients (EC95) with a 
fractured neck of femur using an ultrasound guided femoral 3-in-1 nerve block. 
4.2 Study design 
The EC50 and EC95 for levobupivacaine with an ultrasound guided femoral 3-in-1 
nerve block were determined using the sequential up down (Dixon) methodology 
(Dixon 1965). 
4.3 Study Population 
We recruited competent patients with a fractured neck of femur. 
4.3.1 All patients recruited to this trial were required to meet 
the following inclusion criteria 
• Patients with a fractured neck of femur 
• American Society of Anesthesiology (ASA) grading ≤4/5 (Little 1995) 
• Able to give informed consent 
• Resting pain numerical rating scale (NRS) score of greater than 50 
on a 100 scale before recruitment (moderate pain). 
• Able to cooperate with sensory testing of lower limb function 
4.3.2 The following exclusion criteria were applied to patients 
recruited to this trial 
• Acute mental test score of ≤7/10 at any time preoperatively 
• Allergy to local anaesthetic 
• Contra-indication to levobupivacaine administration 
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• Signs, symptoms or laboratory evidence of: 
o local infection (at intended site of needle insertion) 
o systemic sepsis which would normally preclude regional analgesia 
• Pre-existing known neurological deficit (sensory or motor) affecting the 
lower limb 
• Patient with lower limb amputations or other condition affecting 
sensation in the lower limbs 
4.3.3 Criteria for withdrawal of patient from the trial 
• Patient initiated withdrawal.  Patients could withdraw from the clinical 
trial at any time. 
• Administration of regional anaesthesia or analgesia not in the protocol 
• Failure of rescue analgesia ‘top-up’ with a 20 ml injection of 0.25% 
levobupivacaine through the catheter sited after the initial injection of 30 
ml of levobupivacaine. 
• A protocol violation leading to a patient safety issue or a quality issue 
• An urgent safety issue with the clinical trial protocol 
4.4 Methodology 
All patients were recruited preoperatively and were scheduled for fixation of the 
fractured neck of femur.  Consented patients were transferred to the operating 
theatre suite and initial sensory function testing and a pain NRS score was 
performed on arrival in theatre.  In order to be eligible for recruitment the 
patient had to have a pre-block resting pain NRS score of ≥50/100.  Femoral 
3-in-1 nerve blocks were inserted preoperatively using ultrasound needle 
guidance and 30 ml of levobupivacaine the concentration of which was 
determined by the response of the previous patient.  Needle placement for the 
femoral 3-in-1 nerve block was guided by ultrasound.  Ultrasound images of the 
common femoral artery, femoral vein and nerve in the short axis were obtained 
and a 100 mm or 50 mm 18G Contiplex Tuohy tipped needle (supplied by B-Braun 
Ltd.) was advanced in plane until the tip of the needle was under the fascia 
iliacus membrane immediately lateral to the femoral nerve.  After a ‘negative’ 
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aspiration to detect accidental intravascular placement, the local anaesthetic 
dose was injected.  Real time ultrasound images were used to ensure that the 
injected local anaesthetic (30 ml of levobupivacaine) spread around the femoral 
nerve with associated ‘tenting’ of the fascia iliacus membrane.  After injection 
of 30 ml of levobupivacaine a catheter was threaded through the 100 mm or 50 
mm 18G Contiplex Tuohy tipped needle and its position confirmed by visualising 
movement of the catheter under the fascia iliacus membrane.  The 
concentration of levobupivacaine was 0.10% for the first patient recruited.  
Subsequent concentrations were increased or decreased by 0.025% (the stepping 
value (δ)) dependant on whether the dose provided ineffective or effective 
analgesia respectively.  At 10, 20 and 30 minutes after the injection of 
levobupivacaine pain numerical rating scale (NRS) scores and sensory testing on 
the upper thigh was preformed. 
Effective regional analgesia was defined as a ≥20 point reduction in pain NRS 
score on a 100 point scale with evidence of a sensory impairment in the upper 
anterior thigh (effective regional analgesia) then the concentration of 
levobupivacaine was decreased by 0.025% for the next patient recruited.  
Conversely, if no reduction in sensory impairment was detected on testing in the 
upper anterior thigh and the pain score decreased by less than 20 points on a 
100 scale (ineffective regional analgesia) then the concentration of 
levobupivacaine for the next patient recruited was increased by 0.025%.  If the 
sensory response in the anterior upper thigh and the pain NRS score were at odds 
the response was defined as equivocal and the concentration was repeated.  If 
the 30 ml dose of levobupivacaine failed to provide analgesia at 30 minutes post 
insertion, a further 20 ml of 0.25% levobupivacaine was administered through 
the femoral nerve catheter to provide rescue analgesia.  If, following the 
injection of 20 ml of 0.25% levobupivacaine, the pain NRS score was not ≤30/100 
after a further 30 minutes ineffective regional analgesia was attributed to a 
failure of placement of the initial 30 ml dose of levobupivacaine.  
4.4.1 Interim analysis 
An interim analysis was performed after 16 patients had been recruited to 
estimate the optimal stepping value (δ).  The concentration stepping value (δ) 
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was reduced from 0.025% to 0.005% to increase the accuracy of the final 
estimation of the EC50 and the EC95. 
4.4.2 Assessment of pain scores 
A pain score measures a patient’s pain intensity or other features. Pain scores 
are based on self-report, observational (behavioural), or physiological data.  A 
self-reported score such as the Numeric Rating Score provides the most accurate 
data.  It may be used for adults and children over 10 years old or older.  Pain 
scores were assessed on a 100 point Numerical Rating Scale (NRS) scoring 
system.  The following verbal descriptions were used to guide patients; 0-29 no 
to mild pain, 30-69 moderate pain and 70-100 severe pain.  Pain NRS scores were 
used throughout all clinical studies in this thesis as the pain visual analogue 
scale (VAS) scoring was found to be very difficult to use in patients with a 
fractured neck of femur.  The pain NRS scores were used throughout this 
project. 
4.4.3 Assessment of sensory function  
The primary sensory response was based on the sensory response of the middle 
third of upper thigh.  The patient’s sensory function was assessed by the 
intensity of a pin prick sensation and cold sensation produced by melting ice.  
Pin prick sensation was measured using a blunted 25G orange needle.  The 
patient was asked to grade the intensity of the sensory response to the ‘orange’ 
needle by verbalising or marking a line from 0 (no sensation) to 100.  100 was 
defined as the same intensity of sensation as the contra lateral upper middle 
third of the thigh.  Melting ice was also used as a stimulus and the patient was 
asked if the cold sensation was reduced on the side on which the femoral 3-in-1 
nerve block was performed compared with the contra lateral (unblocked side) on 
the medial (M), anterior(A) and lateral region(L) of the upper thigh (Figure 4-1). 
The change in sensation associated with effective regional analgesia was defined 
as a reduction in sensation to blunted 25G needle in the anterior aspect of the 
upper thigh (area marked as A in diagram 1) of ≤30/100 or a reduction in cold 
sensation to melting ice in comparison with the contra lateral area of the thigh 
in the upper anterior aspect of the thigh. 
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Figure 4-1: The surface anatomy of the upper thigh: The anterior (A), lateral (L) and medial 
(M) aspects of the upper thigh are shown in the diagram below. 
 
Image from personal collection of Dr Malcolm Watson 
 
4.4.4 Summary of an effective or ineffective block 
Effective, ineffective or equivocal femoral 3-in-1 nerve blocks were defined by 
the answers to questions 1 and 2 below and summarised in table 4.1. 
Question 1 
Has there been a reduction in pain NRS score by ≥20 points from pre block pain 
NRS score at 30 minutes post block?  (Yes/No) 
Question 2 
Has there been a sensory change in anterior (A) aspect of thigh at 30 minutes 
post block? (please see section 4.4.3 ‘Assessment of sensory function’) 
 (Yes/No) 
Table 4-1: Summary of outcome: effective, ineffective and equivocal regional 
analgesia 
Outcome of block Next concentration Answers to questions1 and 2 
Ineffective regional analgesia Increased (1-No/2-No) 
Effective regional analgesia Decreased (1-Yes/2-Yes) 
Equivocal regional analgesia Repeat concentration (1-Yes/2-No or 1-No/2-Yes) 
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4.4.5 Secondary end points 
• Regression analysis of sensory scores against pain NRS scores at 10, 20 and 
30 minutes 
• Sensory function of the upper middle third of the thigh (femoral nerve) 
was tested at 0 minutes (before insertion of levobupivacaine) and at 
10 and 20 minutes post insertion of 30 ml of levobupivacaine. 
4.4.6 Standards 
This clinical trial was conducted to ICH–GCP ( 2004), it was audited by Greater 
Glasgow and Clyde Heath board (please see report included in appendix 1) with 
only minor findings, all Investigational and Medicinal Products were produced by 
an accredited pharmacy production unit, the data was recorded and processed 
to comply with ISO 9001:2008 and the statistical analysis has been supervised by 
Dr Alex McConnachie, senior statistician at the Robertson centre, Glasgow 
University. 
4.4.7 Sample size calculation 
Sample size calculation has never been adequately discussed in any published 
study using the sequential up/down Dixon methodology (Pace & Stylianou 2007).  
A full discussion of the initial sample size calculation is included in Appendix 
two; however, in summary, it depends on two variables, the stepping value and 
the difference between the starting value and the actual value of EC50 of 
levobupivacaine.  If the stepping value is large then it will require fewer 
patients to reach the EC50 value but the precision and accuracy with which the 
probability model will be able to estimate the levobupivacaine EC50 will be 
reduced.  In contrast, a small stepping value will increase the precision and 
accuracy with the EC50 can be estimated but will also increase the number of 
patients that need to be recruited.  To minimise this effect a low starting 
concentration of levobupivacaine and a large stepping value was initially chosen 
and the steeping value was optimised using the information from an interim 
analysis.  To estimate the optimal stepping value a probability model was 
constructed with the data (for the first 16 patients) for concentration of 
levobupivacaine against probability of an effective femoral 3-in-1 nerve block 
using probit logistic regression analysis.  The optimum stepping value which 
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needed the minimum number of patients for the greatest accuracy and precision 
is fulfilled when the steeping value (δ) is 2/3 to 3/2 of the standard deviation 
(σ) of the probit logistic regression model. 
4.5 Results 
4.5.1 Demographics 
A total of 40 patients with traumatic proximal femoral fractures were 
prospectively recruited from 1 February 2010 to 17 November 2010.  The 
average age of the 40 patients recruited was 78.9 years with an interquartile 
range of 71.4 to 83.5 years.  The median time taken to insert a femoral 3-in-1 
nerve block was 62 seconds with an interquartile range of 48 to 94 seconds.  The 
mean (median) number of skin punctures and needle advancements was 1.025(1) 
and 1.25(1) respectively with a standard deviation (interquartile range) of ± 0.16 
(1 to 1) and ± 0.6 (1 to 1), respectively. 
4.5.2 Adverse event reported during the clinical trial 
The following adverse events listed in Table 4-2 were reported during the study 
to the MHRA and the ethics committee. 
Table 4-2: Adverse event log 
Patient randomisation 
number 
Adverse event 
13 
Patient of died of metastatic breast cancer complicated 
by chronic obstructive airways disease, morbid obesity, 
congestive heart failure, renal failure and type II diabetes 
mellitus. 
27 Pulmonary tuberculosis 
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4.5.3 Physiological observations 
The physiological observations of the patients pre-block and at 10, 20 and 
30 minutes after the femoral 3-in-1 nerve block are shown in Table 4-3. 
 
Table 4-3: Physiological observations pre-block and at 10, 20 and 30 minutes after the 
femoral 3-in-1 femoral nerve block 
 Pre-block 10 minutes 
post block 
20 minutes 
post block 
30 minutes 
post block 
Systolic BP median 
(interquartile range) 
143 
(126-155) 
142 
(124-162) 
141 
(123-157) 
138 
(122-170) 
Diastolic BP median 
(interquartile range) 
75 
(68-80) 
69 
(62-78) 
72 
(61-78) 
70 
(61-80) 
O2 saturation median 
(interquartile range) 
94 
(93-96) 
95 
(94-97) 
95 
(94-97) 
96 
(93-97) 
Number of litres of 
supplementary O2 median 
(interquartile range) 
0 
(0-1) 
0 
(0-2) 
0 
(0-2) 
2 
(0-2) 
Respiratory rate median 
(interquartile range) 
14 
(12-16) 
14 
(12-16) 
15 
(12-18) 
16 
(12-16) 
Pulse rate median 
(interquartile range) 
79 
(70-92) 
81 
(71-92) 
81 
(71-96) 
76 
(69-91) 
 
No statistically significant changes in physiological observations were found (all 
interquartile ranges for all the parameters measured overlapped) during the 
period of observation. 
4.5.4 Summary of results of sequential up/down Dixon’s 
methodology 
One patient did not respond to a ‘rescue top up’ (an injection of 20 ml of 0.25% 
levobupivacaine through the femoral nerve catheter sited after the initial 
injection of 30 ml of levobupivacaine) with a reduction in pain NRS score to 
≤30/100 after 30minutes.  Therefore, 39 patients had technically successful 
femoral 3-in-1 nerve blocks.  A further three patients had conflicting pain NRS 
scores and the sensory assessments and were therefore deemed to have 
equivocal results and were excluded from the final and interim EC50 and EC95 
analysis.  The data for 36 patients was used for primary analysis to estimate the 
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EC50 and EC95 of 30 ml levobupivacaine required to provide effective analgesia, a 
summary of this data in shown below in table 4-4. 
 
Table 4-4: Summary of data for EC50 and EC95 estimate 
Concentration of 
levobupivacaine (%)  
Effective 
analgesia 
Ineffective 
analgesia 
Equivocal 
/technical 
failure 
% Effective 
anaesthesia 
Number 
patients 
analysed 
0.1 1 0 0 100 1 
0.075 1 0 0 100 1 
0.05 5 0 0 100 5 
0.045 1 0 0 100 1 
0.04 1 0 0 100 1 
0.035 2 0 0 100 2 
0.03 6 1 1 86 7 
0.025 5 9 3 36 14 
0.02 1 2 0 33 3 
0.015 0 1 0 0 1 
Total patients 23 13 4  36 
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4.6 Results Part 1 Calculation of ED50 and ED95  
The aim of this trial was to estimate the levobupivacaine EC50 and EC95 
concentrations from the logistic regression model of the loge natural (ln) 
concentration-response relationship. 
 
Figure 4-2: Graph of natural loge (concentration) of levobupivacaine against percentage of 
effective femoral 3-in-1 nerve blocks 
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In order to estimate the EC50 and EC95 of levobupivacaine with logistic regression 
analysis it was assumed that for a given log natural (loge) concentration, x, the 
probability, P(x), that the concentration will be effective was: 
( ) 




Φ=
σ
µ-x
 xP  
Where Φ was defined as the cumulative density function of a standard Normal 
distribution, µ was the concentration at which 50% of the population would 
achieve pain relief, or EC50 and σ was the standard deviation of the Normal 
distribution. 
Since P(µ) = Φ(0) =0.5. 
The regression model that was used to analyse the binary response data in this 
clinical trial, was the probit model.  This model assumed that for a given 
concentration, x, the probability, P(x), that the concentration will be effective 
was: 
( ){ } xxP 10-1 β+β=Φ  
(Where β0 is the y-intersect and β1 is the gradient of the best fit line) 
 
which is equivalent to the standard linear regression model.  Minitab 15 software 
was used to estimate β0 and β1 and obtain standard errors of these estimates. 
The EC50 or µ can be written as: 
 
( ){ } µββµ 10-1 P +=Φ  
{ } µββ 10-1 0.5 +=Φ   (Since the probability of µ is 50% then ( ){ } 5.0P =µ ) 
 
µββ 100 +=  ( Φ  is the cumulative normal distribution function,  
so { } 00.5-1 =Φ  
1
0- β
β
=µ  
Under the probit model the EC95 is given by: 
 
{ } 9510-1 EC0.95 ββ +=Φ  
1.644854= 9510 ECββ +  
EC95= (1.644854- 0β ) 1β          
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4.6.1 Calculation of the 95% confidence interval (CI) for the 
EC95 and the EC50 
The 95% Confidence Interval (CI) for the EC95 and EC50 of levobupivacaine 
required the use of a mathematical technique (the delta technique) utilising 
matrices as any change in either 0β  or 1β  altered the both parameters.  A 
change in the gradient of the best fit line ( 1β ) affected the Y-axis intersection 
( 0β ).  The delta method was used to give an estimate of the combined errors by 
transformation of the parameters β0, β1 and their variance-covariance matrix. 
4.6.1.1 Estimated values for EC95 and EC50 
The estimate of EC95 and EC50 depended the whether those patients defined as a 
technical failure and equivocal regional analgesia are included in the final 
analysis. 
 
Definition one  If all patients are included in the analysis and those 
with equivocal regional analgesia and the technical failure are included as 
ineffective regional analgesia then 
EC50=0.0266% with 95% CI 0.0240% to 0.0295% 
EC95=0.0381% with 95% CI 0.0345% to 0.0417%  
 
Definition two  If patients with equivocal regional analgesia were 
included as unsuccessful regional analgesia blocks but the technical failure was 
excluded then 
EC50=0.0264% with 95% CI of 0.0237% to 0.0294% 
EC95=0.0381% with 95% CI of 0.0342% to 0.0415% 
 
Definition three  If patients with equivocal regional analgesia and the 
technical failure were excluded then 
EC50=0.0255% with 95% CI of 0.0229% to 0.0284% 
EC95=0.0357% with 95% CI of 0.0332% to 0.0383% 
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In summary, the influence of the technical failure and equivocal blocks was 
minimal and it is possible to argue that the equivocal regional analgesia and or 
the technical failures should be included to maximise the amount of data used in 
the calculation.  The final result for the EC50 and EC95 was given by method three 
as defined in the protocol. 
4.7 Results: Part 2: Calculation to determine the 
concentration stepping value (δ) 
The most accurate estimate of EC50 and EC95 will be given using probit logistic 
regression analysis if the stepping value (δ) was the region of σ (3/2σ to 3/2σ).  
Initially, the stepping value (δ) was set at 0.025; this was revised based on the 
results of a planned interim analysis after the first 16 patients had been 
recruited.  The optimal stepping value (δ) was then changed to be as close to σ 
as possible (please see Appendix three for the interim analysis results). 
4.7.1 Interim analysis Optimum stepping value (δ) (16 patients) 
The probit logistic regression model gave the parameter estimates in table 4-5: 
Table 4-5: Effective and ineffective regional analgesia versus concentration (16 patients) 
Predictor Coefficient SE Coefficient Z P 
Constant(β0) -5.982 615.746 -0.010 0.992 
Concentration(β1) 233.706 24629.804 0.009 0.992 
 
β0=-5.982 
β1=233.706 
 
The estimated value of the standard deviation (σ) was 0.00428% 
The stepping value of 0.025% was outside the optimal range of stepping value 
(3/2σ to 3/2σ).  The concentration stepping value (δ) was therefore reduced to 
0.005%. 
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4.7.2 Final analysis Optimum stepping value (δ) (40 patients) 
Probit logistic regression analysis model gave the parameter estimates in table 4-6: 
Table 4.6: Effective and ineffective regional analgesia versus concentration (40 patients) 
Predictor Coefficient SE Coefficient Z P 
Constant(β0) -5.04224 2.11487 -2.38 0.017 
Concentration(β1) 196.100 80.6845 2.43 0.015 
 
β0=-5.04224 
β1=196.1 
 
The estimated value of the standard deviation (σ) was 0.0051  
This was between 2/3 and 3/2 of the concentration stepping value of 0.005%. 
Chapter 4 
Page 74 of 287 
4.8 Results Part 3 Regression analyses of sensory scores 
against pain NRS scores. 
A placebo analgesic effect may be difficult to separate from true analgesia due 
to the subjective nature of pain.  Sensory testing was included in the protocol to 
confirm that any analgesic effects recorded were associated with a sensory 
change and therefore were a result of the pharmacologic effects of 
levobupivacaine.  Two modes of sensory response were tested; cold sensation in 
response to ice, and prick response to a blunt 25G needle as very little published 
data was available on which to base the protocol.  The contra lateral 
(unblocked) leg was used as the control.  The work of Marhofer et al had 
suggested that the analgesic response was correlated to a ≤30/100 sensory score 
to 25G blunted needle and the protocol was based on this information (Marhofer 
et al. 1997).  We found that the relationship between pin prick sensation rated 
0-100 at 30 minutes after the injection of levobupivacaine and a ≥20/100 
reduction in pain NRS scores was not as described by Marhofer et al (Marhofer et 
al. 1997).  In contrast, the reduction in cold sensation was frequently associated 
with a ≥20/100 reduction in pain NRS score.   
 
In this section of the results we determined whether a relationship existed 
between sensory pin prick response and analgesia and the temporal nature of 
any relationship (please see figures 4-3, 4-4, 4-5 and tables 4-7, 4-8 and 4-9).  A 
receiver operator curve was used to determine the characteristics of the 
relationship between sensory pin prick response and analgesia at 30 minutes 
after 3-in-1 femoral nerve block( please see figure 4-6).  The data from 39 
patients was analysed (1 patient was excluded due to technical failure, i.e. 
failure of the femoral catheter to show an analgesic response to top-up with 20 
ml of 0.25% levobupivacaine). 
4.8.1 Pain reduction against sensation to blunted needle at 30 
minutes 
• Pain NRS score reduction at 30 minutes = The reduction in pain 
score rated 0-100 at 30 minutes after the injection of 30 ml of 
levobupivacaine 
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• Sensation to blunt needle at 30 minutes = Sensation to blunted 25G 
needle on the anterior thigh rated 0-100 at 30 minutes after the 
injection of 30 ml of levobupivacaine 
The calculated regression equation was (please see figure 4-3) 
(Pain NRS score reduction at 30 minutes)=61.1-0.478(Sensation to blunt needle at 30 
minutes) 
Figure 4-3: The best fit regression equation is shown below 
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Table 4-7: Pain reduction against sensation to blunted needle at 30 minutes 
Predictor SE Coef T P 
Constant 61.055 6.201 9.85 <0.001 
Sensation to blunt needle at 30mins -0.47844 0.08006 -5.98 <0.001 
S=16.5820 R-Sq = 49.1% R-Sq(adj)=47.7% 
Giving a correlation coefficient of r=√(49.1/1000.69)=0.70 (please see table 4-7) 
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4.8.2 Pain reduction against sensation to blunted needle at 20 
minutes 
• Pain NRS score reduction at 20 minutes = The reduction in pain 
score rated 0-100 at 20 minutes after the injection of 30 ml of 
levobupivacaine 
• Sensation to blunt needle at 20 minutes = Sensation to blunted 25G 
needle on the anterior thigh rated 0-100 at 20 minutes after the 
injection of 30 ml of levobupivacaine 
 
The calculated regression equation was (please see figure 4-4) 
(Pain NRS score reduction at 20 minutes)=56.5-0.431(Sensation to blunt needle at 
20 minutes) 
Figure 4-4: The best fit regression equation is shown below 
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Table 4-8: Pain reduction against sensation to blunted needle at 20 minutes 
Predictor SE Coef T P 
Constant 56.534 7.636 7.40 <0.001 
Sensation to blunt needle at 
20mins 
-0.43126 0.09615 -4.49 <0.001 
S=20.0522 R-Sq = 34.6% R-Sq(adj) = 32.9% 
Giving a correlation coefficient of r=√(34.6/1000.69)=0.59 (please see table 4-8) 
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4.8.3 Pain reduction against sensation to blunted needle at 10 
minutes 
• Pain NRS score reduction at 10 minutes = The reduction in pain 
score rated 0-100 at 10 minutes after the injection of 30 ml of 
levobupivacaine 
• Sensation to blunt needle at 10 minutes = Sensation to blunted 25G 
needle on the anterior thigh rated 0-100 at 10 minutes after the 
injection of 30 ml of levobupivacaine 
The calculated regression equation was (please see figure 4-5) 
(Pain NRS score reduction at 10 minutes)=28.8-0.110(Sensation to blunt needle at 
10 minutes) 
Figure 4-5: The best fit regression equation is shown below 
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Table 4-9: Pain reduction against sensation to blunted needle at 10 minutes 
Predictor SE Coef T P 
Constant 28.785 9.511 3.03 0.004 
Sensation to blunt needle at 10mins -0.1099 0.1181 -0.93 0.358 
 
S=23.2501 R-Sq = 2.2% R-Sq(adj) = 0.0% 
Giving a correlation coefficient of r=√(2.2/1000.69)=0.14 (please see table 4-9) 
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Linear regression techniques resulted in a statistically significant correlation 
(p<0.001) between sensory testing with a pin prick to a blunt 25G needle and 
pain NRS score reduction at 20 and 30 minutes after injection of the 30 ml dose 
of levobupivacaine response using linear regression techniques.  No correlation 
(p=0.358) was seen at 10 minutes between sensation and pain NRS scores. 
 
Sensory testing with a blunt 25G needle at 30 minutes was associated with 
reduction in pain response.  If the defined analgesic response (reduction in pain 
NRS score of ≥20/100) is the standard, we can calculate the specificity and 
sensitivity of different sensory scores.  A receiver operator curve (ROC) was used 
to calculate the change in pin prick sensory score with a blunted 25G needle 
that was associated with the highest sensitivity and specificity at 30 minutes 
after a femoral 3-in-1 nerve block (please see figure 4-6 and table 4-10). 
 
Standard Definitions: 
True positive =pain reduction>=20 points on 100 point scale 
True negative=pain reduction<20 points on 100 point scale 
 
Specificity= true negatives / (true negatives + false positives) 
 
Sensitivity= true Positives / (true positives + false negatives) 
 
Therefore: 
If sensory score is set to <=80/100 then  true negatives =14 
       False positives=4 
Therefore specificity= 13/13+1=93.3% 
 
       True positives=25 
       False negatives=1 
 
Therefore sensitivity= 21/21+4=84% 
-------------------------------------------------------------------------------------------------- 
If sensory score is set to <=90/100 then  true negatives =14 
       False positives=1 
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Therefore specificity= 13/13+1=93.3% 
 
       True positives=25 
       False negatives=1 
 
Therefore sensitivity= 24/24+1=96.1% 
 
 
If sensory score is set to <=30 then   True negatives =14 
       False positives=19 
 
Therefore specificity= 14/14+0=100% 
 
       True positives=25 
       False negatives=0 
 
Therefore sensitivity= 14/14+19=56% 
 
-------------------------------------------------------------------------------------------------- 
If we use cold sensation as an indicator of pain reduction instead of a blunt 
needle 
 True negatives =14 
       False positives=1 
 
Therefore specificity= 14/14+1=93.3% 
 
       True positives=25 
       False negatives=2 
 
Therefore sensitivity= 25/25+2=92.6% 
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Table 4-10: True positives against false positive (data for receiver operator curve) 
Sensation in anterior Sensory score 
(upper anterior thigh) 
True positive 
(% sensitivity) 
False positive 
rate 
(100-% 
specificity) 
0 8 0 
5 16 0 
10 24 0 
50 56 0 
75 56 7.1 
80 84 7.1 
90 96 7.1 
95 96 14.3 
100 96 14.3 
 
Figure 4-6: Receiver operator curve for sensory scores against analgesia 
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Therefore, the pin prick sensation to a blunt 25G needle that was associated 
with a 20 point/100 or greater reduction in pain NRS score with the highest 
specificity and sensitivity was a sensory score of ≤90/100. 
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4.9 Part 4: Trends in pain scores over time 
All pain scores decreased or remained the same at 10 minutes after the injection 
of 30 ml of levobupivacaine.  However, at 20 minutes and 30 minutes after 
injection some pain scores increased. The pain experienced by the patients 
recruited to this study with a fractured hip was not of a constant intensity; 
therefore, the trends in pain NRS scores observed between 0 and 10 minutes are 
anomalous.  The analgesia observed at 10 minutes has a much weaker 
relationship to pin prick sensation to a 25G needle than the analgesia seen at 20 
and 30 minutes.  Pain NRS scores for each patient were plotted against time, for 
concentration below the EC50 and above the EC50 and separated for effective and 
ineffective regional analgesia to determine if the anomalous pain NRS score 
trends between 0 and 10 minute were related to these factors  
Figure 4-7: Change in pain NRS scores over time 
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Table 4-11: Summary of changes in pain NRS scores over time 
 
0-10 
minutes 
10-20 
minutes 
20-30 
minutes 
Decrease in pain NRS score 23 15 8 
No change in pain NRS score 17 18 24 
Increase in pain NRS 
score 
0 7 8 
Total patients 40 40 40 
 
Figure 4-8: Changes of pain NRS scores over time for concentrations at or below the 
calculated ED50 
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Figure 4-9: Changes of pain NRS scores over time for concentration above the calculated ED50 
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Figure 4-10: Changes of pain NRS scores over time for patients with ineffective regional 
analgesia 
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Figure 4-11: Changes of pain NRS scores over time for patients with effective regional 
analgesia  
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Table 4-12: Summary of the number of patients with increased and decreased pain NRS 
scores for concentrations of levobupivacaine above (Graph 4-8) and below (Graph 4-9) the 
EC50 
Time interval (minutes) 0-10 10-20 20-30 
Pain NRS scores 
Incre
ase 
Dece
ase 
Same 
Incre
ase 
Dece
ase 
Same 
Incre
ase 
Dece
ase 
Same 
Concentrations at 
0.025% and below 
0 10 11 5 8 8 5 3 13 
Concentrations at 
0.030% and above 
0 13 6 3 7 9 4 5 10 
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Table 4-13: Summary of the number of patients with increased and decreased pain NRS 
scores for effective(Graph 4-10) and ineffective (Graph 4-11) analgesia 
Time interval (minutes) 0-10 10-20 20-30 
Pain NRS scores 
Incr
eas
e 
Dec
eas
e 
Sam
e 
Incr
eas
e 
Dec
eas
e 
Sam
e 
Incr
eas
e 
Dec
eas
e 
Sam
e 
Ineffective 0 4 11 3 4 8 3 0 12 
Effective 0 19 6 4 11 10 5 8 12 
 
No trends were noted over time in the pain NRS scores (Figure 4-7) or in 
association with the concentration used (Figure 4-8 and 4-9) or ineffective or 
effective regional analgesia (Figure 4-10 and 4-11). 
4.10 Discussion 
In all published literature available at the start of this clinical trial both the 
total dose and volume of local anaesthetic delivered were changed with each 
stepping value (δ) which is at odds with the primary tenant of the Dixon 
methodology in which only one variable should be altered (Dixon 1965). 
Therefore no information was available on which to base the initial stepping 
value (δ) and range of concentrations to be used in the trial protocol.  As a 
result the protocol included an interim analysis to recalculate the concentration 
stepping value (δ), after the first 16 patients had been recruited.  A relatively 
large concentration stepping value (δ) was chosen initially, which allowed the 
concentration to rapidly trend towards and oscillate around the ED50 
concentration.  We then calculated the optimal concentration stepping value (δ) 
for accuracy using information for the first 16 patients.  A large range was also 
initially chosen (0.1%-0.025%) but 0.025% was close to the estimate final ED50 
concentration. 
If the log concentration against effective analgesia ‘Figure 4-2: Graph of natural 
loge (concentration) of levobupivacaine against percentage of effective femoral 
3-in-1 nerve blocks’ is viewed then levobupivacaine 0.02% appears to have a 
higher success rate than would be expected; however, this estimate is based on 
relatively few patients.  This arose because the lowest value for the initial range 
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of concentrations of levobupivacaine was 0.025% therefore an effective block at 
0.025% resulted in a repeat of this concentration and only the last seven patients 
were recruited with a lower minimal concentration due to the difficultly of 
obtaining approval to amend the protocol of a clinical trial (see Appendix 4).  
The probit logistic regression model used to analyse the data to estimate the 
ED50 and ED95 for levobupivacaine appropriately weighted the small number of 
patients recruited to 0.02% levobupivacaine group. 
 
The most significant omission from the initial protocol was the threading of a 
catheter through the needle used to inject the 30 ml dose of levobupivacaine 
(IMP).  A catheter was sited for every patient as part of their normal care.  The 
pain NRS score response to the ‘top up’ of the catheter provided prolonged 
analgesia for the patients recruited to the study and added to the scientific 
value of the study by providing further clinical information and confirmation that 
the levobupivacaine was delivered to the correct site. 
4.10.1 Quantifiable error in final concentration and volume of 
IMP 
The error associated with the manufacture of a specific volume and 
concentration of levobupivacaine was estimated.  The IMP (levobupivacaine) was 
manufactured to good manufacturing practice (GMP) standards in an accredited 
pharmacy facility. 
 
The stock drug (levobupivacaine 0.75% manufactured by Abbot Ltd.) was diluted 
with saline 0.9% to produce the 30 ml of the test concentration of 
levobupivacaine which was stored for a maximum of 28 days before 
administration (Jappinen et al. 2003).  We obtained the accurate concentration 
assay preformed by Abbot Ltd on each batch of 0.75% levobupivacaine used in 
the clinical trial (Appendix 5).  The actual concentration of levobupivacaine 
0.75% used was between ± (0.2% to 1.4%) of the marked value.  If the average of 
these errors is taken: 
 
(0.4%+0.2%+1.2%+1.4%+0.5%)/5=0.74% was the average error in the concentration 
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The estimated error during manufacture arose from two sources, the estimated 
weight of the saline bag used to dilute the stock levobupivacaine 0.75% (max 
error=0.88% of final concentration) and the volume of the two syringes used to 
measure stock 0.75% levobupivacaine concentration and to store and administer 
the levobupivacaine which was 3.5% per syringe using data from BD Ltd 
(Appendix 6 for BD data sheet). Therefore the maximal error in the 
concentration of the IMP and hence the EC95 is ± (1.4%+0.88%+3.5%+3.5%) ± 9.3%.  
This assumption is likely to be grossly in excess of the true error as it assumes 
that all the errors were maximal and that they all changed the concentration in 
the same direction. 
 
A more reasonable calculation is to sum the squares of the error and take the 
square root of the result.  This assumes that some of the errors will cancel each 
other out (Taylor 1982). 
 
Therefore Final error=√(0.74)2+(0.88)2+(3.5)2+(3.5)2 
   =√(0.5476)+(0.7744)+(12.25)+(12.25) 
   =√(25.822) 
   =5.1% 
 
EC95%= 0.0357% maximal error (±9.3% of the marked concentration)i.e. ±0.003%  
or sum of squares(±5.1% of the marked concentration)i.e. ±0.0018% 
 
4.10.2 Combined biological variation and pharmacological errors 
The probit logistic regression model created using the data from this clinical 
trial estimated a 95% confidence interval of ±7.2% of the final concentration for 
the EC95 value to reduce the pain NRS score by 20/100 points at 30 minutes after 
the injection of 30 ml of levobupivacaine. 
4.10.3 Sensory testing 
Sensory testing was included in the protocol in an attempt to reduce the placebo 
effect attributed to all analgesic procedures.  A placebo analgesic effect is 
possible although great care was taken to explain to the patients that the 
femoral 3-in-1 nerve block may not give any pain relief.  Any change in pain NRS 
Chapter 4 
Page 88 of 287 
score at 30 minutes after the injection of the levobupivacaine was regarded as 
equivocal unless it was accompanied by an appropriate sensory change in one of 
the two sensory modalities in the cutaneous sensory femoral nerve distribution.  
The two methods of assessing sensation were (cold sensation to melting ice and 
sensation to a 25G blunted needle).  Two methods of assessing sensation were 
used as there was very little information in the published literature on the 
correlation between analgesia and sensation on which to base the protocol. 
 
We found that the decrease in sensation to a blunted 25G needle at 30 minutes 
after the injection of levobupivacaine was correlated with analgesia 
(≥20/100 reduction in pain NRS score).  We also used a receiver operator curve 
(ROC) to determine the size of the decrease in sensation to blunt 25G needle 
that was associated with the highest sensitivity and specificity for a ≥20/100 
point reduction in pain NRS scores at 30 minutes.  The sensory score of <90/100 
to a blunted 25G needle was associated with the highest 96% true positive rate 
and the lowest 7.1% false positive rate.  This is in contrast to the work of 
Marhofer et al which suggested that an analgesic response in the same patient 
population was correlated to a ≤30/100 sensory score to 25G blunted needle in 
comparison to the contra lateral side (Marhofer et al. 1997).  In this clinical trial 
a sensory score to pin prick from blunted 25G needle of ≤90/100 was highly 
sensitive and specific measure of the analgesic effectiveness of a femoral 3-in-1 
nerve block.  In contrast to this clinical trial Marhofer et al assessed the 
cutaneous sensory response but he made no independent measure of the pain 
(Marhofer et al. 1997).  In this clinical trial we used the results to determine if 
cutaneous sensory response was associated with pain NRS scores however 
Manhofer simply stated that they were correlated (Marhofer et al. 1997).  In 
summary, cutaneous sensation on the anterior upper thigh to a blunted 25G 
needle or melting ice was a surrogate measure of analgesic effectiveness for the 
femoral 3-in-1 nerve block. 
4.10.4 Analgesia observed at 10 minutes after injection of 
levobupivacaine 
It is possible to use the placebo effect to explain the decreased pain scores at 10 
minutes and then the subsequent increases at 20 and 30 minutes but the limited 
duration and consistent timing make this explanation less than satisfactory.  It is 
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possible that levobupivacaine acts more rapidly than the 20 to 30 minutes 
usually quoted however the lack of an associated sensory change at 10 minutes 
compared to 20 and 30 minutes (using logistic regression analysis) may suggest 
that the analgesic effects observed at 10 minutes could have a different 
mechanism.  An alternative explanation may be provided by the hydrostatic 
pressure exerted on the nerve following injection of levobupivacaine.  The 
hydrostatic effect may be limited in duration by the rapid absorption of the 
injected levobupivacaine and may not be associated with a cutaneous sensory 
response unlike the local anaesthetic effects of levobupivacaine.  
4.10.5 Implications of the low dose need for the EC95 dose 
This study has produced an estimate of the effective dose required to provide 
analgesia which implies that the currently used doses are in excess of what is 
required to provide analgesia.  This study will act as the starting point to further 
work which could allow the safe provision of analgesia to patients with a 
fractured neck of femur by utilising lower (and therefore safer) doses of 
levobupivacaine. 
4.11 Conclusion 
The effective concentration of 30 ml of levobupivacaine required to produce a 
reduction in pain numerical rating scale (NRS) score of ≥20 points on a 100 point 
scale in 50% of patients (EC50) with a proximal traumatic fractured neck of femur 
using an ultrasound guided femoral nerve block was estimated as ( µ ) 
EC50=0.0255% with 95% CI of 0.0229% to 0.0284%.  The effective concentration in 
95% of patients (EC95) was estimated as EC95 =0.0357% with 95% CI of 0.0332% to 
0.0383%. 
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4.12 Summary of chapter 4 
4.12.1 Aim 
The aim of this clinical trial is to determine the dose of levobupivacaine 
required to provide effective pain relief to patients with a fractured neck of 
femur using ultrasound to guide needle insertion. 
4.12.2 Method 
Patients with a fractured neck of femur were recruited prior to surgical fixation.  
An ultrasound guided femoral 3-in-1 nerve block was used to anaesthetise the 
nerves supplying the proximal femur.  At 10 minute intervals the feeling in the 
upper leg and pain numerical rating scale (NRS) scores were recorded for a total 
of 30 minutes.  A successful femoral 3-in-1 nerve block was defined as ≥20/100 
decease in the pain NRS score at 30 minutes with a sensory change in skin 
supplied by the femoral nerve.  The concentration of levobupivacaine was 
increased or decreased if the nerve block was ineffective or effective 
respectively in the previous patient. 
4.12.3 Results 
The EC50 of levobupivacaine was estimated using probit logistic regression 
analysis at EC50=0.0255% with 95% CI of 0.0229% to 0.0284% for 30 ml of 
levobupivacaine and the EC95=0.0357% with 95% CI of 0.0332% to 0.0383%. 
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5 The duration of analgesia and pharmokinetics of 
30 ml. of the effective concentration of 
levobupivacaine in 95% of patients (EC95) with a 
fractured neck of femur. 
5.1 Aim 
To determine the duration of analgesia provided by an ultrasound guided 
femoral 3-in-1 nerve block when 30 ml of 0.036% levobupivacaine (the EC95 
concentration) was used to provide analgesia to patients with a fractured neck 
of femur.  The plasma concentration profile was determined to ensure peak 
serum levels of levobupivacaine were within safe limits. 
5.2 Study design 
Observational prospective cohort study. 
5.3 Study Population 
Competent patients with a fractured neck of femur. 
5.4 Trial inclusion/exclusion criteria and patient 
withdrawal criteria 
5.4.1 Inclusion criteria 
• Patients with a fractured neck of femur 
• American Society of Anaesthesiology grading ≤4/5 (Little 1995) 
• Capacity to give informed consent 
• Resting visual analogue pain score >50 on a 100 scale before 
recruitment (moderate pain) 
• Able to cooperate with sensory testing of lower limb function. 
Chapter 5 
 
Page 92 of 287 
 
5.4.2 Exclusion criteria 
• Acute mental test score of ≤7/10 at any time preoperatively 
• Allergy to local anaesthetic 
• Signs, symptoms or laboratory evidence of  
o local infection (at intended site of needle insertion) 
o systemic sepsis which would normally preclude regional analgesia 
• Pre-existing known neurological deficit (sensory or motor) affecting the 
lower limb 
• Patient with lower limb amputations or other condition affecting 
sensation in lower limbs. 
5.4.3 Criteria for withdrawal of patient from the trial 
• Patient initiated withdrawal.  Patients could withdraw from the clinical 
trial at any time. 
• Administration of regional anaesthesia or analgesia not in the protocol 
• Failure of rescue analgesia ‘top-up’ with a 20 ml injection of 0.25% 
levobupivacaine through the catheter sited after the initial injection of 30 
ml of levobupivacaine. 
• Equivocal sensory and pain test results (see section 5.5 Methodology; for 
definition of equivocal sensory and pain results) 
• A protocol violation leading to a patient safety issue or a quality issue 
• An urgent safety issue with the clinical trial protocol. 
5.5 Methodology 
All patients were recruited preoperatively and were scheduled for fixation of 
fractured neck of femur.  Consented unpremedicated patients were transferred 
to the operating theatre suite and initial sensory testing and pain NRS scores 
were performed.  Femoral 3-in-1 nerve blocks were inserted preoperatively 
using ultrasound needle guidance and 30 ml of the EC95 concentration of 
levobupivacaine.  Needle placement for the femoral nerve block was guided by 
ultrasound.  Ultrasound images of the common femoral artery, femoral vein and 
nerve in the short axis were obtained using a linear high frequency ultrasound 
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probe on a LOGIQe ultrasound machine (supplied by General Electric Ltd.) and a 
100 mm or 50 mm 18G Contiplex Tuohy tipped needle (supplied by B-Braun Ltd) 
which was advanced in plane until the tip of the needle was under the fascia 
iliacus membrane immediately lateral to the femoral nerve.  After a ‘negative’ 
aspiration to detect accidental intravascular placement, the local anaesthetic 
dose was injected.  Real time ultrasound images were used to ensure that the 
injected local anaesthetic (30 ml of levobupivacaine EC95) spread around the 
femoral nerve with associated ‘tenting’ of the fascia iliacus membrane.  After 
injection of the levobupivacaine, a catheter was threaded through the Contiplex 
Tuohy tipped needle and its position confirmed by visualising movement of the 
catheter under the fascia iliacus membrane.  The concentration of 
levobupivacaine used was 0.036% (EC95 of levobupivacaine to 3 decimal places) 
for all patients recruited to this study.  At 10, 20 and 30 minutes after injection 
of levobupivacaine, pain NRS (numerical rating scale) scores and sensory testing 
on the upper thigh were recorded.  Effective regional analgesia was defined as 
reduction in pain NRS score of ≥20/100 points with a pre block resting pain NRS 
score of ≥50/100 in association with a sensory change, 30 minutes after the 
femoral 3-in-1 nerve block.  The sensory change was either a reduction to 
≤30/100 of initial sensory stimuli on testing with a blunted needle or altered 
sensation on testing with melting ice in the area of distribution of femoral nerve 
in comparison to the contra lateral side.  If the sensory response in the anterior 
upper thigh and the pain NRS score were at odds the response was defined as 
equivocal and the patient data removed from the final analysis. 
 
The primary end point, in effective blocks was defined as the duration of 
analgesia (pain NRS score of <30/100 at rest); pain scores were recorded 
postoperatively until a pain score of ≥30/100 was recorded.  Blood samples were 
taken for venous blood gases and liver function tests before the insertion of the 
levobupivacaine.  A further blood sample was taken before the insertion of the 
femoral 3-in-1 nerve block and at 5, 10, 20, 30 and 60 minutes post insertion of 
the femoral 3-in-1 nerve block, from a cannula inserted, to assess the 
pharmokinetics of serum levobupivacaine.  All levobupivacaine blood samples 
were taken 60 minutes after the femoral 3-in-1 nerve block to the biochemistry 
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department at the Western Infirmary.  The levobupivacaine blood samples were 
centrifuged and frozen to -200C for delayed batch analysis. 
 
If the ultrasound guided femoral 3-in-1 nerve block failed to reduce the pain NRS 
score to <30/100 in 30 minutes then 20 ml of 0.25% levobupivacaine was given 
via the femoral nerve catheter to achieve a pain NRS score of <30/100.  If 30 
minutes after the injection of 20 ml of 0.25% levobupivacaine, the pain NRS 
score was not ≤30/100 the ineffective regional analgesia was attributed to a 
failure of placement of the initial 30 ml EC95 dose of levobupivacaine and 
intravenous morphine was titrated according to local protocols to achieve a pain 
NRS score of <30/100. 
5.5.1 Estimation of the number of patients needed 
The primary outcome of this clinical trial was the duration of analgesia.  The 
standard deviation was estimated at approximately 4 hours (from clinical 
experience). The standard error of the mean is the standard deviation divided by 
the square root of the sample size.  Hence a sample size of 16 patients would 
provide a standard error of 1 hour.  Therefore, to estimate the mean duration of 
analgesia with a 95% confidence interval of ±1.96 hours would require a sample 
size of approximately 16 patients, assuming an approximately normal 
distribution.  It was assumed that the mean duration of analgesia provide by the 
levobupivacaine EC95 would be approximately 12 hours and if the standard error 
of the mean was ±1.96 hours then the (1.96/12)*100=16.3%.  A 16.3% error was 
considered an acceptable percentage error for estimation of the mean. 
5.5.2 Pain score assessment 
A pain score measures a patient's pain intensity or other features. Pain scores 
are based on self-report, observational (behavioral), or physiological data.  A 
self-reported score such as the Numeric Rating Score provides the most accurate 
data.  It may be used for adults and children over 10 years old or older.  Pain 
scores were assessed on a 100 point numerical rating scale (NRS) scoring system.  
Pain scores were assessed on a 100 point Numerical Rating Scale (NRS).  The 
following verbal descriptions were used to guide patients; 0-29 mild pain, 30-69 
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moderate pain and 70-100 severe pain.  Pain NRS score was used throughout all 
clinical studies in this thesis as the pain visual analogue scale was found to be 
difficult to use in patients with a fractured neck of femur. 
5.5.3 Assessment of sensory function  
The primary sensory response was based on the sensory response of the middle 
third of the upper thigh.  The patient sensory function was assessed by the 
intensity of a pin prick sensation and cold sensation produced by melting ice.  
Pin prick sensation was measured using a blunted 25G (orange) needle.  The 
patient was asked to grade the intensity of the sensory response to the 25G 
needle by verbalising or marking a line from 0 (no sensation) to 100.  One 
hundred was defined as the same intensity of sensation as the contra lateral 
anterior aspect third of the upper thigh.  Melting ice was also used as a stimulus 
and the patient was asked if the cold sensation was reduced on the side on 
which nerve block was performed compared with the contra lateral (unblocked 
side) on the medial (M), anterior (A) and lateral region (L) of the upper thigh 
(See Figure 5-1). 
 
The change in sensation associated with effective regional analgesia was defined 
as a reduction in sensation to blunted 25G needle in the anterior aspect of the 
upper thigh (area marked as A in Figure 5-1) of ≤30/100 or a reduction in cold 
sensation to melting ice in comparison with the contra lateral area of the thigh 
in the upper anterior aspect of the thigh. 
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Figure 5-1: The surface anatomy of the upper thigh: The anterior (A), lateral (L) and medial 
(M) aspects of the upper thigh are shown in the diagram below. 
 
Image from personal collection of Dr Malcolm Watson 
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5.5.4 Assay of levobupivacaine levels 
All blood samples where stored on ice immediately and centrifuged after the 
collection period and stored at -20oC until they were sent for analysis.  Analysis 
was performed with a specific Liquid Chromatography Tandem Mass 
Spectrometry (LC-MS/MS) assay at ABS Laboratories using GLP (good laboratory 
practice)/GCP (good clinical practice) compliant systems within a GLP 
accredited laboratory.  The levobupivacaine assay used to analyse the plasma 
samples was calibrated between 1 ng/ml – 5000 ng/ml with an inter sample 
variability of <5.1% over this range (see Appendix 7). 
5.5.5 Secondary end points 
• Blood pressure, oxygen saturation, pulse rate and respiratory rate before 
the femoral 3-in-1 nerve block and every 10 minutes for 30 minutes after 
insertion of 30 ml of levobupivacaine 
• Serum concentrations of levobupivacaine from blood samples taken at 5, 
10, 20, 30 and 60 minutes after insertion of the levobupivacaine. 
• The pain NRS score was recorded pre femoral 3-in-1 nerve block and at 
10, 20 and 30 minutes post block in order to estimate the time to half the 
pain NRS score.  These were modelled using both linear and nonlinear 
methods to achieve the best fit for the data and therefore the best 
estimate of half pain time. 
• The sensory function of the femoral, obturator and lateral cutaneous 
nerves was tested at 0 minutes (before insertion of levobupivacaine) and 
at 10 and 20 minutes post insertion of 30 ml levobupivacaine. 
• Venous blood gases and liver function tests results outside the standard 
range of values. 
5.5.6 Standards 
This clinical trial was conducted to ICH-GCP ( 2004)and monitored by Greater 
Glasgow and Clyde Board (the report is included in Appendix 1) with only minor 
findings.  All Investigational and Medicinal Products were produced by an 
accredited pharmacy production unit using the batch of levobupivacaine 0.75% 
assayed in Appendix 8.  The clinical research data was recorded and processed 
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to comply with ISO 9001:2008 and the statistical analysis was supervised by Dr 
Alex McConnachie, senior statistician at the Robertson Centre for Biostatistics, 
Glasgow University. 
5.6 Results 
A total of 14 patients with fractured neck of femur were prospectively recruited 
preoperatively from 20 November 2010 until 4 March 2011.  No patients had 
equivocal sensory and pain results or ineffective analgesia (≤20/100 decrease in 
VAS pain scores) therefore no patient’s data was excluded. 
5.6.1 Demographics 
The mean age of all patients recruited was 76 year with a standard deviation of 
12 years (median 76 years and interquartile range 72-85 years).  Five patients 
recruited were male and nine were female. 
5.6.2 Hospital mortality 
All 14 patients recruited survived to hospital discharge. 
5.6.3 Time taken to insert a femoral 3-in-1 nerve block 
The mean time taken to insert a femoral 3-in-1 nerve block was 71 seconds with 
a standard deviation of 23 seconds and a median of 75 second and interquartile 
range of 50 to 84.seconds. 
5.6.4 Number of attempts to insert block 
Only one skin puncture was required for all patients but an average of 
1.3 needle advancements with a standard deviation of 0.5 advancements were 
required to achieve an ultrasound guided femoral 3-in-1 nerve block. 
5.6.5 Physiological observations 
The physiological observations of the patients pre-block and at 10, 20 and 
30 minutes after the femoral 3-in-1 nerve block are shown in Table 5-1. 
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Table 5-1: Physiological observations preblock and at 10, 20 and 30 mins. after a femoral 3-
in-1 nerve block. 
 Pre-block 10 minutes 
post block 
20 minutes 
post block 
30 minutes 
post block 
Median Systolic BP (mmHg), 
(interquartile range) 
152 
(136-155) 
142.5 
(127-145) 
137.5 
(129-144) 
142.5 
(132-147) 
Median Diastolic BP (mmHg) 
(interquartile range) 
76 
(68-85) 
73 
(70-83) 
73 
(66-81) 
74 
(65-84) 
Median O2 saturation 
(interquartile range) 
93 
(90-95) 
94 
(93-96) 
94 
92-96) 
94 
(93-96) 
Median number of litres of 
supplementary O2 
(interquartile range) 
0 
(0-0) 
1 
(0-2) 
1 
(0-2) 
2 
(0-2) 
Median Respiratory rate 
(interquartile range) 
14 
(12-16) 
13 
(12-16) 
14 
(10-15) 
12 
(10-15) 
Median Pulse rate 
(interquartile range) 
88 
(77-96) 
86 
(76-98) 
82 
(71-96) 
86 
(72-100) 
 
No statistically significant changes in physiological observations were noted (all 
interquartile ranges for all the parameters measured overlapped) during the 
period of observation. 
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5.7 Part 1: Duration of analgesia following injection of 
0.036% levobupivacaine 
A summary of the primary end point data (duration of analgesia) from the 14 
patients recruited to this clinical trial can be seen in Figure 5-2 and Table 5-2 
below. 
Figure 5-2: Bar chart for duration of analgesia in individual patients 
Duartion of analgesia from EC95 dose of 
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Table 5-2: Summary of data from 14 patient’s duration of analgesia in minutes 
Mean (median) 
duration of 
analgesia 
Standard 
error of the 
mean 
95% confidence interval 
of standard error of the 
mean (% of mean 
duration) 
Standard 
deviation 
(interquartile 
range) 
166 (177) 18 3 5(21%) 67 (110-210) 
5.7.1 Justification of termination of trial after 14 patients had 
been recruited 
This trial was terminated after 14 patients had been recruited when the 95% 
confidence interval of the standard error of the mean was ±35 minutes.  The 
actual 95% confidence interval of the standard error of the mean was a similar 
precision to the estimated value from the power calculations (see Table 5-3 
Precision of estimation of mean duration of analgesia) 
Table 5-3: Precision of estimation of mean duration of analgesia 
 
Mean duration 
of analgesia 
Standard error 
(SE) 
95% confidence 
interval (CI) 
Percentage 
(SE)/ mean 
Estimated 
duration of 
analgesia 
12 hours 1 hour 1.96hours 16% 
Actual duration 
of analgesia 
166 minutes 18 minutes 35 minutes 21% 
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A summary of missing data and the adverse event log for this study are shown 
below in Table 5-4 and Table 5-5, respectively. 
Table 5-4: Summary of missing data 
Patient 
number 
Problem Action taken 
1 
Investigator forgot to take blood 
sample at 10 minutes post femoral 3-
in-1 nerve block 
No data available for that time 
point for serum levobupivacaine 
levels 
5 
Faulty glucose electrode on blood gas 
machine 
No data available 
11 
Unable to aspirate blood from 
intravenous cannula 30 minutes post 
block 
No data available for that time 
point for serum levobupivacaine 
levels 
 
Table 5-5: Adverse event log 
Patient number Adverse event 
8 
Patient confused overnight for approximately 8 hours after 
recruitment to study, orientated postoperatively, 
discharged home 4 days later no treatment given for 
confusion. 
5.8 Part 2 Serum levobupivacaine levels 
Blood samples were analysed for serum levobupivacaine concentrations pre-
block (0) and at 5, 10, 20, 30 and 60 minutes post femoral 3-in-1 nerve block.  
The median and upper and lower quartiles of these concentrations have been 
graphed in Figure 5-3 shown below.  The measured serum levobupivacaine 
concentrations were within the range 9.7-256.6 ng/ml and that the maximum 
bias in this range was ±2.65% (see appendix 7). 
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Figure 5-3: Plasma levobupivacaine concentrations against time 
Plasma levobupivacaine levels after femoral 
3-in-1 nerve block with 30mls of 0.038% 
levobupivacaine
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The total plasma levobupivacaine concentration increased rapidly to peak after 
30 minutes.  The highest median level reached (52.3 ng/ml) was substantially 
lower than the plasma concentration associated with symptoms of central 
nervous system and cardiovascular system toxicity (2100ng/ml) in the literature 
(Knudsen et al. 1997).  At 30 minutes the range of median concentrations of 
levobupivacaine was 16-256 ng/ml and a large range was observed at all time 
points examined in this trial.  This may be the result of different absorption 
patterns from the site of action. 
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Part 3 Time to half pain scores 
The pain NRS scores were recorded before (baseline) the femoral 3-in-1 femoral 
nerve block and at 10, 20 and 30 minutes after the block in order to estimate 
the time to half the baseline pain NRS score.  This was modelled using both 
linear and nonlinear models to achieve the best fit for the data. 
 
A linear regression model of time (measured in minutes) for the femoral 3-in-1 
nerve block against percentage analgesia based on pre-block pain scores 
(painRed). 
All linear regression equations can be written as 
 
xy 10 ββ +=   OR (mins))PainRed ( 10 ββ +=  
 
Where y= percentage analgesia and x=time in minutes from nerve block 
If we give y the value 50 (50% decease in pain score from pre block levels) 
Then the equation could be written 
x50 10 ββ +=  
As rearranged to get x the number of minutes at which the equation predicts 
that the pain score will have dropped to 50% of there original value 
 
1
0 )-(50 β
β
=X  
We fitted the 3 regression models (see below for a definitions and a summary 
(Table 5-6) of models 1-3)  
• Model1: With time in minutes and percentage pain score reduction 
from baseline 
• Model 2 With time in minutes and Loge(percentage reduction in pain 
scores from baseline) 
• Model 3 With Loge (time in minutes) and Loge(percentage reduction 
in pain scores from baseline) 
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Table 5-6: The R squared and correlation coefficients are shown below 
 Model 1 Model 2 Model 3 
Regression 
equation 
% pain red 
=32.0+1.01 minutes 
Loge(% pain red) 
=3.4+0.02 minutes 
Loge(% pain red) 
=2.7+0.4 minutes 
R squared 
adjusted 
5.3% 6.2% 7.2% 
Predicted 
half pain 
time 
18 minutes 23 minutes 24 minutes 
 
The normal probability plot for residuals for models 1, 2 and 3 are shown below 
in Figures 5-4, 5-5 and 5-6 respectively. 
Figure 5-4: Model 1 
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Figure 5-5: Model 2 
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Figure 5-6: Model 3 
3.43.23.02.82.62.42.2
4.5
4.0
3.5
3.0
2.5
ln(minutes)
ln
(%
p
a
in
re
d
)
S 0.547161
R-Sq 9.6%
R-Sq(adj) 7.2%
Fitted Line Plot
ln(% pain red) =  2.713 + 0.3906 ln(minutes)
 
In model one (% pain red=32.0+1.01 minutes) the residuals had a positive skew 
and the natural loge of the data was taken to normalise the residuals and 
improve the correlation (increase the R squared value).  The best fit (least 
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residuals and highest r squared value) was given by model three.  The r squared 
adjusted value for model three was only 7.2% which implies that only 7.2% of the 
variance can be explained using this model. 
5.9 Part 4 Sensory function of the femoral, obturator 
and lateral cutaneous nerves  
The sensory scores to a blunt 25G needle for the medial, anterior and lateral 
areas of the upper thigh were plotted against time to examine the pattern of 
onset of the sensory nerve block (please see Figure 5-7).  The part of the 
femoral nerve that supplied the skin on the lateral parts of the thigh was 
blocked first, then the anterior and finally the medial aspect of the thigh.  The 
order that the median values cross the 90/100 line on the y-axis (sensory scores 
to a blunt 25G needle) appears to be related to the proximity of the part of the 
nerve to the injected dose of levobupivacaine. 
Figure 5-7: Sensory scores to a 25G needle in medial, anterior and lateral areas of upper 
thigh at 10, 20 and 30 minutes after a femoral 3-in-1 nerve block. 
Lateral, medial and anterior sensory scores to a blunt 25G needle at 10, 
20 and 30mins post femoral 3-in-1 nerve block
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5.10 Part 5 Venous blood gas and liver function tests 
Table 5-7 below lists the mean ± standard deviation, median, interquartile 
ranges and ranges for the blood results for all 14 patients in the study with the 
normal reference range.  All values outside the normal reference range have 
been shown in bold with an underline.  The vast majority of the interquartile 
ranges are within the reference range.  A few range values are out with the 
reference range and this was expected in a population of patients with multiple 
co-morbidities.  
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Table 5-7: Blood results for all patients recruited to the trial 
 Mean ± 
SD 
Median Interquartile 
range 
Range Reference 
range 
H+(nmol/L) 41 ± 4.4 42 40.2-43.6 30-47 39-49 
pCO2(kPa) 5.6 ± 0.89 5.8 5.1-6.25 3.5-6.6 5.5-6.8 
PO2 (kPa) 5.8 ± 2.3 5.25 4.2-6.7 3.2-11.8 4.0-5.3 
Na+ (mmol/L) 136 ± 2.4 135 135-137 131-140 135-145 
K+ (mmol/L) 4.1 ± 0.34 4.1 4.0-4.3 3.3-4.6 3.5-5.0 
Haematocrit (%) 36 ± 5 36 33-40 26-44 40-54 
Glucose (mmol/L) 7.2 ± 1.4 7.5 5.8-8.4 5.1-9.1 3.5-5.5 
Lactate (mmol/L) 1.4 ± 0.54 1.1 1-1.8 0.7-2.2 <0.5-2.2 
Base excess (mmol/L) 0.45 ± 2.8 1.5 (-1.7)-1.9 (-5.1)-5.7 ±3 
HCO3
- (mmol/L) 25.6 ± 3.1 26.9 23.3-27.7 18.1-28.6 21-28 
Urea (mmol/L) 6.1 ± 1.7 5.6 5.2-6.9 3.6-10.2 2.5-7.5 
Creatinine (µmol/L) 77 ± 24 64 63-85 55-132 40-130 
Bilirubin (µmol/L) 10.6 ± 5.2 9 7.2-13 4-22 <20 
AST (U/L) 22.5 ± 13 20 17-23 11-64 <40 
ALT (U/L) 15 ± 4.2 14 12-16 8-22 <50 
γ-GT (U/L) 59 ± 125 20 16-43 11-488 <40 
Alk-PO3 (U/L) 159 ± 263 90 74-122 43-1069 40-150 
Total protein (g/L) 66 ± 8 66 60-68 55-89 60-80 
Albumen (g/L) 33 ± 6 34 28-37 23-42 32-45 
Globulin (g/L) 33 ± 6 32 30-35 23-47 23-38 
The reference ranges for the majority of the value displayed were taken from Western infirmary, 
Glasgow biochemistry and haematology laboratories but base excess and H+, PCO2 and O2 in 
venous blood gases were taken from 
http://en.wikipedia.org/wiki/Reference_ranges_for_blood_tests which was 
referenced from brooksidepress.org (12 A.D.). 
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5.11 Discussion 
5.11.1 Safety of levobupivacaine 
The measurement of serial plasma levobupivacaine concentrations assessed the 
safety of the EC95 concentration of levobupivacaine when administered to an 
elderly frail patient population with multiple co-morbidities. 
5.11.2 Levobupivacaine plasma concentrations and toxicity 
The levobupivacaine venous concentrations increased rapidly after the femoral 
3-in-1 nerve block and the highest median plasma concentration was obtained 
after 30 minutes.  Paut et al also noted a rapid increase in venous plasma 
ropivacaine concentration after femoral 3-in-1 nerve blocks (Paut et al. 2004).  
In contrast to the study of Paut et al, the peak serum plasma concentrations 
during this clinical trial were well within the ‘safe range’ despite a wide 
variation in the observed plasma levobupivacaine concentrations. 
 
The study by Paut et al was stopped early due to measured serum ropivacaine 
levels above 2200 ng/ml (Paut et al. 2004) in venous samples.  This 
concentration had been associated with central nervous and cardiovascular 
toxicity in healthy adult volunteers by Knudsen et al (Knudsen et al. 1997).  
However Paut et al did not take into account the rapid intravenous infusions 
which were used in the study by Knudsen et al and the consequent arteriovenous 
difference in both plasma levobupivacaine and ropivacaine concentrations 
(Knudsen et al. 1997).  In the rapid infusion model, peripheral arterial and 
venous concentrations will not reflect heart and central nervous system 
concentrations of local anaesthetic and a large peripheral arteriovenous 
difference will be present (please see 5.11.3 Rapid infusion system).  In a ‘slow 
infusion’ model which would be more applicable to the study of Paut et al (Paut 
et al. 2004) the peripheral concentrations are likely to reflect exposure of the 
heart and central nervous system and the peripheral arteriovenous concentration 
difference will be small (please see 5.11.4 Slow infusion system).  It is also 
notable that despite terminating the study early, no child exhibited the signs or 
symptoms of central nervous system or cardiac toxicity.  In contrast, in the 
healthy volunteers study by Knudsen et al, signs of central nervous system 
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toxicity were easily observed by the doctors observing the volunteers.  It is 
possible that children are resistant to local anaesthetic toxicity.  It is possible 
that concomitant general anaesthesia masked the signs and symptoms of central 
nervous system and cardiovascular toxicity.   
 
5.11.3 Rapid infusion system (Injection of local anaesthetic into 
vascular system 
 
 
Local anaesthetic delivered at block site 
Inadvertent injection into the vascular atrial or venous 
system 
 
Return to the mixed venous blood and right side of the 
heart 
High concentration of local anaesthetic in blood to the 
central nervous system and cardiovascular system 
causing unconsciousness/seizures and cardiovascular 
collapse 
Due to rapid cardiovascular collapse very little of the 
local anaesthetic will reach the peripheral circulation 
and 
arterial concentrations will be much higher than venous 
concentrations 
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5.11.4 Slow infusion system (Absorption of local anaesthetic into 
the cardiovascular system) 
 
5.11.5 The relationship between serum local anaesthetic 
concentration and toxicity 
It is often stated that there is a lack of correlation between the serum 
concentration of local anaesthetic and clinical symptoms and it is likely that 
other factors play a significant part and these factors are often overlooked in 
case reports of local anaesthetic toxicity 
5.11.6 Venous arterial difference for serum local anaesthetics 
The vast majority of reports of local anaesthetic toxicity have reported venous 
serum concentration of local anaesthetic. In the event of a rapid infusion of 
 
Local anaesthetic delivered at block site 
 
Slow absorption into the vascular atrial or venous 
system 
 
 
Return to the mixed venous blood and right side of the 
heart 
Rising concentrations of local anaesthetic in blood to 
the central nervous system and cardiovascular system 
causing unconsciousness/seizures and later 
cardiovascular instability and collapse 
A large amount of the local anaesthetic will reach the 
peripheral circulation due to late cardiovascular 
collapse and the arterial concentrations will be slightly 
higher than venous concentrations 
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local anaesthetic into the systemic circulation, venous sampling will not 
correlate well with toxicity (Chazalon et al. 2003;Huet et al. 2003).  The use of 
venous sampling may be justified if the onset of central nervous or cardiac 
toxicity is delayed (slow infusion model) following the administration of the local 
anaesthetic.  In the event of a delay of less than 5 minutes (rapid infusion 
model), arterial sampling will be a more accurate measure of exposure of 
critical organs (heart and central nervous system) to systemic concentrations of 
levobupivacaine. 
5.11.7 Injection of local anaesthetic directly into the central 
nervous system 
Arterial plasma concentrations may not reflect the direct exposure of the 
central nervous system to local anaesthetic.  Systemic vascular concentrations 
may have no correlation to the local exposure of the central nervous system as a 
result of an interscalene approach to the brachial plexus block or to epidural 
anaesthesia (Dhir et al. 2007;Pasquier et al. 2009;Satsumae et al. 2008).  All 
three case reports the authors were unable to aspirate blood via the needle or 
catheter.  The use of both MRI and ultrasound doppler visualisation by Dhir et al 
failed to visualise the vascular placement of a interscalene brachial plexus 
catheter which was associated with seizures (Dhir et al. 2007). 
5.11.8 The effect of acid base balance and protein binding 
The acid base balance affects the action and the protein binding of 
levobupivacaine due to the presence of an amino group.  The structure of 
levobupivacaine can be seen below. 
Figure 5-8: The chemical structure of levobupivacaine 
 
Levobupivacaine a lipophilic benzene ring (on the right) linked by an intermediate amide 
linkage to an amide group on the left. 
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5.11.8.1 Onset of local anaesthesia 
The amino group of levobupivacaine, will adopt the tertiary non-polarised) 
lipophilic or the quaternary (polarised positively charged weak base) water 
soluble form dependant on the pH.  This effect has a practical application in 
obstetric anaesthesia.  Sodium bicarbonate is often added to levobupivacaine to 
reduce the onset time of an epidural block to facilitate delivery.  The 
explanation of this effect is that if the pH is increased there will be an increase 
in tertiary (non polarised) molecules. Those molecules cross more easily through 
the lipophilic axonal membrane to the site of action on the inside of the fast 
voltage dependant sodium channels.  In contrast, in an acidic environment such 
as an abscess the low pH will result in less tertiary (non-polarised) lipophilic 
molecules crossing the axon membrane. 
5.11.8.2 Protein binding 
Acid base balance will also affect the protein binding of levobupivacaine.  
Levobupivacaine is more than 97% protein bound, mainly to acid 
α-1-glycoprotein which is an acute phase protein.  If the environment is acidic 
then more levobupivacaine will be in the ionised form and since acid 
α-1-glycoprotein binds positively charged molecules, a greater percentage of it 
will be protein bound.  The effect; therefore, of a profound acidosis on protein 
binding would be to decrease the availability of free drug but there are no case 
reports or studies describing this effect.  The effect of protein binding is seen in 
studies looking at infusions of local anaesthetic and the increase in acid 
α-1-glycoprotein resulted in the levels of free levobupivacaine remaining 
unchanged despite increasing levels of total levobupivacaine (Ekatodramis et al. 
2003).  The complex effects of protein binding and acid base balance can be 
negated if free levobupivacaine levels are measured; however, this is expensive 
as the samples need to undergo ultrafiltration after centrifugal separation, 
before freezing and storage of the plasma sample for later analysis. 
5.11.9 Free levobupivacaine 
It can be argued that free plasma levobupivacaine will be more closely 
associated with toxicity but during the short time period that this study was 
conducted (less than 1hour) it can be assumed that no significant change in 
plasma proteins will have occurred.  We recorded cardio-respiratory 
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measurements, urea and electrolytes, liver function tests and venous blood 
gases in all patients recruited to this study.  The contribution of acid base 
balance to levobupivacaine toxicity has never been adequately assessed.  The 
amount of free base drug such a levobupivacaine will be influenced by the acid 
base balance.  In the elderly population, the presence of abnormalities will be 
higher and any assessment of levobupivacaine toxicity should take into account 
the effect of pH and plasma proteins. 
5.11.10 The effect of age on the toxicity of levobupivacaine 
If the effect of age is taken into account it is likely that the EC95 calculated is 
only valid for the population of patients recruited to this clinical trial (elderly 
patients).  The efficacy of local anaesthetics in the elderly population has been 
consistently increased in studies examining central neuraxial (epidural blocks) 
(Bromage 1969;Simon et al. 2004) and in peripheral nerves (in the brachial 
plexus) (Paqueron et al. 2002)  In contrast, local anaesthetic toxicity is a greater 
risk in the elderly.  Although plasma concentrations of local anaesthetics are 
unaffected by age (Finucane, Hammonds, & Welch 1987;Veering et al. 1991); 
however, elderly patients have a reduced plasma clearance (Bromage 
1969;Knudsen et al. 1997;Paut et al. 2004) which leads to a greater risk of 
toxicity. 
5.11.11 Pain half time-onset of analgesia 
In order for the analgesic effect of femoral 3-in-1 nerve block to be useful, it 
must be comparable to the alternative analgesic which is morphine in the UK.  
The anaesthetic text books quote an onset time of 15 to 30 minutes for 
intravenous morphine (Bromage 1969;Stoelting 2000).  This is comparable to the 
24 minutes estimated from the time to half pain NRS scores for femoral 3-in-1 
nerve block with an EC95 concentration of levobupivacaine. 
5.11.12 Medial sensory response and time to half pain 
The medial sensory response appears to be temporally linked to the time to half 
the pain NRS score.  It is possible this is a coincidental finding but the 
association between the loss of medial sensation in the upper thigh and 
analgesia has been previously documented (Dolan et al. 2008).  It is possible that 
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loss of medial sensation in the upper thigh could be used as a surrogate marker 
of analgesic efficacy. 
5.11.13 Quantifiable error in final concentration and volume of 
IMP 
The error associated with the manufacture of a specific volume and 
concentration of levobupivacaine should be estimated.  The IMP 
(levobupivacaine) was manufactured to good manufacturing practice (GMP) 
standards in an accredited pharmacy facility. 
The stock drug (levobupivacaine 0.75% manufactured by Abbot Ltd.) was diluted 
with saline 0.9% to produce the 30 ml of the EC95 concentration of 
levobupivacaine.  We obtained the concentration assay preformed by Abbot Ltd. 
on the batch of levobupivacaine marked as 0.75% used in this clinical trial.  The 
actual concentration of levobupivacaine 0.75% used for all 14 doses of 
levobupivacaine EC95 given in this study was 7.605 mg/mL (101.4% of marked 
concentration) (please see Appendix 8). 
The estimated error during manufacture of the IMP arose from two sources, the 
estimated weight of the saline bag used to dilute the stock levobupivacaine 
0.75% (max error=0.88% of final concentration) and the volume of the two 
syringes used to measure stock 0.75% levobupivacaine concentration and to store 
and administer the levobupivacaine which will be 3.5% per syringe using data 
from BD Ltd (please see Appendix 6: The BD Ltd. data sheet).  Therefore, the 
maximal error for the concentration of the IMP and hence the EC95% is ± 
(1.4%+0.88%+3.5%+3.5%) =± 9.3%.  This assumption is likely to be grossly in 
excess of the true error as it assumes that all the errors were maximal and that 
they all changed the concentration in the same direction. 
A more reasonable calculation is to sum the error squared and get the square 
root of the result.  This assumes that some of the errors will cancel each other 
out (Taylor 1982). 
Therefore Final error=√(1.4)2+(0.88)2+(3.5)2+(3.5)2 
   =√(1.96)+(0.7744)+(12.25)+(12.25) 
   =√(27.2344) 
   =5.2% 
EC95%= 0.0357% maximal error (± 9.3% of the marked concentration) i.e ± 0.003%  
or sum of squares(± 5.2% of the marked concentration) i.e ±0.0019% 
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5.11.14 Total estimated experimental error for duration of 
analgesia 
The standard error of the mean was 36 minutes for the duration of analgesia 
with an estimated the duration of analgesia of 166 minutes.  Therefore, the 
estimated biological variation and pharmacological error had a 95% confidence 
interval of ± 21% of the estimated duration of analgesia provided by the EC95 
concentration of levobupivacaine (0.036%). 
5.11.15 Sensory testing 
Sensory testing was included in the protocol in an attempt to reduce the placebo 
effect attributed to the provision of all analgesic procedures.  It was possible 
that a placebo analgesic effect was present although great care was taken to 
explain to the patients that the procedure (femoral 3-in-1 nerve block) may not 
give pain relief.  In order to minimise the placebo effect a change in the pain 
NRS score at 30 minutes after the injection of levobupivacaine was regarded as 
unreliable unless it was accompanied by an appropriate sensory change affecting 
the femoral nerve distribution.  The agreement between the measured analgesic 
response and the sensory testing with melting ice and a blunted 25G needle 
makes it less likely that a placebo response was responsible for the analgesic 
effect measured in this clinical trial. 
5.11.16 Further work 
This clinical trial has produced an estimate of the effective dose required to 
provide analgesia (EC95) and the associated duration of the analgesia.  This result 
suggests that the doses of local anaesthetic commonly used in current clinical 
practice are in excess of what is required to provide analgesia.  A similar clinical 
trial design (the sequential up /down Dixon’s methodology) could be used to 
investigate the dose of levobupivacaine required to provide a clinically useful 
duration of analgesia (10 hours).  The result of this trial would be an estimate of 
the EC95 and the EC50 required for 10 hours of analgesia. 
5.11.17 Conclusion 
The median duration of analgesia from 30 ml of 0.036% (the EC95 of 
levobupivacaine) was 166 minutes with an interquartile range of 110 to 
210 minutes.  The peak median total serum plasma concentration was reached 
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at 30 minutes after the block and was 52 ng/ml and it was well within the ‘safe 
range’ despite a wide variation in the plasma concentrations observed in this 
study (range at 30 minutes 16 to 256 ng/ml).  It was therefore concluded that 
the EC95 dose of levobupivacaine was safe but provided too short a duration of 
action to be of clinical value 
.
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3.1 Summary of chapter 5 
5.11.18 Aim 
The aim of this study was to determine the duration of analgesia provided by the 
EC95 dose of levobupivacaine and ensure that it had a safe pharmacokinetic 
profile in the patients with a fractured neck of femur. 
5.11.19 Method 
The duration of analgesia in 14 patients with a fractured neck of femur provided 
by a femoral 3-in-1 nerve block with 30 ml of 0.036% levobupivacaine (the EC95 
dose of levobupivacaine) was measured.  Blood samples where taken at 5, 10, 
20, 30 and 60 minutes after the block to determine the plasma levobupivacaine 
concentrations. 
5.11.20 Results 
The median duration of analgesia was 166 minutes with a standard error of 
36 minutes.  The plasma concentrations of levobupivacaine varied widely but 
were well within safe limits. 
5.11.21 Conclusion 
The median duration of analgesia provided by 30 ml of 0.036% levobupivacaine 
was too short to be clinically useful but the plasma levels of levobupivacaine 
were within safe limits in the fractured neck of femur population. 
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6 Can nerve block for hip surgery be improved by 
ultrasound and nerve stimulator guidance? 
6.1 Aim 
To determine if the use of ultrasound and nerve stimulator guided femoral 3-in-1 
nerve block can improve the effectiveness of this nerve block in comparison to a 
technique utilising loss of resistance. 
6.2 Study design 
This study was an assessor-blinded, prospective, randomised controlled study of 
three techniques to guide the insertion of a femoral 3-in-1 nerve block; 
ultrasound, nerve stimulator and loss of resistance. 
6.3 Study Population 
One hundred and eighty competent patients scheduled for elective primary total 
hip arthroplasty were prospectively recruited to this study between 1st February 
2009 and 23rd December 2010 in three hospitals in Glasgow, Scotland. 
6.3.1 Inclusion criteria 
The following inclusion criteria were used: 
• Scheduled for elective primary total hip arthroplasty with spinal 
anaesthesia 
• American Association of Anaesthetists classification (ASA) ≤4 ( 1963;Little 
1995). 
• Able to give informed consent 
• Able to cooperate with sensory and motor testing of lower limb function 
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6.3.2 Exclusion criteria 
The following exclusion criteria were used: 
• Abnormal clotting screen or platelet count, (International Normalised 
Ratio (INR) >1.4) or (platelets <100,000/mm3) respectively that would 
normally preclude regional anaesthesia. 
• Acute mental test score of ≤7 at any time pre- or postoperatively 
• History of allergy to any local anaesthetic agent 
• Signs, symptoms or laboratory evidence of local infection or systemic 
sepsis that would normally preclude central neuraxial regional 
anaesthesia 
• Known pre-existing neurological deficit (sensory or motor) affecting the 
lower limb 
• Patients with a lower limb amputation 
6.3.3 Criteria for withdrawing a patient from the study 
• Patients were allowed to withdraw from the study at any time without 
giving any reason or justification 
• Patients with an acute metal test (AMT) ≤7/10 at any time 
intraoperatively or up to 24 hours postoperatively
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6.3.3.1 Summary of clinical anatomy of the femoral nerve 
The femoral nerve is formed in the body of the psoas muscle from the anterior 
primary rami of L2-4, inferiorly it lies on the surface of a groove between iliacus 
muscle laterally and psoas muscle medially.  It is covered by the iliacus fascia 
which also covers the lateral cutaneous nerve of the thigh and separates both 
nerves from the femoral artery and vein.  The femoral nerve passes under the 
inguinal ligament and divides into multiple terminal branches.  The femoral 
nerve is therefore best visualised at or just distal to the inguinal ligament before 
it divides into its terminal branches. 
 
Figure 6-1: Left femoral nerve, vein and artery with fascia lata and superficial structures 
removed 
 
Adapted from Last’s Anatomy Regional And Applied, 4th edition Churchill 
publishing page 193 
Chapter 6 
Page 123 of 287 
6.4 Methodology 
6.4.1 Randomisation 
Patients recruited to the study were randomised into one of the three 
techniques in a ratio of 1(loss of resistance):2(nerve stimulator):2(ultrasound) by 
computer generated block randomisation into groups with random block lengths 
of 5 or 10 patients.  After the patient was consented they were randomised by 
opening a sealed envelope.  The randomisation sequence was held at the 
Robertson Centre for Biostatistics, Glasgow and only on completion of the study 
was the full randomisation sequence unblinded and checked against the actual 
envelopes used to randomise patients recruited to the study. 
6.4.2 Preoperatively  
Consented unpremedicated patients were transferred to the operating theatre 
approximately 45 minutes prior to their scheduled operation and initial sensory 
and motor function testing was performed by an assessor blinded to the 
allocated technique.  A femoral 3-in-1 nerve block was inserted preoperatively 
using one of the three techniques described with the following local anaesthetic 
mixture; 10 ml of 0.25% levobupivacaine mixed with 10 ml of 2% lignocaine.  The 
regional needles used were 18G; 50 mm or 100 mm Contiplex Tuohy tipped 
needles (B. Braun Ltd.) for all femoral 3-in-1 nerve blocks.  Lidocaine 1% 0.5 ml 
was injected intradermally for skin anaesthesia before regional needle skin 
puncture.  The number of skin punctures and time taken to complete the 
femoral 3-in-1 nerve block was recorded. 
6.4.2.1 Methodology for ultrasound guided femoral 3-in-1 nerve block 
A LOGIQ e ultrasound machine (GE Ltd.) with a linear broad band (8-12 MHz) 
probe was used to obtain short axis images of the common femoral artery, vein 
and nerve, parallel to the inguinal ligament (see Figure 6-2 and Figure 6-3) and 
the needle was introduced in plane until the tip was positioned lateral to the 
femoral nerve under the fascia iliacus membrane.  After a ‘negative’ aspiration 
to detect accidental intravascular placement, 1 ml of local anaesthetic mixture 
was injected to ensure spread of local anaesthetic around the femoral nerve 
with associated ‘tenting’ of the fascia iliacus membrane.  If this did not occur 
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then the needle tip was repositioned and the 1 ml test injection repeated.  Only 
after satisfactory local anaesthetic spread had been achieved and a ‘negative’ 
aspiration for inadvertent intravascular placement had been performed was the 
remaining local anaesthetic injected. 
Figure 6-2: Position of ultrasound probe for a left femoral 3-in-1 nerve block 
  
 
Image from personal collection of Dr Malcolm Watson 
Figure 6-3: Short axis ultrasound image of femoral nerve artery and vein 
 
Image from personal collection of Dr Malcolm Watson 
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6.4.2.2 Methodology for nerve stimulator guided femoral 3-in-1 nerve 
block 
The needle punctured the skin 1 cm lateral to the femoral artery and 1.5 cm 
below the inguinal ligament.  A Stimulpex HNS12 nerve stimulator was used with 
the starting current set to 1 milliamp (2 Hz frequency and 0.1 millisecond 
duration) ( 1963a;Tsui 2007).  The needle was positioned to achieve contractions 
of the quadriceps femoris muscle.  Once this motor response had been elicited 
the current was reduced and the needle positioned until the quadriceps motor 
response was elicited at less than 0.5 milliamps and disappeared below 0.3 
milliamps.  After the motor response was achieved and a ‘negative’ aspiration 
for inadvertent intravascular placement had been performed, the local 
anaesthetic dose was injected. 
6.4.2.3 Methodology for loss of resistance guided femoral 3-in-1 nerve 
block  
The needle was inserted perpendicular to the skin at a point 1 cm below the 
junction of the lateral third and medial two thirds of a line that joined the pubic 
tubercle to the anterior superior iliac spine. The needle was advanced until the 
‘2 losses of resistance’ of the fascia lata and the fascia iliacus respectively were 
felt.  After a ‘negative’ aspiration for inadvertent intravascular placement, the 
local anaesthetic dose was injected. 
6.4.3 Assessment of sensory function  
The patient’s sensory function was assessed by the intensity of a pin prick 
sensation using a blunted 25G needle.  The patient was asked to grade the 
intensity of the sensory response to a blunted 25G needle by verbalising or 
marking a 100 mm line scored from 0 (no sensation) to 100 (normal sensation).  
A sensory score of 100 was defined as the same intensity of sensation in the 
corresponding area of the contra lateral thigh.  The patient was asked how the 
sensation to a blunted 25G needle compared to contra lateral (unblocked side) 
on the medial (M), anterior (A) and lateral region (L) of the upper thigh (See 
Figure 6-4).  The change in sensation associated with effective regional analgesia 
was initially defined as a reduction in sensation to a blunted 25G needle in the 
anterior aspect of the upper thigh (which is area marked as A in Figure 6-4) of 
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≤30/100 in comparison with the contra lateral area in the anterior aspect of the 
upper thigh (Marhofer et al. 1997).  As a result of the clinical trial described in 
Chapter 4 the definition of an effective femoral 3-in-1 nerve block was amended 
to a score of ≤90/100 in the anterior aspect of the upper thigh as this sensory 
response was associated with analgesic efficacy. 
Figure 6-4: The surface anatomy of the upper thigh: The anterior (A), lateral (L) and medial 
(M) aspects of the upper thigh are shown in the diagram below. 
 
Image from personal collection of Dr Malcolm Watson 
6.4.4 Assessment of motor function  
6.4.4.1 Assessment of femoral nerve function (quadriceps femoris 
muscles) 
The patient’s ability to extend at the knee with the hip semi flexed (to 20 
degrees) was assessed and defined as follows: 
Grade 4 
Patient was able to raise heel from the bed against force applied by 
assessors arm with assessors elbow flexed at 90 degrees 
Grade 3 
Patient not able to raise heel from the bed against force applied by 
assessors arm with assessors elbow flexed at 90 degrees but patient was able to 
raise heel against gravity alone. 
Grade 2 
Patient able to extend the knee with gravity eliminated 
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Grade 1 
Palpable contraction of quadriceps muscles but no but movement at hip 
joint 
Grade 0 
No movement of joint on voluntary contraction of quadriceps muscles 
Please see section ‘6.5.6 Protocol amendment affecting motor assessments’ for 
a complete description of all the assessment methods used. 
6.4.4.2 Obturator nerve function (hip adductor muscles) 
Obturator motor function was assessed using a method described by Lang et al 
(Lang 1998) which measured the maximal pressure generated on adduction.  The 
patient was asked to adduct both legs with maximal force with the knees and 
hips extended.  The obturator motor function was measured by calculation the 
average of three maximal pressures generated by a manometer cuff inflated to a 
starting pressure of 40 mmHg on the upper thigh.  An obturator nerve block was 
defined as a decrease in pre-block average maximal pressure of ≥20% (Lang et 
al. 1993). 
6.4.5 Intra operatively 
All patients recruited to the study were scheduled for central neuraxial spinal 
anaesthesia using ‘heavy 0.5% bupivacaine’.  The volume of ‘heavy 0.5% 
bupivacaine’ used was decided by the attending consultant anaesthetist.  
Sedation was also used at the discretion of the attending anaesthetist 
(midazolam, propofol or a low dose volatile agent (<1.5 minimum anaesthetic 
concentration [MAC]).  The airway management was determined by the 
attending anaesthetist.  All patients received paracetamol 1 g every six hours 
unless contraindicated.  Intra operative morphine was administered at the 
discretion of the attending consultant anaesthetist and was guided by local 
protocols. 
6.4.6 Postoperatively 
6.4.6.1 Assessment of pain scores 
A pain score measures a patient's pain intensity or other features. Pain scores 
are based on self-report, observational (behavioral), or physiological data.  A 
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self-reported score such as the Numeric Rating Score provides the most accurate 
data.  It may be used for adults and children over 10 years old or older.  Pain 
scores were assessed on a 100 point numerical rating scale (NRS) scoring system.  
Pain scores were assessed on a 100 point numerical rating scale (NRS).  The 
following verbal descriptions were used to guide patients; 0-29 mild pain, 30-69 
moderate pain and 70-100 severe pain.  Pain NRS scores were used throughout 
all clinical studies in this thesis as the pain visual analogue scale (VAS) was found 
to be difficult to use in patients with a fractured neck of femur.  The use of the 
pain NRS scores in both elective hip arthroplasty patients and patients with a 
fractured neck of femur allowed comparison of the data from both studies. 
6.4.7 Estimation of the number of patients needed to answer 
research questions 
The expected percentage of effective femoral 3-in-1 nerve blocks in the three 
groups was 95% (ultrasound), 75% (nerve stimulator) and 50% (loss of resistance) 
(Dolan et al. 2008;Marhofer et al. 1997). The p value was split for the two 
comparisons (Abdi 2007;Tsui 2007), for the ultrasound group and nerve 
stimulator group versus loss of resistance group the alpha error was set at 0.025 
and for the ultrasound versus nerve stimulator comparison the alpha error was 
set at 0.025.  If the Fisher exact method and a two sided comparison were used 
then 72 patients per group need to be recruited to the ultrasound and nerve 
stimulator groups and 36 patients to the loss of resistance group to adequately 
power the study.  The loss of resistance versus nerve stimulator and ultrasound 
comparison would have a 90% power to detect a difference between the groups.  
The ultrasound and nerve stimulator versus loss of resistance comparison would 
have an 80% power to detect a difference between the groups.  It was therefore 
estimated that the study needed to recruit a total of 180 patients in the ratio 
2 (ultrasound):2 (nerve stimulator):1 (loss of resistance). 
6.4.8 Primary end point 
Effective regional analgesia was defined as ≤90/100 of initial sensory stimuli to a 
blunted 25G needle in area of skin supplied by the femoral nerve (anterior 
aspect of upper thigh) and/or evidence of loss of motor power in the quadriceps 
muscles (inability to raise the heel from bed with hip flexed to 20 degrees 
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against the assessors arm) ≤3/4 motor score at 30 minutes post insertion of local 
anaesthetic. 
6.4.9 Secondary end points 
• Sensory function of the anterior, lateral and medial areas of the upper 
thigh at 10 and 20 minutes after insertion of local anaesthetic block. 
• Motor function of the knee extensors and hip adductors at 10 and 
20 minutes after insertion of local anaesthetic block. 
• Sensory function at 30 minutes in the lateral and medial areas of the 
upper thigh and the hip adductor muscle function at 30 minutes. 
• Time taken and number of attempts to insert femoral 3-in-1 nerve block 
• Acute mental test scores six hours postoperatively and at 24 hours post-
anaesthesia  
•  Morphine usage six hours post-anaesthesia, and 24 hours post-operatively 
•  Patient satisfaction score six hours and 24 hours post-operatively  
•  The day and time the patient was mobilised on hip joint by physiotherapy. 
•  Hospital mortality 
6.4.9.1 Standards and quality control 
The current study was conducted to the standards detailed in the guidelines by 
the Chief scientist office, Scotland in ‘Research Governance Framework for 
Health and Community Care’ 2nd edition published in February 2006 ( 2006).  
This study was audited by NHS Greater Glasgow and Clyde Heath Board (report 
included in Appendix 9) and the data was recorded, stored and processed to 
comply with the Data Protection Act 2008 (Data protection act 2008). 
6.4.10 Summary of data management 
Case Report Forms (CRFs) which contained the original study data and all 
identifiable patient data were stored in a locked filing cabinet in a locked office.  
Original data was entered without any personally identifiable data into a 
password protected computer database to which the chief investigator has never 
had access.  On completion of the study, the data in the database was error 
checked by two investigators involved in the study (not the chief investigator) 
against the data on the CRFs.  Patient case notes were requested when 
necessary to obtain the most complete data set.  The chief investigator was 
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given access to a copy of the complete data set, for analysis  To allow future 
audit of this study a complete copy of the original complete data set has been 
retained to which the chief investigator will never have access. 
6.4.11 Standardisation of assessments and study procedures 
To minimise the bias from different assessment methods only four assessors 
carried out all the sensory and motor assessments (please see Appendix 10) and 
all were trained by Dr Malcolm J Watson and supervised for the first five 
assessments to ensure accuracy and consistency.  The assessor of the primary 
and secondary end points was blinded to the method used to site the femoral 3-
in 1 nerve block (i.e. assessor blinded). 
 
Two digital manometers were used to record the motor power of the obturator 
never during this study.  The accuracy and precision of the BP cuffs used for 
obturator (adductor) motor power testing was recorded before they were used in 
the study, after 50 patients had been recruited and at the end of the study when 
all 180 patients had been recruited.  The final quality assurance reports for both 
manometers are included in Appendix 11. The variation in manometer precision 
and accuracy was <1 mmHg throughout the study for both manometers. 
 
6.4.12 Statistical methods 
All statistical tests used to analyse the results of this study were 
non-parametric; however, both parametric and non-parametric methods where 
used to describe the distribution of values.  The results of this study were 
analysed using Minitab (Version 15).  The statistical analysis was conducted by Dr 
Malcolm Watson and supervised by Dr Alex McConnachie, a senior statistician at 
the Robertson Centre for Biostatistics, Glasgow University. 
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6.5 Results 
A total of 180 patients scheduled for elective primary hip replacement were 
prospectively recruited from 1 February 2008 to 23 December 2010.  Seventy one 
patients were recruited and randomised to the nerve stimulator group, 72 
patients to the ultrasound group and 37 patients to the loss of resistance group. 
6.5.1 Demographics 
Tables 6-1 and 6-2 show the demographics of the patients recruited in this 
study.  Table 6-1 shows the percentage of patients recruited at each site. Table 
6-2 shows the age, gender, weight, height and BMI of patients of the patients 
with respect to the technique used to guide the femoral 3-in-1 nerve block. 
Table 6-1: The number of patients recruited on each site 
 
Gartnavel General 
hospital 
Glasgow Royal 
Infirmary 
Golden jubilee 
hospital 
Number of patients 
recruited/total 
120/180 31/180 29/180 
Percentage of total 
recruitment 
66.7% 17.2% 16.1% 
 
Table 6-2: The age, weight, height and BMI* of patients recruited to the study 
 Loss of resistance Nerve stimulator Ultrasound 
Median age 
(Ave. ± SD) 
62.6 
(64.0 ± 12.7) 
64.1 
(64.2 ± 12.7) 
65.5 
(63.9 ± 12.3) 
Gender 
Male, n(%) 
Female, n(%) 
 
12/37(32.4) 
25/37(67.6) 
 
28/71(39.4) 
43/71(60.6) 
 
28/72(38.9) 
44/72(61.1) 
Median Weight (Kg), 
(mean ± SD) 
73.6 
(74.7 ± 13.3) 
80 
(78.4 ±18.6) 
75.5 
(78.4 ± 16.6) 
Median Height (m) 
(mean ± SD) 
1.63 
(1.63 ± 0.085) 
1.64 
(1.66 ± 0.094) 
1.635 
(1.65 ± 0.085) 
Median BMI* (Kg/m2) 
(mean ± SD) 
27.7 
(28.1 ± 4.0) 
29.7 
(28.5 ± 6.1) 
28.2 
(28.8 ± 5.2) 
*BMI-Body mass index = weight in Kg/ (height in metres)2 
6.5.2 Hospital mortality 
All 180 patients recruited survived to hospital discharge. 
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6.5.3 Time taken to insert femoral 3-in-1 nerve block 
Table 6-3 shows the time taken to insert the femoral 3-in-1 nerve block from 
skin puncture to completion of local anaesthetic injection.  A statistically 
significant difference was seen in the time taken to complete the femoral 3-in-1 
nerve block between the techniques when compared to the ultrasound group; 
loss of resistance took the least time, ultrasound was the next quickest and 
nerve stimulator took the most time.  The statistical significant differences in 
time taken to insert femoral 3-in-1 nerve block are not clinically significant. 
Table 6-3: Time taken to insert femoral 3-in-1 nerve blocks 
 Loss of 
resistance 
Nerve stimulator Ultrasound 
Time (seconds) 
median 
interquartile range 
(mean ± SD) 
 
38 
30-46.25 
(41 ± 20) 
 
86 
56-146 
(130 ±127) 
 
51 
44-75 
(66± 46) 
Mann Whitney test against time to insert 
ultrasound guided block 
P= 0.0001 P= 0.0001  
6.5.4 Number of skin punctures and needle advancements 
Table 6-4 shows the number of skin punctures and needle advancements 
required to complete the femoral 3-in-1 nerve block.  A statistically significant 
difference was seen between the ultrasound and nerve stimulator techniques.  
Significantly fewer skin punctures and needle advancements were needed to 
complete a femoral 3-in-1 nerve block using ultrasound compared with nerve 
stimulator (p=0.0001). 
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Table 6-4: Number of skin punctures to insert femoral 3-in-1 nerve blocks 
 Loss of resistance Nerve stimulator Ultrasound 
Number of patients: 
with data 
with missing data 
 
36 
1 
 
70 
1 
 
72 
0 
Median number of skin 
punctures 
Interquartile range 
(mean ± SD) 
1 
1-1 
(1.02 ± 0.167) 
1 
1-2 
(1.54 ± 1.151) 
1 
1-1 
(1.04 ± 0.201) 
Mann Whitney test against 
ultrasound guided skin 
punctures 
0.7273 0.0002  
Median number of needle 
advancements 
Interquartile range 
(mean ± SD) 
1 
1-1 
(1.14 ± 0.35) 
1 
1-3 
(2.51 ± 2.65) 
1 
1-1 
(1.30 ± 0.68) 
Mann Whitney test against 
ultrasound guided 
advancements 
0.2657 0.0001  
 
6.5.5 Adverse event log 
Table 6-5 shows a sequential list of all the adverse events in the study and the 
associated randomisation number of the patient.  No causal relationship was 
observed between any of the adverse events and this clinical study. 
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Table 6-5: Adverse event log 
Patient randomisation number Description of adverse event 
26 Postoperative pulmonary thromboembolism 
28 Respiratory infection 
34 Postoperative pulmonary thromboembolism 
52 
Bilateral postoperative pulmonary thromboembolism on 
CTPA scan, treated with heparin and then warfarin 
56 
Atheromatous plaque discovered incidentally, in the right 
common femoral artery 
57 
Morphine PCA discontinued on day 0, 15:00 due to patient 
inability to use equipment. AMT score 10/10 (as assessed 
by chief investigator), but ward staff and family believed 
patient to be confused. 
89 
Developed renal failure postoperatively.  The maximum. 
creatinine was 540 µmol/L and urea 15.4 mmol/L on day 
3 postoperatively; electrolytes improved to normal on day 
10 postoperatively.  Renal dialysis was not required 
117 
Haematemesis postoperatively. transferred to Western 
Infirmary 
127 
Episode of congestive cardiac failure postoperatively, 
treated with single dose of frusemide of 20 mg. 
154 Blisters on heel on same side as hip hemiarthroplasty 
157 
Pus in joint-primary hemiarthroplasty not done, 1st stage 
revision completed 
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6.5.6 Protocol amendment affecting motor assessments 
For patient allocations 1 to 15 the following grading system was used: 
 
• Grade 3:  Patient was able to raise heel from the bed against force applied 
by assessors arm with assessors elbow flexed at 90 degrees 
• Grade 2:  Patient not able to raise heel from the bed against force applied 
by assessors arm with assessors elbow flexed at 90 degrees but are able to raise 
heel against gravity alone. 
• Grade 1: Patient able to extend the knee with gravity eliminated (lying on 
their side) 
• Grade 0:  No movement of joints on voluntary contraction of quadriceps 
muscle 
 
It was felt that this grading system lacked sensitivity as had no motor grading 
between ‘movement with gravity eliminated’ and ‘no movement’.  Therefore, a 
protocol amendment was made to include the following grade. 
• Grade 1 Palpable contraction of joint but no but movement at hip joint 
(lying on their side)  
 
Therefore, the motor assessment utilised for patient allocations 16-180 was: 
 
• Grade 4:  Patient was able to raise heel from the bed against force applied 
by assessors arm with assessors elbow flexed at 90 degrees 
• Grade 3:  Patient not able to raise heel from the bed against force applied 
by assessors arm with assessors elbow flexed at 90 degrees but are able to raise 
heel against gravity alone 
• Grade 2: Patient able to extend the knee with gravity eliminated (lying on 
their side) 
• Grade 1: Palpable contraction of quadriceps muscle but no but movement 
at hip joint (lying on their side) 
• Grade 0:  No movement of joints on voluntary contraction of quadriceps 
muscle 
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6.5.6.1 Action taken to utilise data from patient allocations 1 to 15 
To take account of this in the final analysis for the first 15 patients; 1 was added 
to all the motor scores of 1 or more to allow the motor data to be used in the 
final analysis. 
6.5.7 Data anomalies and missing data 
The subjective nature of the sensory and motor assessment, assessor and patient 
error combined to produce a variety of anomalous responses.  The nature of 
these responses and the actions taken to reduce bias on the final result analysis 
are summarised below in ‘anomalous sensory scores’, ‘anomalous motor scores’ 
and Table 6-6: Summary of missing data. 
6.5.7.1 Anomalous sensory scores 
The sensory score for the contra lateral side was defined as 100 and as a result 
the baseline sensory score (for the ipsilateral lower limb) was higher or lower 
than 100 in 8 patients.  The sensory scores for these 8 patients were adjusted so 
that in effect the starting ipsilateral limb sensory score was 100.  This was 
achieved by dividing the patient’s 10, 20 and 30 minute sensory scores by the 
ipsilateral pre-block score and multiplying by 100 (to rebase the score to 100).  
Effective regional analgesia was then defined as a score ≤90/100 of initial 
ipsilateral sensory response to blunted 25G needle in area of skin supplied by the 
femoral nerve (anterior aspect of the upper thigh). 
6.5.7.2 Anomalous motor scores 
A total of 35 patients were recruited to the study with a pre block motor score 
of 3/4 or less which would have fulfilled the criteria for effective regional 
analgesia with no change in femoral nerve motor power. 
The primary end point was redefined as a sensory change of ≤90/100 in the 
anterior upper thigh or a motor score of 3/4 or less if the starting score was 4/4.  
Thus effective regional analgesia was defined only on the sensory response in 
these 35 patients. 
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6.5.7.3  Missing data  
Table 6-6: Summary of missing data 
Patient allocation number Problem Action 
5 
Sensory records recorded on 
a scale of 0-5 
Score were rebased to scale 
of 0-100 
91,123 
Missing number of skin 
punctures, needle 
advancements and time for 
femoral 3-in-1 nerve block 
Primary analysis performed 
without this patients motor 
data 
102 
No motor scores recorded 
for 20 and 30 minutes 
Patient excluded from the 
motor analysis 
150,128,148,156,163,173, 
153,169,175,176,179 
Unable to perform adductor 
power measurements due to 
pain, muscle wasting or poor 
patient cooperation 
The results of these patients 
were excluded from the 
final analysis of obturator 
nerve function 
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6.5.8 Results Part 1-Primary endpoint: 
6.5.8.1 Effective and ineffective regional analgesia using sensory scores 
and motor scores for the femoral nerve at 30 minutes 
The primary end point used combined femoral nerve motor and sensory end 
points to assess the effectiveness of three techniques to site a femoral 3-in-1 
nerve block.  However, although nerve stimulator is routinely used for femoral 
3-in-1 nerve blocks for elective arthroplasty it is unlikely to be used for patients 
with a fractured neck of femur due to the electrical stimulation of the femoral 
nerve and resultant movement of an unfixed fracture.  The important clinical 
and research question was whether loss of resistance was an effective 
alternative to ultrasound.  Loss of resistance represents a significantly simpler 
technique to guide a femoral 3-in-1 nerve block than ultrasound.  A total of 17 
practitioners were used, all of whom were considered competent to site a 
femoral 3-in-1 nerve block (Please see Appendix 10) as is unlikely that an expert 
practitioner would be available. 
The first research question was whether loss of resistance was as effective at 
providing a femoral 3-in-1 femoral nerve block as techniques using nerve 
stimulator and ultrasound.  The second research question was whether the nerve 
stimulator or ultrasound was most effective at providing a femoral 3-in-1 
femoral nerve block.  The first question is arguably the most important as the 
use of the nerve stimulator in patients with a proximal femoral fracture would 
result in significant discomfort and potential displacement of an unfixed 
fracture.  Two primary end points were used to answer these two research 
questions and using the Bonferroni correction (Abdi 2007) the p-value was set at 
p<0.025) for each primary comparisons. 
6.5.8.2 Summary of primary end points 
Question 1: Is loss of resistance as effective as nerve stimulator and ultrasound? 
and 
Question 2: Is ultrasound as effective as nerve stimulator? 
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6.5.9 Question 1:  
Is loss of resistance as effective as nerve stimulator and 
ultrasound? 
A total of 35 patients recruited to this study had a starting motor score of 3/4 or 
less and as a result of the original chosen definitions of effective and ineffective 
regional analgesia these patients were all defined as effective even if their 
motor and sensory scores did not change from their starting values.  The chosen 
sensory end point was correlated with analgesia but there is no evidence of an 
association between motor scores and analgesia. 
Table 6-7 shows the primary end point results if the 35 patients (with pre-block 
motor scores of ≤3/4) were included in the primary analysis (for research 
question 1) and their outcome was based only on their sensory data. 
Table 6-7: The primary end point as originally defined for sensory and motor scores for 143 
patients.  However in the 35 patients with a starting motor score of 3 or less the primary end 
point was only defined by their sensory scores 
 
Ultrasound and nerve 
stimulator 
Loss of resistance 
Number of patients (Ineffective) 28 15 
Number of patients (Effective) 114 22 
Total 142 37 
Percentage effective blocks 80.3% 59.5% 
p-value (using Fisher exact, p ≤0.025) p=0.0159  
(NB patient 102 allocated to the ultrasound group was not included in the combined motor and 
sensory analysis as no motor end point data was recorded for this patient) 
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6.5.10 Question 2:  
Is Ultrasound as effective as nerve stimulator? 
Table 6-8 shows the primary end point results if the 35 patients were included in 
the primary analysis (for research question 2) and their outcome was based only 
on their sensory data. 
Table 6-8: Primary end point using motor and sensory scores (with patients with a starting 
motor score of ≤3/4 the primary end point was defined only by their sensory scores) 
 Ultrasound Nerve stimulator 
Number of patients (Ineffective) 16 12 
Number of patients (Effective) 55 59 
Total 71 71 
Percentage effective blocks 77.5% 83.1% 
p-value (using Fisher exact p ≤0.025) p=0.527  
(NB patient 102 allocated to the ultrasound group was not included in the combined motor and 
sensory analysis as no motor end point data was recorded for this patient) 
 
6.5.10.1 Alternative definition for the motor endpoint for an effective 
femoral 3-in-1 nerve block  
It would have been possible to use a one point drop in the motor score as the 
motor endpoint (see Table 6-9); however, the motor scale was not linear (see 
section 6.5.12 Results Part 3, Analysis of efficacy of femoral 3-in-1 block by 
femoral motor data).  There is no evidence that a one point drop in the motor 
score from 3/4 to 2/4 would be equivalent to the original primary end point (a 
decrease from 4/4 to 3/4).  Table 6-9 shows the results with an effective motor 
end point defined as a one point drop in the femoral motor score. 
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Table 6-9: Primary end point using motor and sensory scores (redefined motor end point as 
one point drop in motor score or greater defined as effective regional analgesia) 
 
Ultrasound and nerve 
stimulator 
Loss of resistance 
Number of patients (ineffective) 19 9 
Number of patients (effective) 123 28 
Total 142 37 
Percentage effective blocks 86.6% 75.7% 
p-value (using Fisher exact, p ≤0.025) p=0.127  
(NB patient 102 allocated to the ultrasound group was not included in the combined motor and 
sensory analysis as no motor end point data was recorded for this patient) 
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6.5.11 Results Part 2:  
Primary end point efficacy of femoral 3-in-1 nerve block defined 
by sensory scores  
The results of Chapter 4 suggested that a pin prick sensory score in the anterior 
upper thigh of ≤90/100 was associated with analgesia with a sensitivity and 
specificity of 93.3% and 92.6%, respectively.  Table 6-10 and 6-11 show the 
primary end point analysis to answer research questions 1 and 2 using only 
sensory data. 
6.5.11.1 Research question 1: 
Is loss of resistance as effective as nerve stimulator and ultrasound? 
Table 6-10: Primary end point with effective and Ineffective regional analgesia defined only 
using sensory data 
 
Ultrasound and nerve 
stimulator 
Loss of resistance 
Number of patients (Ineffective) 42 18 
Number of patients (Effective) 101 19 
Total 143 37 
Percentage of effective blocks 70.6% 51.4% 
p-value (using Fisher exact, Sign p≤0.025) p=0.0321  
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6.5.11.2 Research question 2:  
Is ultrasound as effective as nerve stimulator? 
Table 6-11: Primary end point with effective and Ineffective regional analgesia defined only 
using sensory data 
 Ultrasound 
Nerve 
stimulator 
Number of patients (Ineffective) 25 17 
Number of patients (Effective) 47 54 
Total 72 71 
Percentage of effective blocks 65.3% 76.1% 
p-value(using Fisher exact, p ≤0.025) p=0.199  
 
If the efficacy of the femoral 3-in-1 nerve block is defined by sensory data a 
larger difference was observed (10.8% in comparison to 5.6% in Table 6-10) 
between ultrasound and nerve stimulator treatment groups in comparison to the 
use of the combined motor and sensory end points used in Results part 1.  This 
suggests that that the inclusion of the femoral motor (knee extensor) data to 
define the efficacy of a femoral 3-in-1 nerve block may have reduced the ability 
of the study to discriminate between the treatment groups. 
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6.5.12 Results Part 3:  
Analysis of femoral 3-in-1 nerve block by femoral motor response 
The motor power of two nerves was tested during the study; the femoral and the 
obturator nerve. The femoral motor response (extension of a flexed knee against 
resistance with the hip flexed to 20 degrees) formed one part of the assessment 
for the primary outcome.  In contrast to the sensory data which was correlated 
with an analgesic response, there is no evidence in the literature of a correlation 
between femoral nerve motor scores and analgesia. 
 
The correlation between the femoral motor score at 30 minutes and the sensory 
score (to a blunt 25G needle on the anterior upper thigh) was investigated to 
find the best fit model.  Thirty five patients with pre-block motor scores of three 
or less were excluded and one patient had no motor scores recorded (patient 
102) was also excluded.  The remaining 143 patients were analysed using the 
spearman rank correlation coefficient to determine the best fit model.  A linear 
relationship between the motor scores and the sensory scores gave an r squared 
value of 3.2% or r squared adjusted of 2.5% which implied that the relationship 
was very weak (see Figure 6-5).  This implies that 2.5% of the all the changes in 
value of the motor scores can be explained by the sensory scores by using a 
simple linear relationship. 
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Figure 6-5: Femoral motor scores against femoral sensory scores at 30minutes 
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If the natural log of the femoral motor scores is calculated (omitting the two 
motor scores of 0 (as the natural log of 0 can not be calculated then the Pearson 
correlation coefficient was r=0.151 and the r-squared value was 1.5% and r 
squared adjusted was 0.5%. 
Figure 6-6: ln(Femoral motor score) power against femoral sensory score at 30 minutes 
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Patients with a sensory score of 0 were excluded from the analysis.  If the 
natural log is taken of the remaining sensory scores and the motor scores 
(106 patients were analysed) then the r value was r=-0.0430 and the r squared 
value was 0.2% and an r squared adjusted of 0% (see Figure 6-7).   
Figure 6-7: ln(femoral motor scores at 30mins) against ln(femoral sensory scores at 30mins) 
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The femoral motor scores at thirty minutes do not correlate to the femoral 
sensory scores to a blunt 25G needle at 30 minutes.  Sensory scores to blunted 
25G needle are correlated to analgesia (please see Chapter 4).  It is therefore 
likely that if the motor scores are correlated to analgesia the relationship is 
independent of the relationship between femoral sensory scores and analgesia.  
The inclusion of the motor scores in the primary outcome may have decreased 
the sensitivity and specificity of the primary analysis. 
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6.5.12.1 The obturator motor response 
The obturator nerve has a limited cutaneous sensory distribution to the upper 
medial aspect of the thigh in a minority of patients (Bouaziz et al. 2002b); as a 
result, it is accepted that the only reliable way of determining obturator nerve 
block is by testing for a weakness in adductor power (Lang et al. 1993).  The 
results of testing for adductor motor power reduction are summarised in table 6-
12. 
Table 6-12: Obturator nerve involvement assessed using adductor strength measured by 
thigh manometer cuff using the method of Lang et al (Lang 1998). 
 Loss of resistance Nerve stimulator Ultrasound 
Number of patients effective 2 10 7 
Number of patients ineffective 34 56 60 
Excluded (patient unable to 
cooperate) 
1 5 5 
Total 37 71 72 
Percentage obturator block 5.9% 17.9% 11.7% 
 
In this study, <20% of patients had motor evidence of an obturator nerve block 
using the definition first described by Lang et al (Lang et al. 1993).  In this 
study, the nerve stimulator technique had the highest incidence of obturator 
nerve block. 
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6.5.13 Results Part 4 
Trends in sensory scores over time 
We analysed the trends in sensory scores over time for the different methods of 
guiding a femoral 3-in-1 nerve block.  The null hypothesis was that if all methods 
of guiding local anaesthetic administration acted on the nerves in the same way 
then the sensory change onset and profile would not be significantly different 
for each of the three techniques.  We analysed only effective sensory blocks as 
arguably ineffective blocks were not sited correctly.  Figure 6-8 and 6-9 show 
the mean and median sensory scores, respectively, plotted against time and 
lateral, medial or anterior position on anterior upper thigh for all effective 
femoral 3-in-1 nerve blocks. 
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Figure 6-8: Mean sensory scores for all effective femoral 3-in-1 nerve blocks against time 
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Figure 6-9: Median sensory scores for all effective femoral 3-in-1 nerve blocks against time 
Median sensory scores tends against time after effective 
femoral 3-in-1 nerve block
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6.5.14 Sensory score against technique used for femoral 3-in-1 
nerve block 
The distribution of sensory scores was very wide indicating a large variation in 
the sensory scores reported by unpremedicated elective primary hip arthroplasty 
patients (see Table 6-13).  A statistically significant difference was noted in the 
sensory scores at 10, 20 and 30 minutes in the medial section of the upper thigh 
for the loss of resistance technique in comparison to the nerve stimulator 
technique.  A statistically significant difference was also recorded in the sensory 
scores at 20 and 30 minutes in the medial section of the upper thigh for the loss 
of resistance technique in comparison to use of ultrasound (see Table 6-14).  
There was no statistically significant difference in sensory scores between 
ultrasound and nerve stimulator techniques.  This implies that there was no 
difference between the techniques in terms of their effect on sensory scores 
and, by association, no difference in analgesic efficacy. 
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Table 6-13: Summary of the results for sensory scores for all effective femoral 3-in-1 nerve blocks (/100) 
 Loss of resistance Nerve stimulation Ultrasound 
Sensory score Medial Anterior Lateral Medial Anterior Lateral Medial Anterior Lateral 
10 minutes 
Median 
(mean ± SD) 
 
100 
(73±44) 
 
91 
(68±38) 
 
100 
(79±36) 
 
60 
(53±43 
 
65 
(57±41) 
 
78 
(65±45) 
 
80 
(66±39) 
 
70 
(62±38) 
 
90 
66±39 
20 minutes 
Median 
(mean ± SD) 
 
80 
(74±41) 
 
25 
(40±37) 
 
77 
(58±38) 
 
38 
(44±42) 
 
50 
(45±39) 
 
56.5 
(59±45) 
 
50 
(46±40) 
 
30 
(38±36) 
 
60 
57±39 
30 minutes 
Median 
(mean ± SD) 
 
75 
(63±47) 
 
25 
(38±35) 
 
50 
(55±40) 
 
5 
(36±42) 
 
22 
(34±34) 
 
50 
(52±44) 
 
20 
(34±38) 
 
10 
(25±30) 
 
40 
(41±36) 
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Table 6-14: Summary of statistical analysis of methods used for a femoral 3-in-1 nerve block 
and sensory scores (comparisons with a p<0.05 are shown in bold) 
Statistical test used Comparison p-value 
Loss of resistance and 
nerve stimulator 
0.0097 
Mann Whitney between sensory scores at 
30 minutes in medial area of the upper thigh 
Loss of resistance and 
ultrasound 
0.0161 
Loss of resistance and 
nerve stimulator 
0.0100 
Mann Whitney between sensory scores at 
20 minutes in medial area of the upper thigh 
Loss of resistance and 
ultrasound 
0.0152 
Loss of resistance and 
nerve stimulator 
0.0480 
Mann Whitney between sensory scores at 
10 minutes in medial area of the upper thigh 
Loss of resistance and 
ultrasound 
0.3278 
 
Chapter 6 
 Page 154 of 287 
6.5.15  Results Part 5: 
 Secondary end point analysis: pain NRS scores, morphine 
consumption, acute metal test scores and patient satisfaction 
scores at 6 and 24 hours after a femoral 3-in-1 nerve block.  
This part of the results section will examine the secondary end points of pain 
numerical response scale (NRS) scores, AMT scores, morphine consumption and 
patient’s satisfaction scores at six and 24 hours after femoral 3-in-1 nerve block.  
The definition of effective and ineffective femoral 3-in-1 nerve block relied on a 
surrogate end point which assessed femoral nerve cutaneous sensation and 
motor power.  The relationship between sensory and motor score and analgesia 
is complex and it has not been fully described by the previous studies by Dolan, 
Marhofer and Urbanek (Dolan et al. 2008;Marhofer et al. 1997;Marhofer et al. 
1998;Urbanek et al. 2003).  As a result of this the definition of an effective 
femoral 3-in-1 nerve block was altered during the study and after its completion.  
If the starting motor score was 3/4 or less then only the sensory score to a 25G 
blunted needle was used to define an effective femoral 3-in-1 nerve block 
(results part 1) this definition was used to define an effective regional analgesia 
in this section of the results. 
 
The secondary end points of pain numerical response scale (NRS) scores, AMT 
scores, morphine consumption and patient’s satisfaction scores at six and 24 
hours after femoral 3-in-1 nerve block where analysed against the technique 
used to insert a femoral 3-in-1 nerve block and shown in Tables 6-17 and 6-18. 
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In this section efficacy was defined using sensory score (<90/100) and/or femoral 
motor score using four different definitions (please see Table 6-15 for the 
definitions). 
 
Table 6-15: The femoral motor score definition of a effective femoral 3-in-1 nerve block was 
defined in the following four ways 
Number Motor definition of an effective femoral 3-in-1 nerve block 
1 
The efficacy of the femoral 3-in-1 block in patients with pre-testing motor 
scores of ≤3/4 was defined only by their sensory data 
2 
In patients with pre block motor scores of ≤3/4 an effective motor block 
was defined by a reduction in femoral motor score of 1 or more and/or a 
sensory response 
3 Patients with pre block motor scores of ≤3/4 were defined as ineffective 
4 
Patients with pre-block motor scores of ≤3/4 were excluded from all 
analysis 
 
In this chapter the secondary end points in Tables 6-17 and 6-18 were analysed 
using the combined sensory and motor end points as defined in method 1 in 
Table 6-15 and as used in results part 1 for the primary end point analysis.  The 
data handling for patients with serious protocol violations has been detailed in 
Table 6-16.  The secondary end points results using the femoral motor definition 
of efficacy described in method 2, 3 and 4 (see Table 6-15) are detailed in 
Tables 12-1 to 12-6 in Appendix 12. 
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6.5.15.1  Analysis of secondary end points against efficacy with data from 
those patients with serious protocol violations treated 
Table 6-16 contains a list of the patients with violations of the protocol and a 
summary of the violation and the action taken with respect to the secondary end 
point analysis. 
Table 6-16: Patients with serious protocol violations and the action taken  
Patients Protocol violation Action 
119,120,179 and 180 
Wound infiltration performed 
by surgeon 
All six and 24 hour AMT, patient 
satisfaction, morphine usage and pain 
scores and mobilisation times removed 
from analysis 
82,89 and 93 
Patient had General 
Anaesthesia due to failed 
spinal 
All six and 24 hour AMT, patient 
satisfaction, morphine usage and pain 
scores and mobilisation times removed 
from analysis 
155 
Venflon tissued six and 24 
hour scores invalid 
All six and 24 hour AMT, patient 
satisfaction, morphine usage and pain 
scores and mobilisation times removed 
from analysis 
130 
Diamorphine in spinal 
anaesthesia 
All six and 24 hour AMT, patient 
satisfaction, morphine usage and pain 
scores and mobilisation  times removed 
from analysis 
160 
Morphine not used for 
postoperative pain relief 
All six and 24 hour AMT, patient 
satisfaction, morphine usage, pain scores 
and mobilisation  times removed from 
analysis 
157 
Pus in joint, 1st stage 
revision done 105 
All results included in analysis 
28 
Ward staff pressed morphine 
PCA which they though was 
not working (once) 
All results included in analysis 
62 
Morphine PCA disconnected 
at 18.5 hours after block, 
started on oxycontin and 
oxynorm but no doses given. 
All results included in analysis 
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6.5.15.2 Analysis of secondary end points against efficacy for a femoral 3-
in-1 nerve block (with data from those patients with serious 
protocol violations treated as described in Table 6-16) 
Tables 6-17 and 6-18 shows the results of the analysis of secondary end points 
with protocol violations treated as described in Table 6-16.  The efficacy of the 
femoral 3-in-1 block in patients with pre-testing motor scores of ≤3/4 was 
defined only by their sensory data) 
Table 6-17: Summary of secondary end points against efficacy at six hours 
 
Number of patients 
Ineffective/Effective 
Ineffective Effective 
Mann 
Whitney 
(p-value) 
Pain NRS score (0-100) 
median 
(interquartile range)  
36/133 
 
42.5 
(19-60) 
 
40 
(20-60) 
0.8896 
AMT(1-10) 
median 
(interquartile range) 
35/130 
 
10 
(10-10) 
 
10 
(10-10) 
0.6235 
Morphine consumption(mg) 
median 
(interquartile range) 
36/133 
 
11 
(7-16) 
 
10 
(5-16) 
0.7322 
Patient satisfaction(1-10) 
median 
(interquartile range) 
36/131 
 
10 
(8-10) 
 
10 
(8-10) 
0.8828 
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Table 6-18: Summary of secondary end points against efficacy at 24 hours 
 
Number of patients 
Ineffective/Effective 
Ineffective Effective 
Mann 
Whitney 
(p-value) 
Pain NRS score (0-100) 
Median 
(interquartile range)  
36/131 
 
25 
(10-50) 
 
30 
(11-50) 
0.5133 
AMT(1-10) 
median 
(interquartile range)  
35/131 
 
10 
(10-10) 
 
10 
(10-10) 
1.0 
Morphine consumption(mg) 
median 
(interquartile range) 
36/131 
 
31 
(18-42) 
 
30 
(17-46) 
1.0 
Patient satisfaction(1-10) 
Median 
(interquartile range) 
36/130 
 
9 
(8-10) 
 
9 
(8-10) 
0.9121 
 
6.5.15.3 Summary of secondary endpoints against efficacy 
The secondary endpoint results were not significantly affected by the inclusion 
or exclusion of data from patients with serious protocol violations and by the 
definition of efficacy of a femoral 3-in-1 nerve block.  Please see Appendix 12 
tables 12-1 to 12-6 for multiple analyses of the secondary endpoints using 
different definitions of effective and ineffective analgesia. 
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6.5.15.4 Secondary end points against technique for femoral 3-in-1 nerve 
block  
Table 6-19: Secondary endpoints for techniques of ultrasound, nerve stimulator and loss of 
resistance at six hours 
Technique used 
(Number of patients analysed) 
Loss of 
resistance 
(34) 
Nerve 
stimulator 
(67-69) 
Ultrasound 
(66-64) 
Pain NRS score (0-100) 
median 
(interquartile range)  
 
47.5 
(20-60) 
 
42 
(20-70) 
 
30 
(20-50) 
AMT(1-10) 
median 
(interquartile range)  
 
10 
(10-10) 
 
10 
(10-10) 
 
10 
(10-10) 
Morphine consumption(mg) 
median 
(interquartile range) 
 
9.5 
(6-16) 
 
10 
(5-15) 
 
11 
(5-18) 
Patient satisfaction(1-10) 
median 
(interquartile range) 
 
9 
(8-10) 
 
10 
(8-10) 
 
10 
(8-10) 
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Table 6-20: Secondary endpoints for techniques of ultrasound, nerve stimulator and loss of 
resistance at 24 hours 
Technique used 
(Number of patients analysed) 
Loss of 
resistance 
(34) 
Nerve stimulator 
(68-69) 
Ultrasound 
(64) 
Pain NRS score (0-100) 
median 
(interquartile range)  
 
35 
(10-58) 
 
30 
(20-50) 
 
28 
(10-50) 
AMT(1-10) 
median 
(interquartile range)  
 
10 
(10-10) 
 
10 
(10-10) 
 
10 
(10-10) 
Morphine consumption(mg) 
median 
(interquartile range) 
 
32 
(18-42) 
 
29 
(17-48) 
 
29 
(17-42) 
Patient satisfaction(1-10) 
median 
(interquartile range) 
 
9 
(8-10) 
 
9 
(8-10) 
 
10 
(8-10) 
6.5.15.5 Summary of secondary endpoints against technique analysis 
No statistically significant differences were observed in the secondary end points 
against the technique used; however, a trend towards higher pain NRS scores 
and morphine usage was associated in the loss of resistance group of patients at 
six and 24 hours (please see Tables 6-19 and 6-20 and tables 12-1 to 12-6). 
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Results Part 6: Day postoperatively first mobilised on hip joint by 
physiotherapy 
This section of the results will examine the effect of a femoral 3-in-1 nerve 
block had on mobilisation after hip joint arthroplasty.  Data on mobilisation 
times were available for 174 patients, 35 in loss of resistance group, 68 in nerve 
stimulator group and 71 in ultrasound group.  Ten patients were excluded for 
protocol violations (see Table 6-16).  The inclusion or exclusion of those patients 
with serious protocol violations did not affect the statistical significance of this 
outcome. 
 
Table 6-21: Method 1 table 6-15 used to define effective and ineffective block 
 
Number of 
patients 
ineffective/ 
effective 
Ineffective 
Median 
(interquartile 
range) 
hours 
Effective 
Median 
(interquartile 
range) 
hours 
Mann 
Whitney 
(p-value) 
Mobilisation times in 
hours all patients 
included 
37/137 
23.8 
(21.7-24.7) 
24.3 
(21.9-26.4) 
0.2739 
Mobilisation times in 
hours (10 patients 
excluded for protocol 
violations) 
34/131 
23.9 
(21.6-24.9) 
24.3 
(21.9-26.4) 
0.3479 
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Table 6-22: All patients included (no protocol violation removed) 
 
Loss of 
resistance 
(35 patients) 
Nerve stimulator 
(68 patients) 
Ultrasound 
(71 patients) 
Time from nerve block 
to first mobilisation in 
hours 
Median 
(interquartile range) 
 
 
 
24.7 
(21.9-27.4) 
 
 
 
23.2 
(21.5-26.3) 
 
 
 
24.2 
(22.25-25.6) 
 
No statistically significant differences where observed in mobilisation time as a 
result of the efficacy of the femoral 3-in-1 nerve block or the technique of 
insertion.  The vast majority of the 180 patients in this study mobilised at 
around 24 hours from their operation. 
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6.6 Discussion: 
6.6.1.1 Study design 
This study was designed to determine which method we should use to guide the 
needle insertion for a femoral 3-in-1 nerve block in patients with a traumatic 
fractured neck of femur.  Elective total primary hip arthroplasty patients were 
the chosen as the population for the following reasons: 
• Initial power calculations estimated that a large number of patients (180 
patients) would be required. 
• It was deemed necessary to undertake multi-site recruitment due to the 
large number of patients required. 
• Less that half of the patients admitted with a fractured neck of femur 
have capacity to cooperate with sensory and motor testing. 
• Patients with a fractured neck of femur are admitted as an emergency to 
hospital which would have made recruitment of large numbers difficult. 
The nerve stimulator technique was included because the study population was 
elective primary hip arthroplasty patients.  The use of a nerve stimulator on 
patients with an unfixed fracture would be considered unjustifiable when less 
painful techniques are available.  It was; however, considered to be unethical 
not to include a nerve stimulator treatment group as it was the ‘gold standard’ 
for patients scheduled for elective hip arthroplasty. 
The primary research question to be answered by this study is (research question 
1 chapter 1) is ‘Which method do we use to site the local anaesthetic in patients 
with a fractured neck of femur?’  This study therefore had a split primary end 
point.  The two end points used were 
1 Loss of resistance treatment group against a combined nerve 
stimulator and ultrasound treatment groups. 
2 Nerve stimulator treatment group against the ultrasound treatment 
group. 
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In retrospect it would have been better to have used a single primary end point 
to answer the first research question.  This single end point should have been a 
comparison of the loss of resistance treatment group against the ultrasound 
treatment group.  The comparison of the nerve stimulator group to ultrasound 
group or loss of resistance group should have been included as a secondary end 
point. 
 
6.6.1.2 Sensory and motor testing 
The primary end point in this study, which was used to define effective or 
ineffective femoral 3-in-1 nerve block, was the sensory and motor testing after 
the insertion of the local anaesthetic.  The vast majority of prior work into 
analgesic effectiveness of nerve blockade has used the requirement for 
supplementary anaesthesia or analgesia as the primary end point (Abrahams et 
al. 2009).  Prior to the start of this study the only studies to use sensory scoring 
as the primary end point for a effective blockade were studies of Marhofer et al 
and Kapral et al (Dolan et al. 2008;Marhofer et al. 1997;Marhofer et al. 
1998;Urbanek et al. 2003) and only one study used a combined motor and 
sensory end point to determined whether the blockade was effective or 
ineffective (Dolan et al. 2008).  The results from Chapter 4 of this thesis 
provided evidence of a correlation between the sensory changes and an 
analgesic response with a 96% sensitivity and 92.9% specificity.  This evidence 
was used to alter the primary outcome in a substantial ethics amendment before 
the final patient was recruited and the data was unblinded and analysed.   
The motor component for the efficacy of the femoral 3-in-1 nerve block did not 
have any independent validation.  The motor scores recorded were not recorded 
on a linear or congruent scale and it is not possible to convert those 35 patients 
with a starting motor score of 3/4 or less to be analogous to those patients with 
a starting motor score of 4/4.  The motor definition of an effective femoral 3-in-
1 nerve block was derived from the motor endpoint used in the study by Dolan et 
al prior to its publication (Dolan et al. 2008).  In order to prevent the results of 
those 35 patients with motor score of 3/4 or less from biasing the study in those 
35 patients efficacy was defined solely on the patient’s sensory score at 30 
minutes.  The decision to analyse the femoral motor scores in this way was made 
after the final patient was recruited and the data was unblinded.  In results part 
Chapter 6 
 Page 165 of 287 
3 the correlation between the sensory scores and femoral motor scores was very 
low.  This implied that either the femoral motor scores were not associated with 
analgesia or that the relationship between femoral motor score and analgesia 
was independent of the relationship between sensory scores and analgesia. 
6.6.1.3 Primary end point: Efficacy of the femoral 3-in-1 nerve block 
The primary analysis has shown that the loss of resistance technique was 
statistically significantly less effective than nerve stimulator or ultrasound 
guided techniques for a femoral 3-in-1 nerve block.  The study also showed that 
ultrasound was less effective than nerve stimulator at guiding a femoral 3-in-1 
nerve block but this result was not statistically significant.  These blocks were 
sited by 17 different anaesthetists (see Appendix 10) so the results reflect the 
general skill levels of practicing anaesthetists who stated that they were 
competent to site a femoral 3-in-1 nerve block using all three methods with no 
assistance.  The high efficacy of the nerve stimulator group may perhaps be 
explained by the assessment method.  It has been claimed that the use of a 
nerve stimulator may be associated with an increased incidence of intra-
neuronal injection due to the unreliability of threshold current at determining 
intra-neuronal placement and the lack of clinical evidence of motor or sensory 
deficit following intra-neuronal injection (Lupu et al. 2010;Robards et al. 2009).  
It was hypothesized that intra-neuronal injection of local anaesthetic may be 
associated with a more rapid onset and profound sensory anaesthesia than and 
extra-neuronal injections due to shorter diffusion distances.  There was no 
significant difference between the sensory changes in the upper thigh to blunted 
25G needle associated with nerve stimulator and ultrasound treatment groups.  
These methods were equal in terms of sensory testing and there was no evidence 
that the nerve stimulator produced a rapid onset sensory blockade 
 
In summary, the loss of resistance treatment group had a higher incidence of 
effective blocks and the ultrasound was less effective than was expected.  A 
number of factors may be responsible but the large number of operators used in 
this study may have influenced this outcome.  Ultrasound guided femoral 3-in-1 
nerve block may be more technically demanding than generally appreciated and 
loss of resistance may have a relatively high efficacy when performed by non-
experts.  The use of a nerve stimulator and/or ultrasound improved the 
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effectiveness of the femoral 3-in-1 block by a statistically significant absolute 
difference of 20.8%.  It is likely that in clinical practice the relative efficacy of 
nerve stimulator, loss of resistance and ultrasound techniques for a 
femoral 3-in—1 nerve block appears to differ significantly from the reported 
efficacy of experts. 
6.6.1.4 Secondary end points 
The medial sensory area in the upper thigh had a significantly less sensory 
anaesthesia for the loss of resistance group than for ultrasound and nerve 
stimulator groups at 20 and 30 minutes post insertion of the femoral 3-in-1 nerve 
block.  The most likely explanation for this was the anatomical distance of the 
needle insertion point from the medial aspect of the femoral nerve in 
comparison to the other two techniques. 
 
The obturator nerve involvement in the femoral 3-in-1 nerve block has been 
debated since Winnie et al first proposed the 3-in-1 block (Winnie, Ramamurthy, 
& Durrani 1973).  It was accepted that the obturator nerve is only blocked in a 
minority of cases following femoral 3-in-1 nerve block using nerve stimulator and 
loss of resistance methods (Bouaziz et al. 2002;Lang 1998).  A recent publication 
by Dolan et al implied that the use of ultrasound may significantly increase the 
incidence of obturator motor block to 44% (Dolan et al. 2008).  Obturator nerve 
involvement was less than 20% for all the femoral 3-in-1 nerve block techniques 
in this study, this correlated very well with the work of Lang et al (Lang et al. 
1993) but conflicts with the findings of Dolan et al (Dolan et al. 2008).  The 
reason for this may be that the assessors used by Dolan et al did not keep the 
patient’s knee fully extended during the assessment (Dolan et al. 2008).  Failure 
to do so would have resulted in recruitment of the quadriceps femoris muscles 
and increased pre-block pressures.  Therefore, reduced pressure measurement 
would be the result of a femoral nerve block not an obturator nerve motor 
block.  Higher average pressures were generated by Dolan et al patients with a 
mean of 120 mmHg and standard deviation of 46 mmHg.  In contrast to the 
patients in this study generated a mean pressure of 64 mmHg with a standard 
deviation of 15 mmHg (Dolan et al. 2008).  It is therefore possible that the 
relatively high incidence of obturator block reported by Dolan et al was as a 
result of the methods used to measure obturator (adductor) motor function. 
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The secondary end points showed a slight reduction in opiate requirements (1-2 
mg) of morphine at six hours and at 24 hours in effective femoral 3-in-1 nerve 
blocks.  This reduction was not statistically or clinically significant and was not a 
consistent finding depending on the definition of effective and ineffective 
femoral 3-in-1 nerve block used (see tables 6-17, 6-18 and 12-1 to 12-6).  The 
time to first active weight bearing mobilisation on the replaced hip joint did not 
vary with the different methods used to insert a femoral 3-in-1 nerve block.  No 
patient had delayed mobilisation due to prolonged motor blockade in this large 
patient cohort with multiple operators undertaking the femoral 3-in-1 nerve 
blocks. 
 
6.7 Conclusion 
The first research question was whether loss of resistance was as effective at 
providing analgesia as techniques using nerve stimulator and ultrasound. 
The combined efficacy for the ultrasound and nerve stimulator techniques was 
80.3% and the efficacy of the loss of resistance technique was 59.5% with a 
p=0.016 using fisher exact test (p≤0.025).  The null hypothesis was therefore 
rejected and a statistically significant difference accepted between the efficacy 
of the loss of resistance technique and combined ultrasound and nerve 
stimulator techniques. 
 
The second research question was whether the nerve stimulator or ultrasound 
was the most effective at providing analgesia.  The efficacy of the ultrasound 
technique was 77.5%, the nerve stimulator technique was 83.1% with a p=0.527 
using fisher exact (p≤0.025).  The null hypothesis was therefore accepted for the 
comparison between the efficacy of the ultrasound and nerve stimulator 
techniques. 
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7 The anatomy of the femoral 3-in 1 block 
7.1 Research question 
What is the maximal distribution of local anaesthetic injected using the inguinal 
paravascular lumbar plexus block technique as described by Winnie et al 
(Winnie, Ramamurthy, & Durrani 1973), which is better known as the ‘femoral 3-
in-1 nerve block’? 
7.2 Aim 
To determine the maximal anatomical distribution of 30 ml of black 10% latex 
injected using ultrasound guidance lateral to the femoral nerve under the fascia 
iliacus membrane in unembalmed cadavers. 
7.3 Study design 
A pilot dissection study on two cadavers after ultrasound guided femoral 3-in-1 
block with 30 ml of black 10% latex. 
7.4 Study Population 
Two cadavers were dissected in Glasgow University Anatomy Department after 
injection with 30ml of black 10% latex dye and fixation by embalming using the 
right carotid artery and internal jugular route. 
7.5 Introduction 
Twenty eight years ago Winnie et al described the inguinal paravascular lumbar 
plexus block technique, which is better known as ‘the femoral 3-in-1 nerve 
block’ and hypothesised the existence of a fascial sheath around the femoral 
nerve (Winnie, Ramamurthy, & Durrani 1973).  Winnie hypothesised that this 
fascial sheath could conduct local anaesthetic from below the inguinal ligament 
to the lumbar plexus, anaesthetising the femoral, lateral cutaneous, and 
obturator nerves.  Winnie et al claimed that, ‘if a volume of 20 ml or more is 
utilised, anaesthesia of all three nerves is virtually assured’.  Although the 
anatomical existence of a fascial sheath around the femoral nerve has been 
confirmed it does not appear to consistently act as a conduit for proximal spread 
of local anaesthetic injected under the fascia iliacus membrane.  The majority 
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of investigators have been unable to consistently anaesthetise the femoral, 
obturator and lateral cutaneous nerves with a single injection (Capdevila et al. 
1998;Lang et al. 1993;Madej, Ellis, & Halsall 1989;Parkinson et al. 1989;Ritter 
1995;Spillane 1992;Winnie, Ramamurthy, & Durrani 1973).  The course of the 
obturator nerve is anatomically distant from the site of injection (see Figure 7-
1A and B) of the 3-in-1 nerve block (Ritter 1995).  It is difficult to envisage how 
the obturator nerve could be consistently anaesthetised by an injection at this 
level without proximal spread. 
 
A recently published study by Dolan et al reignited this debate by demonstrating 
a motor block of the obturator nerve in 44% of cases and a loss of sensation in 
the medial aspect of the upper thigh in 60% of ultrasound guided femoral 3-in-1 
nerve blocks (Dolan et al. 2008).  It is possible that retrograde spread to the 
lumbar plexus and anaesthesia of the obturator nerve resulted in the motor and 
sensory blockade of the adductors muscles and medial aspect of the upper thigh 
as described by Dolan et al. 
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Figure 7-1A and 7-1B: Anatomy of upper thigh 
The left image (1A) shows the skin, superficial fascia, fascia lata and fascia iliacus have been 
removed to show the femoral vein, artery and nerve from medial to lateral.   
The right image (1B) shows pectinus muscle reflected to reveal the anterior division of 
obturator nerve emerging from obturator foramina piercing obturator externus muscle and 
lying on abductor brevis (NB the posterior division is posterior to adductor brevis). 
 
Image from personal collection of Dr Malcolm Watson 
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7.6 Methodology 
7.6.1 Injection and fixation 
This work was performed in the Anatomy Department of Glasgow University 
which is licensed under the Anatomy Act 1984 ( 1984).  Two adult female 
cadavers who had donated their bodies to medical science where used for this 
study.  The two cadavers studied had no external evidence of surgery, pathology 
or invasive procedures to the lower abdomen, pelvis, inguinal regions or lower 
limbs.  Immediately before fixation of both cadavers, the tip of an 18G Tuohy 
needle was sited under ultrasound guidance (using a GE logiq E ultrasound 
machine with an 8-12 MHz linear probe) under the fascia iliacus membrane 
lateral to the femoral nerve.  Thirty ml of black 10% by volume liquid latex was 
injected bilaterally.  The two cadavers were then embalmed by injection under 
pressure into the right carotid artery and internal; jugular vein within 1 hour of 
the ultrasound guided black 10% latex injection.  The embalming fluid used was 
the Cambridge formulation, which contained by volume 62.5 % water, 12.5 % 
phenol (80%), 7.5% formaldehyde (37%), 17.5% and 0.5% phenoexetol.  Three 
months later both cadavers were dissected to determine the distribution of the 
black 10% latex. 
7.6.2 Dissection 
7.6.2.1 Methodology of the dissection 
The four dissections were performed using the method described below.  A 
transverse incision was made one centimetre below and parallel to the inguinal 
ligament and a vertical incision was made down the centre of the thigh.  The 
skin was reflected and the superficial fascia, fat and fascia lata removed.  The 
femoral, lateral cutaneous nerve of the thigh, medial cutaneous nerve of the 
thigh were all identified and traced proximally and distally to determine if they 
had been stained with black 10% latex.  The nerves stained with black 10% latex 
were then traced proximally and distally.  To determine the proximal extent the 
abdominal cavity was opened and following reflection of the bowel and 
peritoneum the branches of the lumbar plexus on the iliacus and in the psoas 
muscle in the abdomen were examined.  The distal spread was determined by 
dissecting the Hunter’s (adductor) canal and the sciatic nerves and its terminal 
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branches in the popliteal fossa.  The medial cutaneous nerve of thigh and the 
obturator nerve and its terminal branches were examined by reflecting 
pectineus and adductor brevis muscles.  
7.7 Results 
7.7.1 Summary table 
Table 7-1: Summary of result of dissection 
 
Femoral 
nerve 
Lateral 
cutaneous 
nerve 
Sciatic 
nerve at 
popliteal 
fossa 
Proximal 
spread to 
stain 
obturator 
nerve 
Distal 
spread 
to 
Sciatic 
nerve 
Distal 
spread 
down 
Hunter’s 
canal 
Number of 
nerves 
stained/total 
4/4 4/4 4/4 0/4 4/4 4/4 
Percentage 
staining 
100% 100% 100% 0% 100% 100% 
7.8 Description of results 
In all four dissections the black 10% latex stained the femoral nerve (Figure 7-2: 
femoral nerve) and spread distally to the adductor or Hunter’s canal (Figure 7-3: 
subsartorial spread into the Hunter’s canal) through the adductor hiatus in the 
adductor magus muscle into the popliteal fossa.  The distal spread resulted in 
staining the sciatic nerve and its terminal branches at the apex of the popliteal 
fossa (Figure 7-4: Sciatic nerve at the apex of the popliteal fossa).  The lateral 
cutaneous nerve (Figure 7-5: lateral cutaneous nerve) and the medial cutaneous 
nerve of thigh (Figure 7-6: medial cutaneous nerve of thigh) were both 
consistently stained but no dye was found around the obturator nerve (Figure 7-
7: Obturator nerve) or its terminal branches. 
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Figure 7-2: Femoral nerve 
 
Image from personal collection of Dr Malcolm Watson 
Significant staining was observed of femoral nerve and its branches below the 
inguinal ligament.  The staining was limited by the iliopsoas muscle inferiorly 
and the fascia iliacus superiorly.  The femoral vein can be seen pushed medially 
by the forceps. 
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Figure 7-3: Sub sartorial spread into the Hunter’s canal  
 
Image from personal collection of Dr Malcolm Watson 
Dense staining by black 10% latex can be seen in the adductor (Hunter’s) canal 
with associated staining of the nerves supplying the sartorius muscle.  The 
femoral artery can be seen (with white paper underneath it) and further 
medially and superficially the tributaries of the femoral vein can be seen.  The 
sartorius muscle has been reflected and the forceps are placed under a motor 
branch to the sartorius muscle. 
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Figure 7-4: Sciatic nerve at the apex of the popliteal fossa  
Image from personal collection of Dr Malcolm Watson 
After injection at the level of the inguinal ligament the black 10% latex has 
spread distally down the adductor (Hunter’s) canal and through the adductor 
hiatus into the popliteal fossa and around the terminal divisions of the sciatic 
nerve (the common peroneal and tibial nerves).  The probe is under the common 
peroneal nerve and over the tibial nerve with the undivided sciatic nerve 
superiorly. 
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Figure 7-5: Lateral cutaneous nerve  
 
Image from personal collection of Dr Malcolm Watson 
The lateral cutaneous nerve is seen under the forceps.  The probe has pierced 
and holding back the fascia ilaicus membrane. 
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Figure 7-6: Medial cutaneous nerve of thigh  
 
Image from personal collection of Dr Malcolm Watson 
The medial cutaneous nerve of the thigh, a branch of the femoral nerve, can be 
seen emerging from the black 10% latex. 
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Figure 7-7: Obturator nerve  
Image from personal collection of Dr Malcolm Watson 
The obturator nerve is seen piercing the obturator externus muscle and dividing 
into the anterior (black paper beneath the anterior division lying on the 
obturator brevis muscle) and posterior division (below the adductor brevis 
muscle). 
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7.9 Discussion: 
The femoral 3-in-1 nerve block is performed frequently but the anatomical 
maximal extent of the local anaesthetic distribution is currently unknown.  If the 
femoral 3-in-1 nerve block is to be utilised to improve analgesia for patients, the 
anatomy of a femoral nerve block must be understood.  Previous work on the 
anatomical basis of the femoral 3-in-1 block by Ritter et al (Ritter 1995) focused 
on the proximal spread of methylene blue to test the hypothesises of Winnie et 
al (Winnie, Ramamurthy, & Durrani 1973).  The complete distribution of the 
methylene blue dye was not described.  In order to correct this omission the full 
extent of the spread of black 10% latex in the two cadavers was dissected.  The 
anatomical model used in this study (injection of black 10% latex) was most 
likely to represent the maximal extent of spread rather than the average 
distribution following injection of local anaesthetic under the fascia iliacus 
membrane and lateral to the femoral nerve.  It is also arguable that black 10% 
latex is a better model for maximal local anaesthetic distribution as it is a very 
large molecule which leaves a residue in the tissue plane rather than staining 
the adjacent tissues.  The distal spread may explain the occasional clinical 
observation of sciatic nerve motor weakness following an ultrasound guided 
femoral 3-in-1 nerve block (personal observation by Dr Malcolm J Watson).  The 
use of unembalmed cadavers should have given a realistic model in comparison 
to using embalmed cadavers however the effect of arterial perfusion in the 
tissue compartments on local anaesthetic spread is unknown. 
 
This pilot study confirmed the widely held belief that distal spread and a 2-in-1 
block (femoral and lateral cutaneous nerves) is the most likely outcome of an 
injection underneath the fascia iliacus and lateral to the femoral nerve.  The 
lack of obturator involvement is further supported by the paucity of obturator 
motor (adductor muscle involvement) in Chapter 6) 
 
The preliminary dissection work in this chapter and the results of Chapter 6 may 
give an alternative explanation of the motor and sensory changes observed by 
Dolan et al (Dolan et al. 2008).  The sensory anaesthesia described by Dolan et 
al. on the medial part of the upper thigh may have been due to anaesthesia of 
the medial cutaneous nerve of the thigh (a branch of the femoral nerve).  The 
obturator (adductor) motor blockade demonstrated was possibly due to 
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anaesthesia of the obturator nerve as it travelled distally in the adductor canal 
as part of the subsartorial plexus or simply a difference in the assessment 
methods used to determine obturator motor block ( see discussion in Chapter 6 
section 6.6.1.4 Secondary end points). 
 
In order to provide analgesia for a total knee arthroplasty, both the sciatic and 
the femoral nerves (which both supply the knee joint) should be anaesthetised.  
The distal spread to the branches of the sciatic nerve in the popliteal fossa 
observed in this study may explain the effectiveness of a femoral 3-in-1 nerve 
block for total knee arthroplasty. 
 
7.10 Conclusion 
The distribution of 30 ml of black 10% latex in two unembalmed adult cadavers 
injected lateral to the femoral nerve under the fascia iliacus membrane was to 
stain the lateral cutaneous and femoral nerve and to travel distally in the 
Hunter’s canal through the adductor hiatus into the popliteal fossa to stain the 
sciatic nerve and its terminal branches. 
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7.11 Chapter summary 
7.11.1 Background 
Since the publication by Winnie in 1972 of the femoral 3-in-1 nerve block, there 
has been a debate about the distribution of the local anaesthetic and the 
inclusion of the obturator nerve. 
7.11.2 Aim:  
To determine the distribution of 30 ml of black 10% latex following an injection 
under the fascia iliacus membrane lateral to the femoral nerve. 
7.11.3 Method 
Two unfixed fresh cadavers were injected with 30 ml of black 10% latex under 
the fascia iliacus membrane lateral to the femoral nerve using ultrasound 
guidance.  These cadavers were then fixed using the Cambridge formulation 
embalming fluid within one hour of injection and dissected three months later to 
determine the spread of the black 10% latex. 
7.11.4 Results 
In this model using black 10% latex and unfixed cadavers significant distal spread 
was observed but no evidence of proximal spread of the black 10% latex was 
seen.  This result was consistent with the results of Chapter 6 and the clinical 
findings of the majority of other workers. 
7.11.5 Conclusion 
This preliminary dissection study confirms that the majority of the spread of 
black 10% latex dye injected under the fascia iliacus membrane is likely to be 
distal. 
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8 Summary of results and future work 
8.1 Introduction 
Fractured neck of femur is a significant cause of morbidity and mortality in the 
developed world.  The majority of the mortality and morbidity associated with 
traumatic fracture neck of femur was due to cardiac and respiratory 
complications (Perez et al. 1995).  The use of regional anaesthetic techniques in 
patients with a high risk of cadiorespiratory complications has tended to show an 
outcome benefit (Scott et al. 2001;Yeager et al. 1987).  However, the impact on 
mortality has diminished as improvements in surgical and anaesthetic techniques 
have also resulted in a reduction in the overall mortality.  The mortality from 
high risk elective surgery is now less than 5%; therefore, to quantify the effect 
of regional analgesia higher incidence secondary outcome measures (i.e. lower 
respiratory tract infections, the need for ventilation and combined cardiac end 
points) have been used (Rigg et al. 2002).  In contrast to the marked 
improvements in mortality for elective surgery, the overall mortality from 
emergency surgery and in particular surgery for fractured neck of femur patients 
has remained unchanged (Bottle & Aylin 2006;Heikkinen, Parker, & Jalovaara 
2001). 
 
It is possible that effective regional analgesia could improve outcome if 
delivered to patients with a fractured neck of femur early in their admission to 
hospital.  The femoral 3-in-1 nerve block (also called the femoral nerve fascia 
iliacus block or anterior psoas compartment block) appeared to offer a viable 
solution to provide analgesia to patients with a fractured neck of femur prior to 
definitive surgical fixation.  The nerve block is technically undemanding in 
contrast to epidural anaesthesia which requires extensive training of 
practitioners and continuous cardio-respiratory monitoring and increased nursing 
care.  Ultrasound guidance may increase the block success rate and lower 
complication rates but it is associated with the extra cost of the ultrasound 
machine, disposables and staff training.  In contrast, loss of resistance is 
technically simple and cheap but potentially inaccurate and, as a result, less 
effective.  The use of the nerve stimulator is the current gold standard for 
elective femoral 3-in-1 nerve blocks but if used on patients with a fractured 
neck of femur it is likely to cause unnecessary discomfort in a limb with an 
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unfixed fracture.  In order to determine the comparative efficacy of all three 
methods of guiding femoral 3-in-1 nerve blocks we performed femoral 3-in-1 
nerve blocks in 180 patients scheduled for elective primary total hip 
arthroplasty. 
 
Further work on levobupivacaine dosing was then undertaken and this work 
utilised ultrasound to guide femoral 3-in-1 nerve blocks to determine the 
effective dose and duration of analgesia provided.  This information was needed 
as no levobupivacaine dosing information was available for fractured neck of 
femur patients.  The further information on dosing based on efficacy and 
duration of action will allow a reduction in dose and hence an improvement in 
safety of the femoral 3-in-1 nerve block. 
 
8.2 Summary of primary end points of this project 
In Chapter 3, six research questions to be answered by this PhD project were 
defined.  The second question was answered by undertaking a literature review 
and the summary of the answers to questions one, and three to six are provided 
below. 
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8.2.1 Question 1: Which method do we use to site the local 
anaesthetic? 
From Chapter 6 
The success rates of methods of guiding insertion of a femoral 3-in-1 nerve block 
were as follows in table 8.1. 
Table 8-1: Percentage of successful femoral 3-in 1 nerve blocks in elective hemiarthroplasty 
patients 
Method: Ultrasound Nerve stimulator Loss of resistance 
Number of 
patients(ineffective) 
16 12 15 
Number of 
patients(effective) 
55 59 22 
Total analysed 71 71 37 
Percentage successful 
blocks 
77.5% 83.1% 59.4% 
*The definition of a successful block was cutaneous sensory response of <90/100 and/or a 
motor score decrease of <1 with a starting value of 4/4(in patients with a starting values of 
<3/4 the efficacy of the block was determined by the sensory change). 
 
The use of ultrasound or a nerve stimulator resulted in a statistically significant 
absolute increase in the effectiveness of the femoral 3-in-1 femoral nerve block 
by 20.8% (p=0.0159) respectively in comparison to loss of resistance giving a 
number needed to treat to see a difference of approximately 5.  It is difficult to 
advocate the use of a nerve stimulator on a limb with an unfixed fracture for 
analgesia; therefore, ultrasound is the most effective viable guidance method 
for the femoral 3-in-1 nerve block in patients with a fractured neck of femur. 
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8.2.2 Question 3: What is the effective dose of levobupivacaine 
for a femoral 3-in-1 femoral nerve block? 
From Chapter 4 
The effective concentration of 30 ml of levobupivacaine required to produce a 
reduction in pain numerical rating scale (NRS) of ≥20 points on a 100 point scale 
in 50% of patients (EC50) with a fractured neck of femur using an ultrasound 
guided femoral nerve block was EC50=0.0255% with 95% confidence interval (CI) 
of 0.0229% to 0.0284%.  The effective concentration of levobupivacaine in 95% of 
patients (EC95) was calculated as EC95=0.0357% with 95% CI of 
0.0332% to 0.0383%. 
8.2.3 Question 4: What is the duration of analgesia from the 
EC95 dose of levobupivacaine? 
From Chapter 5 
The median duration of analgesia from 30 ml of 0.036% (the EC95 of 
levobupivacaine) was 177 minutes and the interquartile range of the duration of 
analgesia was 110 to 210 minutes.  The mean duration of analgesia was 166 
minutes with a standard error of the mean of ±18 minutes and a standard 
deviation was ± 67 minutes. 
8.2.4 Question 5: What is the pharmacokinetic profile of 
levobupivacaine in the population of patients with a 
fractured neck of femur? 
From Chapter 5 
The peak median total serum plasma concentration of levobupivacaine was 
reached at 30 minutes after the femoral 3-in-1 nerve block was 52 ng/ml with 
95% confidence interval (CI) of 16-256 ng/ml which is within the ‘safe range’ (of 
<2100ng/ml). 
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8.2.5 Question 6: What is the clinical anatomy of the femoral 
3-in-1 nerve block  
From Chapter 7 
The distribution of 30 ml of black 10% latex in two unembalmed adult cadavers 
injected lateral to the femoral nerve under the fascia iliacus membrane was 
investigated by dissection.  In all four dissections the lateral cutaneous and 
femoral nerves were stained and the black 10% latex travelled distally in the 
Hunter’s canal (or adductor canal) through the adductor hiatus into the popliteal 
fossa to stain the sciatic nerve and its terminal branches. 
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8.3 Summary of primary end points 
The use of ultrasound and nerve stimulator for the delivery of local anaesthetic 
in the femoral 3-in-1 nerve block for elective total hip replacement was 
statistically significantly more effective than loss of resistance with a number 
needed to treat of 5.  There was no statistically significant difference in the 
success of using the nerve stimulator and ultrasound to guide insertion of a 
femoral 3-in-1 nerve block.  Since the use of nerve stimulator would result in 
unnecessary discomfort in patients with an unfixed fractured neck of femur we 
concluded that ultrasound was the optimal technique in this population.  The 
estimated effective dose in 95% of patients (EC95) of levobupivacaine for the 
femoral 3-in-1 nerve block in patients with a fractured neck of femur was 
(0.036%); however, the mean duration of analgesia was short (166 minutes with 
a standard error of the mean of ±18 minutes).  The plasma levels of 
levobupivacaine observed while using the estimated EC95 were well within ‘safe’ 
limits.  The total peak median plasma levobupivacaine concentration observed 
(52 ng/ml) indicated that if the dose of levobupivacaine was increased to 
provide a clinically useful duration of analgesia (i.e. ≥10 hours) then the plasma 
levels were likely to be within safe limits (<2100ng/ml) (Knudsen et al. 1997).  
The results of the 4 cadaveric dissections following ultrasound guided femoral 3-
in-1 nerve block injections of black 10% latex suggest the site of action of local 
anaesthetic may be distal to the point of injection contrary to the currently held 
belief. 
8.4 Summary of secondary end points 
In elective total hip arthroplasty patients there was a slight reduction (not 
statistically significant) in both pain NRS scores (10-20 points on a 100 point 
scale) and opiate requirements (1 to 2 mg) at six hours.  No change in pain NRS 
score or opiate requirement was observed at 24 hours in successful femoral 
3-in-1 nerve blocks.  The reductions in pain NRS and opiate requirement at 
six hours were not clinically significant.  The time to first active weight bearing 
mobilisation on the replaced hip joint did not vary with the different method 
used or efficacy of the femoral 3-in-1 nerve block. 
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The correlation observed between reduced sensation to melting ice and pin prick 
sensation (<90/100) to a blunted 25G needle with analgesia in patients with a 
fractured neck of femur may be a useful surrogate measure for analgesia in 
other patient populations.  The pain half time (estimated time for pain (NRS) 
score to reduce to half the original value) with the EC95 levobupivacaine dose 
was 24 minutes (P=0.052).  The association of sensory changes with pain (NRS) 
scores at 10, 20 and 30 minutes implied that levobupivacaine has a delayed 
onset and that analgesic effects seen before 20 minutes may be due to another 
mechanisms such as hydrostatic pressure.  Wide variations in the plasma 
concentrations of levobupivacaine were observed (maximal median value of 
52 ng/ml with a range of 16-256 ng/ml at 30 minutes after the femoral 3-in-1 
nerve block) despite stringent controls on the administration and production of 
the levobupivacaine.  The wide variation may represent variable absorption of 
levobupivacaine from the site of action. 
8.5 Further work- 
To estimate the dose of levobupivacaine required to 
provide analgesia for greater than 10 hours  
The EC95 of levobupivacaine did provide an estimate of the effective dose but as 
the effective dose was relatively low the duration of analgesia was too short to 
be clinically useful.  In order to provide a clinically useful duration of analgesia 
the EC95 and EC50 to provide ≥10 hours of analgesia will need to be determined. 
 
The sequential up/down Dixon’s method (Dixon 1965) may be utilised to 
determine the concentration of levobupivacaine necessary to provide 10 hours of 
analgesia.  The binary end point will be the successful provision of 10 hours of 
analgesia (with pain NRS <50/100).The number of patients required to obtain a 
precise estimate for levobupivacaine EC95 and EC50 will be decreased by the use 
of iterative re-estimate of the optimal stepping value (δ). 
 
The review article by Pace et al provided a number of improvements to the 
original Dixon up/down methodology (Pace & Stylianou 2007).  Pace et al 
suggested the use of the Bias coin method of patient allocation to target the 
EC95 instead of targeting the EC50 of levobupivacaine.  In order to estimate the 
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EC95 with the same precision as the EC50 20 times the number of patients would 
need to be recruited, as every failure will be accompanied by 19 successes at 
the EC95 concentration.  If a sequential up/down Dixon’s method dosing study 
requires 20 to 40 patients to estimate the EC5o then 400 to 800 patients would 
be required to estimate EC95 with the same precision. 
 
In Chapter 4 the stepping value was altered on the basis of an interim probit 
regression analysis to achieve increased accuracy with a reduced number of 
patients.  If the interim analysis used in Chapter 4 was repeated several times 
during the clinical trial it would theoretically result in an improvement in 
accuracy with a reduced number of patients in comparison to the traditional 
sequential up/down Dixon’s method.  The protocol for the dosing study in 
Chapter 4 initially set a large stepping value (δ) (difference between the 
concentrations of levobupivacaine used) and decreased it after 16 patients had 
been recruited so that the stepping value (δ) was between 2/3 and 3/2 of the 
estimated standard deviation (σ) using the probit regression analysis techniques 
to model the concentration against chance of a successful femoral 3-in-1 nerve 
block.  If this process had been repeated on multiple occasions during the trial 
progressively better estimations for the stepping value could have been 
obtained.  Iterative re-calculation of the mean and standard deviation (σ) would 
have resulted in progressively increased precision when fitting a probit model to 
estimate the EC50 and EC95 for levobupivacaine. 
 
The iterative re-calculation of σ (standard deviation) and µ (the estimated 
EC50) would have several other advantages: 
• The initial stepping value (δ) can be relatively large which will 
result in a decrease in the number of patients required to reach a 
turning point (change in direction from effective to ineffective or 
vice versa) 
• The number of patients needed would be less dependent on the 
starting concentration 
• Repeated measures of µ (the estimated EC50) will give a measure 
of variation and therefore stability of the model and therefore the 
precision of the final estimate of the levobupivacaine EC50 and EC95 
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• Objective criteria for stopping the trial can be set at the beginning 
of the trial which will relate to the stability of the probit model 
created using probit binary regression analysis. 
The following assumptions have been made when designing the protocol to use 
iterative re-calculation of the stepping value (δ). 
 
• The iterative calculation of (δ) will only yield a different result if the test 
result has reached a turning point. 
• If the turning point has been reached then, if a further 2 patients 
are recruited, the information from these will allow determination 
of whether the turning point was above the mean, below the mean 
or at the mean. 
• Therefore, an iterative re-calculation of the Standard deviation 
(σ) and the estimated mean µ (the estimated EC50) will be made 
after a turning point has been reached and 2 further patients have 
been recruited and the stepping value(δ) concentration will be 
adjusted to be within 3/2 and 2/3 of the σ. 
• The new starting concentration after recalculation will be the 
estimated mean plus the new stepping value (δ). 
• The result of the iterative process will be rounded to achieve the 
most accurate result possible within the error limits imposed by the 
pharmaceutical manufacturing process (see Chapter 4, discussion 
section 4.10.1 Quantifiable error in final concentration and volume 
of IMP, manufacturing errors were estimated at 5.1% of stated 
concentration.  
• The iterative process will be repeated after recruiting two patients 
after each turning point until agreement is reached between three 
estimations of µ (the estimated EC50) within a predetermined 
precision (<10% variance).  This will imply that the probit 
regression model is stable and that a reliable estimate of EC95 and 
EC50 can be derived. 
• Utilising these principles a protocol for a clinical trial to determine 
the dose required for ≥10hours analgesia and to ensure its safety 
has been written (please see appendix 13) 
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In summary, the use of iterative probit analysis techniques to set the setting 
value will decrease the number of patients needed to provide an accurate and 
precise answer to the EC50 and EC95 dosing question.  It will also provide 
objective criteria to stop the trial once it has achieved a stable probit binary 
regression model. 
8.6 Further work  
Outcome benefit of femoral 3-in-1 nerve blocks for 
patients with a fractured neck of femur 
This reason for undertaking this PhD project was to develop a method of 
improving analgesia for patients with a traumatic fractured neck of femur.  The 
results of the project have done the majority of that development work; 
however, it may be that by improving analgesia we may also improve the patient 
outcome.  A multicentre clinical trial will be needed to determine if improved 
analgesia could result in an improvement in outcome.  In order to design a 
protocol the following research questions need to be answered. 
 
 
Research questions: 
1. Which adverse event should be measured? 
2. What is the current incidence and timing of the adverse event? 
3. What impact could the intervention make on the adverse event? 
 
A power calculation can then be made to estimate the number of patients that 
need to be recruited to the study. 
8.6.1 Which adverse events should be measured? 
The principal aetiology of mortality and morbidity early (in the first 48-72 hours) 
after a fractured neck of femur was cardiac (Perez et al. 1995) and the risk was 
further increased in those patients with a history of cardiac disease (Marsch et 
al. 1992).  In contrast, bronchopneumonia and pulmonary embolism accounted 
for the majority of late deaths (7-14 days after fractured neck of femur) (Perez 
et al. 1995).  Early surgical fixation, early mobilisation, antibiotics, and 
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prophylactic anticoagulation have been shown to reduce death from 
bronchopneumonia and pulmonary embolism after hip fracture (Morrison, 
Chassin, & Siu 1998;Perez et al. 1995).  An intervention which reduced the early 
severe pain associated with a fractured neck of femur would potentially reduce 
the harmful stress response with a concomitant improvement in early (first 72 
hours after injury) morbidity and mortality from adverse cardiac outcomes.  
Mangano et al and other research groups have used beta-blockers (β-blockers) or 
alpha 2 (α2) blockers to reduce stress and improved cardiac outcomes in non-
cardiac patients (Mangano et al. 1996;Stuhmeier et al. 1996;Wallace et al. 
1998).  The use of the femoral 3-in-1 nerve block could reduce the pain and 
hence ‘stress response’ of patients with a fractured neck of femur and would 
have the potential to improve early adverse cardiac outcomes (Matot et al. 
2003;Scheinin et al. 2000)  
 
8.6.2 What is Incidence and timing of adverse events? 
Marsch et al found a 31% incidence of perioperative ischaemic events measured 
using Holter monitors which were fitted to patients preoperatively up to six days 
postoperatively in an unselected population of patients admitted with fractured 
neck of femur (Marsch et al. 1992).  The majority of the ischaemic episodes 
occurred preoperatively, intraoperatively and the first 48 hours postoperatively.  
Scheinin et al found an incidence of myocardial ischaemia detected by Holter 
monitors in the control group (prescribed opiate and non steroidal anti 
inflammatory drugs (NSAIDS) for analgesia) varied between 27% to 42% (Scheinin 
et al. 2000).  Matot et al (Matot et al. 2003).  Matot et al examined a combined 
cardiac end point (cardiac death, myocardial infarction, unstable angina, 
congestive heart failure (CHF), and new-onset atrial ﬁbrillation) based on the 
definitions used by Magano et al (Mangano et al. 1996).  Matot et al found that 
the control group (prescribed intramuscular meperidine) had and preoperative 
incidence of combined cardiac end points of 20% (Matot et al. 2003). 
The use of epidural analgesia by Scheinin et al and Matot et al reduced both the 
combined cardiac end points and ischaemic episodes in the preoperative, 
intraoperative and immediate postoperative period (48 hours after hip fixation) 
(Matot et al. 2003;Scheinin et al. 2000).  The use of serial sensitive troponin 
measurement has replaced Holter monitoring in detecting cardiac ischaemia 
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episodes.  Troponin has been well validated as a sensitive specific test and 
elevated levels have been associated with adverse cardiac outcomes in vascular 
and cardiac surgery patients populations (Christenson & Phillips 2011;Flu et al. 
2010;Mair 1997;Marsch et al. 1992;Sadony et al. 1998). 
 
If combined cardiac end points and serial troponin measurement are used then 
an incidence of adverse events of 30-40% can be expected in the control 
population.  The preoperative, intraoperative and immediate postoperative (48 
hours after fixation of the hip) periods are the most susceptible to intervention 
based on previous study by Marsch et al (Marsch et al. 1992). 
 
8.6.3 What impact could a femoral 3-in-1 nerve block make on 
pre and intraoperative cardiac events? 
Scheinin et al observed an absolute reduction in ischaemic episodes of 17% 
preoperatively, 27% intraoperatively and 9% postoperatively in those patients 
treated with epidural analgesia (Scheinin et al. 2000).  Matot observed an 
absolute reduction in combined cardiac end points of 20% preoperatively and a 
6.6% reduction postoperatively (Matot et al. 2003).  It should be assumed that 
femoral 3-in-1 nerve blocks will be less effective than epidural analgesia as no 
sympatholyic cardiac effect will be observed with peripheral nerve blocks in 
contrast with neuraxial blocks.  The power curve plots for various sample sizes 
are shown below in figure 8-1 and table 8-2 for an absolute reduction in 
combined cardiac end points and elevated troponin measurements of 5%, 7.5% 
and 10% with an alpha error of 0.05. 
Chapter 8 
 Page 194 of 287 
 
8.6.4 Power calculation if combined cardiac end points and 
troponin was used as the primary endpoint 
If it is assumed that the control group have an incidence of combined cardiac 
end points and elevated serial troponin measurements of 35%.  The power curves 
shown below show the number of patients to achieve an 80% and 90% power and 
an alpha error of 0.05.  The sample sizes required for an 80% and 90% power and 
a 5%, 7.5% and 10% percentage change in combined cardiac end points and 
elevated serial troponin measurement with an alpha error of 0.05 are shown 
above in Figure 8-1 and below in Table 8-2. 
Figure 8-1: Combined cardiac end points and elevated serial troponin measurement cardiac 
morbidity (as a proportion) (x-axis) is plotted against the power of the study to detect the 
difference (y-axis). 
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Table 8-2: Number of patients required in each group to power trial for 5%, 7.5% and 10% 
difference in combined cardiac end points and elevated serial troponin measurement and 
p=0.05 
 
Difference in combined cardiac end points and elevated serial troponin 
measurement 
 5% 7.5% 10% 
80% power of 
trial 
1377 
Patients in each group 
599 
Patients in each group 
329 
Patients in each group 
90% power of 
trial 
1842 
Patients in each group 
801 
Patients in each group 
440 
Patients in each group 
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8.6.4.1 Power calculation if hospital mortality is used as the primary 
outcome 
If it is assumed that the effect of the femoral 3-in-1 nerve block was a 10% 
relative reduction in hospital mortality from 14.6% (Bottle & Aylin 2006) (i.e. 
1.5% absolute reduction).  If hospital mortality is used as the end point of an 
outcome study then 8524 patients would be needed (for an 80% power and an 
alpha error of 0.05) in each group to detect a 10% relative mortality benefit in 
comparison to 329 patients for the combined morbidity and mortality end point 
and serial troponin testing (or Holter monitoring)(please see figure 8.2 for 
sample size calculation).  Therefore, combined cardiac end points and elevated 
serial troponin measurement could provide an end point for a clinical trial which 
has an achievable patient recruitment target due to a relatively high event rate 
and potentially relatively large intervention effect. 
Figure 8-2:  The power graph demonstrates the number of patients in each group needed to 
give the study an 80% (8524 patients) and 90% (11411 patients) power with an alpha error of 
0.05. 
0.200.180.160.140.120.10
1.0
0.8
0.6
0.4
0.2
0.0
Hospital mortality-proportion
P
o
w
e
r
 t
o
 d
e
t
e
c
t 
m
o
r
ti
li
t
y
 d
if
fe
re
n
c
e
A lpha error 0.05
C ontrol incidence of hospital mortailty 0.15
A lternativ e Not =
A ssumptions
8524
11411
Size
Sample
Power against hospital  mortality
 
Chapter 8 
 Page 197 of 287 
8.7 Medical/economic arguments for the use of 
ultrasound guided femoral 3-in-1 femoral nerve 
blocks in fractured neck of femur patients 
8.7.1 DALYs and QALYs  
In order to asses the potential benefits of any intervention it is necessary to 
assess the harm directly attributable to the disease process in terms of increased 
morbidity and mortality in DALYs (disability adjusted life years).  The beneficial 
effects of any intervention are usually measured in reduced morbidity and 
mortality in QALYs (quality adjusted life years) gained.  These two measures are 
complementary, QALYs measure the number of healthy years gained and DALYs 
(disability adjusted life years) combines information about morbidity and 
mortality in numbers of healthy years lost.  In both the DALYs and QALYs 
approach, each state of health is assigned a disability or utility weighting 
respectively on a scale from zero (perfect health-DALYs or death-QALYs) to one 
(death-DALYS to perfect health-QALYs) by an expert panel.  In summary, QALYs 
are years of healthy life lived; DALYs are years of healthy life lost.  If QALYs and 
DALYs are displayed graphically (see Figure 8-3) multiply the number of years (x 
axis) by the quality of those years (y axis).  QALYs use “utility” weights of health 
states; DALYs use “disability weights” to reflect the burden of disease states.  
The use of DALYs by the World Bank and World Health Organisation has been 
controversial due to the discounting of future disability weights at a rate of 3% 
per year, and the practice of using a lifetime weighting so that years of life in 
childhood and old age are weighted less (Arnesen & Nord 1999). 
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If we use the example of a patient suffering a fractured neck of femur at age 55 
with previously perfect health the disability weighting would be 0.468 (Kanis et 
al. 2001) in the first year and 0.272 (Murray & Lopez 1997) for subsequent years 
therefore the utility weighting is 1-0.468=0.532 for the first year and 1-
0.272=0.728 for subsequent years.  If that patient then had a myocardial 
infraction and died at 60 then Figure 8-3 shows the QALYs and DALYs. 
 
Figure 8-3: QUALY and DALYS for fractured neck of femur patient 
  
8.7.1.1 Summary of DALYS and QUALYS: 
DALYs lost due to fractured hip=0.468*1+0.272*4=1.556 in 5 years due to 
fractured hip 
QALYs gained after hip fracture=1*5-1.556=3.444 in 5 years following the 
fractured hip 
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8.7.2 Cost over 10 years (ultrasound machine, extra 
disposables, medical and nursing time and training) 
NICE consider that the threshold cost/benefit for an intervention to be 
considered cost effective is 1 QALYs =£20000 or less ( 2012).  The costs of 
providing ultrasound guided regional analgesia in a small hospital are detailed 
below. 
• Equipment: Ultrasound machine with an equipment life span of 10 
years will treat 300 patients per year in an average size hospital 
(i.e. Western infirmary, Glasgow). Total cost £24000 
• Extra disposables:  
(Costs from procurement system in NHS GGC, 6thJune 2010) 
 £5.00 per sterile pack 
 £2.00 per ultrasound probe sheath  
 £15.00 per needle 
 £2.00 per sachet of ultrasound gel 
 £1.00 0.5% Chorohexidine with 70% alcohol skin preparation  
• Total cost over 10 years of disposables would be £25 multiplied by 
3000 patients=£75000 in total 
• Total equipment and disposables cost over 10years = £99,000 
• Extra medical and nursing time for 3000 patients 
 10 mins, extra consultant time, consultant, paypoint 5 (2011) 
• 30000minutes/255minutes(1 PA)= 118 PAs extra at 
£161 per PA (Programmed Activity)= £19000 in total 
 10 minutes of extra nursing time, band 6 paypoint 5 (2011) 
• banding 6 (29,464/52=566.62 
• 566.62/37.5 hours=£15.11/per hour) 
• 30000 minutes/60 minutes= 500 hours at £15.11per 
hour= £7555 in total 
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8.7.3 Training costs 
• Cost of course £250 per day for 10 days= £2500 in total 
• Cost of back filling post: 2.5 PA (Programmed Activity) per day 
with 5 years seniority (consultant salary scale 2010-2011)= 
83,829/10 = 8380 in total 
• 8,382.90/52=£161.21 per PA=£403.02 per day 
10 days in 10 years= £4030 in total  
 
Total extra cost =£132910 for 10 years in Western Infirmary, Glasgow 
8.7.4 Outcome benefit versus cost of treatment: 
If we use the costs calculated above and apply the improvements (QALYs) 
needed by NICE to justify automatic inclusion as a guideline (£132910 (total 
cost) over 10 years /£20000 = 6.6 QALYs or more would be needed by NICE ( 
2012b) in the total population over 10 years to justify the cost of treatment. 
8.7.5 The benefit associated with ultrasound guided femoral 3-
in-1 nerve block needs to be greater than 6.6 QALYs  
In order to determine if 6.6 QALYs is an achievable benefit we need to examine 
the total QALYs lost due to a hip fracture.  In the first year after a hip fracture 
0.468 QALYs are lost (Kanis, Oden, Johnell, Jonsson, de Laet, & Dawson 2001).  
It may only be possible to improve 10% of the total disability in the first year 
(therefore 0.0468 QALYs will be gained per patient in the first year for a 10% 
relative reduction.  If this effect is achieved for all 3000 patients then a total of 
140 QALYs will be gained.  
Another way of examining the ‘achievable benefit’ question would be to 
examine the effect of the pathologies that a femoral 3-in-1 nerve block may 
prevent.  The combined mortality and morbidity effect of one myocardial 
infarction is the loss of 5.14 QALYs (Hong et al. 2011).  If ultrasound guided 
femoral 3-in-1 nerve blocks prevented 2 myocardial infarctions in ten years then 
it would be a cost effective intervention ( 2012). 
 
In this cost benefit analysis all possible costs have been included and rounded 
up.  Since the cost of the ultrasound machine is a fixed cost and the largest cost 
Chapter 8 
 Page 201 of 287 
then if more patients are treated then the number of QALYs required will 
decrease.  I therefore conclude that the use of ultrasound guided femoral 3-in-1 
nerve blocks would only require a small improvement in morbidity and morality 
for it to represent a cost effective intervention using current NICE guidance. 
8.8 Final summary of thesis 
 
Patients with a fractured neck of femur have a significant morbidity and 
mortality: the hospital mortality in this patients group is approximately 1 in 7 
patients.  Regional anaesthesia and analgesia appeared to offer benefits to 
almost all patient populations studied.  Although epidural analgesia and has 
been shown to offer improved outcomes for patients with a fractured neck of 
femur this has not led to a change in practice.  It is unlikely that the resources 
required to implement epidural analgesia for all patients with a fractured neck 
of femur will ever be available within this NHS.  The use of femoral 3-in-1 nerve 
block to provide analgesia would require increased training in accident and 
emergency departments but should not increase nursing or medical staff 
workload and could result in improved outcome for patients. 
 
The aim of this PhD was to develop a method of providing safe, effective 
regional analgesia to the 60,000 to 70,000 patients admitted annually to UK 
hospitals with a traumatic fractured neck of femur.  It was hypothesised that 
ultrasound guided femoral 3-in-1 nerve blocks could provide a superior method 
of analgesia to the current standard of care (parenteral opiates). 
 
An initial randomised trial compared the efficacy of using ultrasound and 
traditional insertion techniques to guide the needle for the femoral 3-in-1 nerve 
blocks in elective primary total hip arthroplasty patients.  The most successful 
method was nerve stimulator however this was not statistically significant and it 
is unlikely to be widely utilised for preoperative analgesia in the fractured neck 
of femur patients.  The use of ultrasound or nerve stimulator improved the 
efficacy of the technique over loss of resistance by 20.8%, giving a number 
needed to treat of approximately five patients although this was also not 
statistically significant. 
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We determined the levobupivacaine dosing using a sequential Dixon’s up/down 
study.  A femoral 3-in-1 nerve block was performed and the concentration of 
levobupivacaine was increased or decreasing for an ineffective or effective 
nerve block respectively.  The EC50 of levobupivacaine was calculated as 
EC50=0.0255% with 95% confidence interval (CI) of 0.0229% to 0.0284%.  The 
effective concentration in 95% of patients (EC95) was calculated as EC95=0.0357% 
with 95% CI of 0.0332% to 0.0383%. 
 
A final clinical trial assessed local anaesthetic pharmacokinetics (to ensure that 
serum levels of the EC95 dose of levobupivacaine were within the safe range) and 
pharmacodynamics (to assess duration of analgesia) in fractured neck of femur 
patients using serial blood sampling and by monitoring pain scores respectively.  
The peak median total serum plasma concentration was reached at 30 minutes 
after the block and was 52ng/ml.  This concentration of levobupivacaine was 
well within the ‘safe range’ for levobupivacaine and the mean duration of 
analgesia was two hours and 46 minutes with a standard error of the mean of ± 
18minutes. 
 
The dissection of 2 cadavers following ultrasound guided femoral 3-in-1 nerve 
blocks and injection of 30 ml of black 10% latex dye showed that the dye did not 
spread proximally as Winnie et al (Winnie, Ramamurt .S, & Durrani 1973) 
hypothesised.  In all cases it tracked distally through the Hunters canal and 
through into the adductor hiatus to stain the sciatic nerve and its terminal 
branches in the popliteal fossa. 
 
This PhD project was funded by a Chief Scientist Office fellowship award which 
paid all the research costs and the salary of the chief investigator for three 
years.  A total of 234 patients were recruited between 1 February 2009 and 4 
March 2011 in four Glasgow hospitals.  It required the completion of one multi 
site clinical study ethics application with four substantial amendments and one 
ethics application for a clinical trial of an investigational and medicinal product 
with an associated MHRA (Medicines and Healthcare Regulatory Agency) 
application and one substantial amendment.  It was the first comparative study 
of all three methods of guiding a femoral 3-in-1 nerve block and provided new 
information on the association of sensory and motor changes with analgesia for 
Chapter 8 
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the femoral 3-in-1 nerve block and an assessment of the effect of a femoral 3-in-
1 nerve block on mobilisation, analgesia and morphine consumption.  The 
clinical trial provided the first estimate of the minimum effective dose of 
levobupivacaine to provide analgesia in patients with a fractured neck of femur 
and the estimated the duration of analgesia and pharmokinetics of 
levobupivacaine.  As a result of this PhD project improvements have been made 
to the sequential up/down Dixon’s methodology which should reduce the 
number of patients needed and increase precision and accuracy of this method.  
The dissection provided initial data on the maximal distribution of a 30 ml 
volume injected under the fascia iliacus membrane, lateral to the femoral 
nerve.  In summary, this project provided new information which could provide 
analgesia to 60000 to 70000 patients admitted annually to UK hospitals with a 
fractured neck of femur. 
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Appendix 1: NHS GGC monitoring report 
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Appendix 2: Statistical justification of sample size and 
interim analysis 
Dixon’s up/down methodology explained 
The Up-Down study design requires the specification of an initial dose (x0), and 
the difference between successive doses (δ).  The first experiment takes place 
at dose x0: if it is a success, the second experiment takes place at dose x0-δ; if it 
is a failure the second experiment takes place at x0+δ. The dose for each 
successive patient is therefore determined by the success or failure of the 
previous patient and as a result the dose will tend to move towards a value 
where 50% of patients are successful and 50% fail and oscillate around that 
value. 
 
Estimation of sample size (Dixon) 
It is assumed that for a given log (dose), x, the probability, P(x), that the dose 
will be effective is 
Px=Φ
x- µ
σ  
where Φ is the cumulative density function of a standard Normal distribution. µ 
is the concentration at which 50% of the population would achieve pain relief, or 
EC50, since P(µ) = Φ(0) = ½. 
 
If the numbers of successes is less than the number of failures, then µ= y1− δ2 , 
where y1  is the mean concentration over the successful experiments; otherwise 
µ= y0+δ 2 , with y0  being the mean concentration over experiments that were 
failures. 
 
The standard error of µˆ  is estimated by 
SEµ=Gσ /nk  
with σ estimated by 
σ= 1. 620δ
sk
2
δ2
0 . 029 
and k = 1 or 0 depending on whether µˆ  was estimated from the successful or 
unsuccessful experiments, sk
2
 is the sample variance of the concentration levels 
and nk is the number of experiments used in the estimation of µˆ . The constant G 
is an approximately linear function of δσ : for δ=σ, G≈1; for δ=2σ, G≈1.2. 
Since nk is approximately ½N, where N is the total number of experiments 
conducted, the required sample size for a study can be calculated depending 
upon the desired width of the confidence interval for µ, relative to σ. Since the 
95% CI for µ will be approximately µ± 2SE , the required sample size will be 
N=8∆2 , if δ≈σ, where ±∆ is the width of the 95% CI required for µ in units of σ, 
i.e. the 95% CI for µ is µ± ∆σ . Thus for a 95% CI of ½σ each way, the required 
sample size will be about 32. 
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Estimation of percentiles other than the 50th, e.g. the concentration at which 
95% of patients would achieve pain relief, or EC95, is given by 
 
µ+z0 .95 σ  
 
where z0.95=1.645 is the 95
th percentile point of a standard Normal distribution. 
The standard error of this estimate is 
SEµ
2
+z0 .95
2 SEσ2  
where SEσ=Hσ /nk , with H following an approximately quadratic function of 
δσ , taking its smallest values over the range σ<δ<2σ, where H≈1.3-1.4. 
 
Comments 
The estimation method as described by Dixon is straightforward in the sense that 
it provides an estimate of µ based on a mean concentration, and leads to a 
simple sample size calculation. However, many of the steps taken to reach 
parameter estimates and their standard errors are not transparent, and the 
estimates of standard errors involve multiplication by factors (G and H) that are 
not well defined.  Furthermore, the standard error estimate for quartiles other 
than the EC50 does not take account of the correlation between estimates for µ 
and σ. 
 
Justification of interim analysis 
Number of patients needed  
An interim analysis will be performed at 16 patients to ensure that δ (the 
incremental change in the concentration i.e. 0.025) is approximately ½ σ (the 
standard error of the mean for the EC50) and δ will be altered if necessary to 
increase the accuracy of the estimate obtained for the EC50 concentration and 
hence the estimate of EC95. 
 
The number of patient needed is affected by two variables: 
 
1- A suitable starting value for x0 
2- A value for the concentration change between experiments (δ) which 
should ideally be in the region of σ-1.5σ.  
 
Recommendations 
 
The formula N=4∆2  should be used as an initial estimate of the required 
sample size for a study. 
 
The appropriateness of the value used for δ should be modified throughout the 
study based on the accrued evidence, and modified if necessary. 
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Appendix 3: Interim probit logistic regression analysis 
after 16 patients had been recruited 
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Appendix 4: List of Amendments to the Protocol for the 
clinical trial 
 
Table 1: Summary of Substantive amendments 
 
Area of study  and 
part of study 
affected 
Summary of amendment 
1 Storage of IMP Extend shelf life of IMP(levobupivacaine) from 7 days to 28 days 
2 Insertion of catheter  
 
Insertion of catheter and bolus dose of levobupivacaine 
to provide analgesia ( pain NRS<30/100) for 12 hours 
and confirm correct positioning of initial dose of IMP 
3 
Inclusion/Exclusion 
criteria 
 
Inclusion of patients with proximal femoral fractures 
treated non operatively and patients with peri-prosthetic 
proximal femoral factures 
4 
Minimum 
concentration of IMP 
 
Reduce the minimum concentration of the 
IMP(levobupivacaine) from 0.025% to  0.005%  
5 
Data collection 
sheet(CRF) 
 
Improved layout to record data 
6 
End point of study 
 
A reduction in sensory stimuli to pin prick of <50/100 in 
two or more regions out of three (medial, anterior and 
lateral of upper thigh) with an associated reduction in 
cold sensation (to melting ice) in the same region will 
be the minimum sensory change associated with 
successful analgesia (=>20/100 point drop in pain NRS 
scores) 
Amendment 1 -Storage of IMP 
Justification of amendment 
Storage and of IMP- 
Further information regarding the shelf life and temperature stability was 
made available to the research team after the initial ethics submission in 
October 2009. 
 
See attached paper:  
 ‘Stability of sufentanil and levobupivacaine solutions and a mixture in a 
0.9% sodium chloride infusion stored in polypropylene syringes.’1 
 
Please see summary of information in paper 
‘the levobupivacaine hydrochloride solution maintained chemical 
stability for 28 days at 4°C and 21°C,  8°C and for 23 days at 36 °C .’ 
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We will store the drug at 4-8 (°C) degrees Celsius in a temperature 
monitored environment (the temperature is recorded every 5 minutes using a 
Testo® 175-T2 temperature data logger, with 2 channels with internal and 
external sensor; ISO calibrated to 2 °C degrees and 8°C) for up to 28 days. 
Due to the temperature stability of this drug we will not report temperature 
deviations of less than 2 degrees for less than ten temperature recordings at 
5 minute intervals.  This will not affect the stability of the IMP 
(levobupivacaine) and is safe practice in terms of bacteriological 
considerations please see attached letter from Graham Conkie from the 
Pharmacy Production Unit at the Western Infirmary Glasgow dated the 22nd of 
May 2008. 
Supporting documentation 
Stability of sufentanil and levobupivacaine solutions and a mixture in a 0.9% 
sodium chloride infusion stored in polypropylene syringes.  
Jappinen A. Turpeinen M. Kokki H. Rasi A. Ojanen T. Pelkonen O. Naaranlahti T.  
European Journal of Pharmaceutical Sciences. 19(1):31-6, 2003 May.  
[Journal Article]  
UI: 12729859 
 
See letter dated 22/05/2008 from Graham P Conkie qualified person of the 
Pharmacy Production Unit. 
Amendment 2 – Insertion of catheter and bolus dose of 
levobupivacaine to provide analgesia  
Justification of amendment 
The patients recruited to this clinical trial are in moderate to severe pain and 
despite the analgesia provided by the IMP (levobupivacaine) they will require 
further analgesia.  The insertion of a catheter at the end of the injection of the 
bolus dose of IMP will allow multiple doses of local anaesthetic to be given to 
provide analgesia using standard protocols for up to 3 days.  This amendment 
also increase the scientific value of the trial as a failure of the local anaesthetic 
injected using the catheter to provide analgesia would indicate that the bolus 
dose of the IMP is likely to have been incorrectly sited. This will allow exclusion 
of these patients’ results from the final analysis and increase the accuracy of the 
primary end point. 
Amendment 3 – Inclusion of non operatively managed patients 
and patients with peri-prosthetic fractures  
Justification of amendment 
The inclusion criteria have been broadened to include those patients with 
proximal femoral fractures managed non-operatively and patients with a 
previous hip joint replacement with a fracture of the femur (peri-prosthetic 
fractures). Femoral nerve blocks provide effective analgesia for both these 
groups of patients and both these groups of patients could benefit from the 
regional analgesia provided by the study. 
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Amendment 4 - Minimum concentration of IMP  
Justification of amendment 
After recruiting 16 patients to the study an interim analysis was performed as 
stated in the protocol version 1. The results of that analysis are stated in the 
attached letter from Dr Alex McConnachie (senior consultant statistician at 
the Robertson centre Glasgow university) dated 11/05/2010. 
 
In summary 
The calculated effective concentration in 50% was(EC50) of 
patients(estimated µ= 0.0256) is probably close to the original minimum 
concentration set in the protocol version 1 (0.025%) so in order to determine 
the distribution of concentrations around the EC50 Dr Alex McConnachie 
(senior consultant statistician at the Robertson Centre Glasgow university) 
suggested decreasing the interval between IMP concentrations to 0.005% 
(which has been done as allowed in the original protocol) and decreasing the 
minimum concentration to 0.005%. The maximum concentration has been set 
to 0.1% to reduce the dosage that can be given by following the protocol as 
the protocol now allows for a bolus of 0.25 % levobupivacaine via the 
catheter if the original concentration of IMP (levobupivacaine) does not 
reduce the pain NRS score to < 30/100 at 30 minutes after the injection.   
Supporting documentation 
A Letter from Alex McConnachie (senior consultant statistician at the 
Robertson centre Glasgow University) dated 11th of May 2010, Title ‘Fracture 
neck of femur up down dosing finding study interim analysis’ 
 
A letter dated (11th May 2010) from Dr Alex McConnachie (senior consultant 
statistician at the Robertson centre Glasgow University) is attached. 
 
A further letter dated (16th July 2010) from Dr Alex McConnachie (senior 
consultant statistician at the Robertson centre Glasgow university) is 
attached. 
Amendment 5 - Data collection sheet (clinical research form, CRF) 
Justification of amendment 
In order to facilitate accurate data recording minor changes should be 
incorporated in the Data collection sheets for part A and B of the study (CRF 
Part A and B).  In addition in part A the response to an additional dose via a 
catheter sited after injection of the IMP dose (see amendment 2) would 
provide evidence of correct placement of the IMP dose if an analgesic 
response was seen(pain NRS score <30/100 at 30minutes after bolus dose). 
 
Specific changes to data collection form (CRF): 
 
• Record if the visual analogue pain score of < 30/100 is achieved by 
administration of 20ml of 0.25% levobupivacaine 30minutes after the 
administration of IMP dose of levobupivacaine. 
 
• Record the division of the sensory changes to pin prick sensation into 
the medial, anterior and lateral regions of the upper thigh and the 
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response to cold stimuli in the same area (medial, anterior and lateral 
segments of the upper thigh). 
• Increase in the area for recording the cardiovascular and respiratory 
observations. 
Amendment 6 - End point of study 
Justification of amendment 
I have been unable to replicate the 30% drop in sensory score (using a blunted 
25G needle compared to the contra lateral side) following a successful (> or =2 
point drop in the visual analogue pain scores femoral nerve block) reported by 
Manhofer et al1. Manhofer et al have never provided any clinical or statistical 
justification for the choice of 30% as the determinant of a femoral nerve block 
associated with analgesia but it did appear to be a consistent result from in the 
study in published in 1997. 
 
I have recorded that a significant analgesic effect is consistently associated with 
a less profound sensory change than originally reported by Manhofer et al1 in a 
similar study population.  The result of the first 31 patients recruited to the 
current clinical trial show that the analgesic effect (>=20 point reduction in pain 
NRS) has been associated with a change to cold sensation (melting ice).  The 
association of analgesia and altered sensation to melting ice has been recorded 
consistently in the previous 31 patients.  There is currently no need to change 
the protocol as the analgesic effect has been consistently associated with a 
sensory change (to melting ice) and inconsistencies between the sensory(tested 
by both cold and pin prick sensation) and analgesic response have been treated 
by repeating the concentration. 
 
I therefore propose to model the sensory scores (using a blunted 25G needle 
compared to the contra lateral side) using the analgesic( pain NRS) and sensory 
responses to melting ice to determine if they add predictive value and at what 
pattern of sensory score response to pin prick  is associated with analgesic 
outcome.  This will allow a more detailed analysis of my other study (see 
below). 
 
Short title: Can nerve block for hip surgery be improved by ultrasound guidance? 
 
 Ethics reference number 08/S0703/122 
 
 
The current offices are beginning renovated for use by the Research and 
development department and the ultrasound research office and laboratory has 
been moved to F-block, Lower Ground Floor, Western Infirmary General, 38 
Church Street, Glasgow, G11 6NT 
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Appendix 5: Actual concn of Levobupivacaine 0.75% 
Date Prepared/manufact WIG B.N.  Abbott B.N. Conc. from C of A 
 
Batch 1 of levobupivacaine 0.75% 
    011826   124756W02 99.6% = 7.47mg/mL 
 
1-10/11/10   011816  124756W02 
2-08/11/10   011811  124756W02 
3-21/10/10   010829  124756W02 
4-19/10/10   010825  124756W02  
5-18/10/10   010823  124756W02  
 
Batch 2 of levobupivacaine 0.75% 
    010821   119612W01 101.4% = 7.605mg/mL 
 
6-25/08/10   008853  119612W01 
7-17/08/10   008834  119612W01 
8-05/08/10   008813  119612W01 
9-03/08/10   008806  119612W01 
10-29/07/10   007866  119612W01 
11-20/07/10   007845  119612W01 
12-16/07/10   007841  119612W01  
 
Batch 3 of levobupivacaine 0.75% 
    007834   119612W03 100.5% = 7.537mg/mL 
 
13-08/07/10   007821  119612W03 
14-09/07/10   007824  119612W03 
15-13/07/10   007831  119612W03 
16-01/07/10   007803  119612W03 
17-22/06/10   006856  119612W03 
18-17/06/10   006845  119612W03 
19-16/06/10   006840  119612W03 
20-09/06/10   006820  119612W03 
21-31/05/10   005880  119612W03 
22-18/05/10   005842  119612W03 
23-12/05/10   005829  119612W03 
24-07/05/10   005814  119612W03 
25-30/04/10   004876  119612W03 
26-23/04/10   004861  119612W03 
27-22/04/10   004854  119612W03 
28-21/04/10   004848  119612W03 
29-19/04/10   004837  119612W03  
 
 
Batch 4 of levobupivacaine 0.75% 
    004833   107885W01 101.2% = 7.59mg/mL 
 
30-09/04/10   004816  107885W01 
31-07/04/10   004807  107885W01 
32-31/03/10   003883  107885W01 
33-29/03/10   003873  107885W01 
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34-12/03/10   003832  107885W01 
35-09/03/10   003825  107885W01 
36-08/03/10   003821  107885W01 
37-02/03/10   003803  107885W01 
38-25/02/10   002953  107885W01  
 
Batch 5 of levobupivacaine 0.75% 
    002947   106734W02 99.8% = 7.485mg/mL 
 
39-22/02/10   002940  106734W02 
40-16/02/10   002921  106734W02 
41-09/02/10   002896  106734W02 
42-02/02/10   002876  106734W02 
43-26/01/10   001857  106734W02  
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 Appendix 6: Tolerances for syringes used to prepare 
levobupivacaine from BD Ltd. 
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Appendix 7: Calibration of analysis for levobupivacaine 
by ABS laboratories 
Advanced Bioanalytical Service Laboratories  
BioPark 
Broadwater Road  
Welwyn Garden City  
Hertfordshire, AL7 3AX 
Telephone:+44(0)1707 358666 Fax:+44(0)1707 358667 
Email: abslabs@biopark.org.uk 
Analytical Report for ABS Laboratories Ref. ABS/39/11 
Client: Dr Malcolm Watson 
Department of 
Anaesthesia 
30 Shelley Court 
Gartnavel Hospital 
Glasgow 
G12 0YN 
Date of 
Sample 
Receipt: 
10-May-
2011 
  Date of 
Analysis: 
19 to 20-
May 2011 
  Date of 
Report: 
14-Jul-
2011 
Contact: Dr Malcolm Watson   
Project Name: Analysis of human plasma samples to quantify the 
presence of levobupivacaine 
Client Project 
Number: 
Not known   
ABS Project 
Number: 
ABS/39/11   
 
Client Sample Identity and Method Summary 
ABS Sample 
Number 
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Samples were generated from a Clinical study 
conducted by Dr Malcolm Watson.  The client 
supplied these samples directly to ABS Laboratories in 
a frozen condition.  These samples were stored below 
-15°C prior to analysis.  The samples were analysed 
using a method set up and validated to the FDA 
guidelines for the validation of Bioanalytical methods 
by ABS Laboratories’ personnel, Method SOP 5-77.2.  
This method describes the determination and 
quantification of bupivacaine using mepivacaine to 
internally standardise the procedure.  The analytes 
are precipitated from the plasma proteins using 
acetonitrile, reduced to dryness under nitrogen, and 
reconstituted in 0.05% formic acid for quantitative 
determination using liquid chromatography tandem 
mass spectrometry (LC-MS/MS) with multiple 
reactions monitoring (MRM).   The samples were 
analysed in two batches with duplicate calibration 
standards containing levobupivacaine in control 
human plasma at 0 (blank), 1.0, 2.0, 5.0, 10.0, 25.0, 
50, 100, 250 and 500 ng/m and duplicate quality 
control samples (QCs) at 3, 75 and 300 ng/mL (These 
were prepared in bulk and stored frozen at 
approximately -20°C until required.) Stability of 
levobupivacaine has been demonstrated at -20ºC for 
3 months in K3+ EDTA human plasma, and for 24 
months in lithium heparin human plasma.  Samples 
were analysed by LC-MS/MS on system API4000D using 
the following MRM transitions, levobupivacaine m/z 
289.2 > 140.2 and mepivacaine m/z 247.2 > 98.2. 
1 to 82 
  
 
Results 
Quantification was performed by analyzing the calibration standards in duplicate 
with one series being analyzed at the beginning of a batch and one series being 
analyzed at the end of a batch. At least 75% of the calibration standards should 
have back-calculated values <± 15% of their nominal concentration except at the 
lower limit of quantification (LLOQ) where it should be <± 20%. The LLOQ and 
upper limit of quantification (ULOQ) must be present from at least one series of 
the calibration standards. The correlation coefficient (r) should be >0.98 for 
each calibration curve. The actual back calculated calibration standards in this 
study are shown in Table 8.  In addition the accuracy (% bias) of the method 
should be <± 15% for 2/3rds of the spiked control sample concentrations.  The 
actual back calculated concentrations of the QCs analyzed in this study are 
shown in Table 8. 
Example MRM chromatograms from 1 and 500 ng/mL calibration standards and a 
test sample ABS No. 50 are shown in Tables 8 and  9 respectively. 
Appendix 7 
Page 234 of 287 
 
 
Table 2: Results of the calibration standards from ABS/39/11 
Bupivacaine (ng/mL) 
Run ID 
1.000 2.000 5.000 10.000 25.000 50.000 100.000 250.000 
1.020 2.058 4.976 10.224 25.002 52.580 100.759 247.974 
20110519AB2.rdb 0.954 2.022 5.057 9.966 25.369 52.266 101.610 243.583 
1.090 1.890 5.017 10.049 26.192 51.969 103.812 266.676 
20110520AB2.rdb 0.940 1.975 5.154 9.631 23.728 48.481 102.249 236.629 
Mean 1.00 1.99 5.05 9.97 25.07 51.32 102.11 248.72 
SD 0.07 0.07 0.08 0.25 1.03 1.91 1.29 12.85 
CV% 6.88 3.66 1.51 2.50 4.09 3.72 1.26 5.17 
%Bias 0.10 -0.69 1.02 -0.33 0.29 2.65 2.11 -0.51 
 
 
Table 3: Results of the quality control samples from ABS/39/11 
Bupivacaine (ng/mL) 
Date Run ID 
3.000 75.000 300.000 
3.083 76.156 312.136 
20110519 20110519AB2.rdb 2.938 77.930 306.403 
3.138 76.308 317.781 
20110520 20110520AB2.rdb 3.136 79.858 323.840 
Mean 3.07 77.56 315.04 
SD 0.09 1.73 7.48 
CV% 3.06 2.23 2.38 
% Bias 2.46 3.42 5.01 
Comments: There are no additional comments for this study 
Analyst Date 
: A. E. Bryant 
 
14-Jul-2011 
Reviewed by Laboratory & QA Date 
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Manager  
 
M. V. Doig 
 
14-Jul-2011 
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Appendix 8: Concentrations of 0.75% levobupivacaine 
batch used to prepare EC95 levobupivacaine batches 
 
Date Prepared  WIG B.N. Abbott B.N. Conc. from C of A 
 
 
1st Dec 2010   all Batches 128787W01 101.4% = 7.605mg/mL 
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Appendix 9: Research audit report 
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Appendix 10: List of operators and assessors for clinical 
study 
 
List of operators (sitting femoral 3-in-1 nerve blocks) 
 
1. Dr Malcolm Watson 
2. Dr Robert Zimmer 
3. Dr John Luck 
4. Dr Neil Storey 
5. Dr Emily Walker 
6. Dr Simone Rowell 
7. Dr Judith Ramsey 
8. Dr John Dolan 
9. Dr Kenneth O’Conner 
10. Dr Sarah Ramsey 
11. Dr Jane Duffty 
12. Dr Judith Todd 
13. Dr Marcin Ciechomski 
14. Dr Graeme Hilditch 
15. Dr Julia Roberston 
16. Dr Carole Gray 
17. Dr Colin Rae 
 
 
 
 
 
List of assessors of motor and sensory function 
 
1. Dr Malcolm Watson 
2. Dr Alison Wood 
3. Kate Lochran 
4. Karen Allen 
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Appendix 11: Blood pressure cuff quality assurance 
reports 
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Appendix 12: Secondary endpoints against efficacy 
See table 6-15 femoral motor definition 2 
Analysis of secondary end points effective against block efficacy with patients 
with data from those patients with serious protocol violations treated as 
described in table 6-16.  In patients with pre block motor scores of ≤3/4 an 
effective motor block was defined by a reduction in femoral motor score of 1 or 
more and/or a sensory response. 
Table 12-1: Summary of secondary end points against efficacy at 6 hours, definition 2 
 
Number of patients 
Ineffective/effective 
Ineffective Effective 
Mann 
Whitney 
(p-value) 
Pain scores-median 
(0-100) 
(interquartile range) 
28/140 
50 
(18.8-62.5) 
40  
(20-60) 
P=0.5595 
AMT(1-10) 
median(interquartile 
range) 
28/136 
10 
(10-10) 
10 
(10-10) 
P=0.4686 
Morphine 
consumption(mg) 
median(interquartile 
range) 
28/140 
12.5 
(7-16.5) 
 
10 
(5-16) 
P=0.3344 
Patient 
satisfaction(1-10) 
median(interquartile 
range) 
28/138 
10 
(8-10) 
10 
(8-10) 
P=0.9698 
Table 12-2: Summary of secondary end points against efficacy at 24 hours, definition 2 
 
Number of patients 
ineffective/effective 
Ineffective Effective 
Mann 
Whitney 
(p-value) 
Pain scores 
(0-100), 
median(interquartile 
range) 
28/139 
20 
(8-50) 
30 
(11-50) 
P=0.2268 
AMT(1-10) 
median(interquartile 
range) 
28/138 
10 
(10-10) 
10 
(10-10) 
No 
difference 
Morphine 
consumption(mg) 
median(interquartile 
range) 
28/139 
34 
(18.75-43) 
29 
(17-45) 
P=0.5996 
Patient satisfaction 
(1-10)median 
(interquartile range) 
28/138 
9 
(8-10) 
9 
(8-10) 
P=0.5854 
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See table 6-15: femoral motor definition 3 
Analysis of secondary end points effective against block efficacy with patients 
with data from those patients with serious protocol violations treated as 
described in table 6-16.  Analysis of secondary end points with patients with pre 
testing motor scores of ≤3 or less all treated as failures. 
 
Table 12-3: Summary of secondary end points against efficacy at 6 hours, definition 3 
 
Number of patients 
Ineffective/effective 
Ineffective effective 
Mann 
Whitney 
(p-value) 
Pain scores-median 
(0-100) 
(interquartile range) 
 
59/110 
37.5 
(22.5-70) 
36.5 
(20-60) 
P=0.0665 
AMT(1-10) 
median(interquartile 
range) 
57/108 
10 
(10-10) 
10 
(10-10) 
P=0.2481 
Morphine 
consumption(mg) 
median(interquartile 
range) 
59/110 
11 
 (7-17.5) 
 
10 
(4.25-16) 
P=0.2384 
Patient 
satisfaction(1-10) 
median(interquartile 
range) 
58/109 
9.5 
(8-10) 
10 
(8-10) 
P=0.600 
Table 12-4: Summary of secondary end points against efficacy at 24 hours, definition 3 
 Number of patients 
ineffective/effective 
Ineffective Effective Mann 
Whitney 
(p-value) 
Pain scores 
(0-100), 
median(interquartile 
range) 
59/108 
20 
(10-50) 
30 
(10-50) 
P=0.9879 
AMT(1-10) 
Median 
(interquartile range) 
59/109 
10 
(10-10) 
10 
(10-10) 
No 
difference 
Morphine 
consumption(mg) 
Median 
(interquartile range) 
59/108 
 
29 
(18-52) 
 
28.5 
(17-42) 
P=0.2061 
Patient satisfaction 
(1-10) 
Median 
(interquartile range) 
58/108 
 
8.75 
(8-10) 
 
9.0 
(8-10) 
P=0.9040 
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See table 6-15: femoral motor definition 4 
Analysis of secondary end points effective against block efficacy with patients 
with data from those patients with serious protocol violations treated as 
described in table 6-16.  Patients with pre-block motor scores of ≤3/4 were 
excluded from all analysis 
Table 12-5: Summary of secondary end points against efficacy at 6 hours, definition 4 
 
Number of patients 
ineffective/effective 
Ineffective Effective 
Mann 
Whitney 
(p-value) 
Pain scores- 
(0-100) 
Median 
(interquartile range) 
25/109 
40  
(15-50) 
38 
(20-55) 
P=0.8588 
AMT(1-10) 
median(interquartile 
range) 
25/107 
10 
(10-10) 
10 
(10-10) 
P=0.2722 
Morphine 
consumption(mg) 
median(interquartile 
range) 
25/109 
 
11 
 (7-16) 
 
10 
(4-16) 
P= 0.586 
Patient 
satisfaction(1-10) 
median(interquartile 
range) 
25/108 
 
10 
(8-10) 
 
10 
(8-10) 
P=0.7282 
Table 12-6: Summary of secondary end points against efficacy at 24 hours, definition 4 
 
Number of patients 
ineffective/effective 
Ineffective effective 
Mann 
Whitney(p-
value) 
Pain scores 
(0-100), median 
(interquartile 
range) 
25/108 
20 
(10-50) 
30 
(10-50) 
P=0.2325 
AMT 
(1-10)Median 
(interquartile 
range) 
25/108 
10 
(10-10) 
10 
(10-10) 
No 
difference 
Morphine 
consumption(mg) 
Median 
(interquartile 
range) 
25/108 
34 
(18-42) 
28.5 
(17-42.5) 
P=0.7123 
Patient satisfaction 
(1-10)Median 
(interquartile 
range) 
25/111 9(8-10) 9 (8-10) P=0.7503 
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Appendix 13, Protocol: A dose finding study to determine 
the duration of pain relief for patients with a broken hip 
Protocol 
Short title:  A dose finding study to determine the duration of 
pain relief for patients with a broken hip 
 
Full title:  A dose finding study to determine the duration of 
analgesia provided by an ultrasound guided 
femoral 3-in1 nerve block in patients with a 
fractured neck of femur 
 
Sponsor: Greater Glasgow and Clyde Health Board 
 
Funder:  
 
Public data base registration: 
At http://www.clinicaltrials.gov/ct2/home:   
  
Ethics reference number:     
EUDRACT Number:      
Research and development number:    
Compound:       
 levobupivacaine 
Sponsors Protocol Number:    MW001 
Version Number       
 
This study will be performed according to the Research Governance 
Framework for Health and Community Care (Second edition, 2006) 
and The Medicines for Human Use  (Clinical Trials) Regulations, 2004 
SI 2004:1031 (as amended) and WORLD MEDICAL ASSOCIATION 
DECLARATION OF HELSINKI  Ethical Principles for Medical Research 
Involving Human Subjects 1964 (as amended). 
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Chief investigator 
Dr Malcolm J. Watson MB ChB, BSc, MRCP, FRCA 
 
 
 
Principal investigator 
 
 
 
Co-investigators 
 
 
 
 
Recruitment sites 
Western Infirmary, Glasgow, Scotland 
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4 Contact details 
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Email:   mwatson@doctors.org.uk  
6 Chief investigator: 
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Abbreviations 
AE Adverse event 
CRF Case report form 
EC Ethics Committee 
GP General Practitioner 
ICH GCP International Conference on Harmonization of Good Clinical Practice 
SAE Serious adverse event 
SUSAR Suspected Unexpected Serious Adverse Reaction  
SOP Standard Operating Procedure 
pain VAS Pain Visual Analogue Score 
EC50 Effective concentration in 50% of patients 
EC95 effective concentration in 95% of patients 
ASA American Society of Anesthesiologists 
US Ultrasound 
IV Intravenous 
US Ultrasound 
SmPC Summary of Product Characteristics 
IB Investigator’s Brochure 
CTIMP Clinical trial of an investigational and/or medicinal product 
IMP Investigational and/or medicinal product 
CI Confidence Interval 
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Terminology Definition 
Sequential Dixon’s up down 
methodology  
In order construct a probability 
response curve for a binary outcome 
against concentration patients will be 
allocated to the next concentration 
dependant on the response of the 
previous patient 
Stepping value (δ) The difference between sequential 
concentrations in Dixon’s up/down 
methodology 
Standard deviation (σ) The estimated standard deviation of 
probability data using probit logistic 
regression analysis  
Turning point If the analysis result changed from 
successful to unsuccessful or vice a 
versa  
Interim analysis using probit logistic 
regression analysis  
Probit logistic regression re-analysis of 
the data will be undertaken two 
patients after each turning point 
Effective analgesia Pain score decreased by ≥20/100, 
associated sensory changes in femoral 
nerve distribution, 30 minutes after 
femoral 3-in-1 nerve block 
Ineffective analgesia Pain score decreased by <20/100 with 
no associated sensory changes in the 
femoral nerve distribution, 30 minutes 
after femoral 3-in-1 nerve block 
Equivocal block Pain scores and sensory changes 
conflict 
Successful block Pain score ≤50/100 for greater than 10 
hours 
Unsuccessful block Pain score >50/100 for greater than 10 
hours 
 
Appendix 13 
Page 255 of 287 
 
Clinical question 
What dose of levobupivacaine is required to provide pain relief for greater than 
or equal to 10 hours in patients with a broken hip using an ultrasound to guided 
femoral 3-in-1 nerve block? 
Overall study design 
The first 32(range 16-50) patients eligible for recruitment will be recruited to 
Part A 
 
The next 16 (range5-30) patients eligible for recruitment will be recruited to 
Part B 
 
Clinical trial Synopsis-PART A 
 
Aim 
Part A: To estimate (using probit logistic regression analysis) the 
levobupivacaine EC50 (concentration required to provide analgesia for greater 
than or equal to 10 hours in 50% of patients) using an ultrasound guided femoral 
3-in-1 nerve block.  Probit logistic regression analysis will then be used to 
estimate the levobupivacaine EC95 (concentration required to provide successful 
analgesia in 95% of patients). 
Primary outcome 
Part A: EC50 and EC95 concentrations of 30mls of levobupivacaine for 
≥10hours of analgesia after a femoral 3-in-1 nerve block. 
 
Methodology 
Part A: An ultrasound guided femoral 3-in-1 nerve block will be performed 
pre-operatively with a catheter left in-situ.  An effective block will be defined 
as reduction in resting pain VAS of 20 points or more with a pre block resting 
pain VAS of greater than or equal to 50/100 (defined as effective analgesia if 
also associated with sensory change).  To ensure the validity of an effective 
block the patient must also be associated with a <90% of initial sensory stimuli 
on testing with a blunted needle or altered sensation on testing with melting ice 
in central area of distribution of femoral nerve in comparison to the contra 
lateral side at 30 minutes after the insertion of local anaesthetic.  An 
ineffective block will have a less than 20 point reduction in pain scores with no 
change in sensation.  If the sensory testing and pain scores changes conflict then 
the concentration will be repeated and the femoral 3-in-1 nerve block will be 
defined as equivocal.  If the block is ineffective then confirmation of correct 
position of the IMP (levobupivacaine) dose will be given by the reduction in 
resting pain VAS scores to <30/100 after rescue dosing of 20mls of 0.25% 
levobupivacaine via the femoral nerve block catheter.  A successful block will 
provide analgesia for ≥10 hours with VAS pain scores less than or equal to 
50/100.  An unsuccessful block will provide analgesia for <10 hours. 
 
Rescue analgesia 
Part A: If the ultrasound guided femoral 3-in-1 nerve block fails to reduce 
the resting pain VAS by <20/100 in 30 minutes (ineffective block) then 20mls of 
0.25% levobupivacaine will be given via a femoral nerve catheter to achieve a 
resting pain VAS of <30/100 and if necessary intravenous morphine will be 
titrated according to local protocols to achieve a resting pain VAS of <30/100. 
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Study design  
Part A:  Sequential Dixon’s up/down study 
Femoral 3-in-1 nerve blocks will be performed and the concentration of 
levobupivacaine will be increased or decreased for an unsuccessful or 
successful nerve block respectively until the concentration of local anaesthetic 
is successful (effective analgesia for ≥10 hours in 50% of patients (EC50)).  The 
stepping value (δ) will be recalculated two patients after each turning point has 
been reached and changed to increase the accuracy of the final estimate for the 
EC50 of levobupivacaine. 
Inclusion criteria 
Part A:  
 Emergency proximal fractured neck of femur 
Resting pain VAS at rest of ≥50mm on a 100mm scale before recruitment 
American Society of Anaesthesiology (ASA) grading ≤4 
Able to give informed consent 
Patient is able to cooperate with sensory testing of lower limb function 
 
     Exclusion criteria 
Part A: 
Acute mental test score of <7 at any time pre-operatively 
Allergy to local anaesthetic 
Contra-indication to levobupivacaine 
No pre-existing neurological deficit (sensory or motor) affecting the lower 
limb 
Patients with lower limb amputations 
Patients with a history of chronic pain 
 
Number of patients needed 
Part A: A single 30ml dose of levobupivacaine prepared by the pharmacy 
production unit (PPU) at the Western Infirmary, Glasgow with the 
levobupivacaine concentration increased (by the stepping value δ ) after an 
unsuccessful femoral 3-in-1 nerve block and decreased (by the stepping value δ) 
following an effective femoral 3-in-1 nerve block and starting dose of 0.20%.  An 
effective femoral 3-in-1 nerve block (reduction in resting pain VAS of ≥20/100 
with an associated sensory change) will be defined as providing successful 
analgesia (resting pain VAS <30/100 at rest) for greater than 10 hours.  The total 
number of patients needed will be approximately 32 (estimated range 25-50) 
successful and unsuccessful blocks (Please see attached sample size justification 
in a letter from Dr Alex McConnachie senior statistician at the Robertson centre, 
Glasgow University).  Multiple interim re-analyses will be performed in 2 
patients after each turning point to ensure that δ (the stepping value) is 
approximately 2/3 to 3/2 σ of (the standard deviation of the mean for the EC50 
calculated using probit logistic regression analysis) an δ will be altered if 
necessary to increase the accuracy of the estimate obtained for the EC50 and 
EC95 concentration.
 (Please refer to section ‘3.8 Statistical justification of 
sample size Part A’ for more details) 
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Clinical trial synopsis-PART B 
Aim 
Part B: To estimate the duration of analgesia provided by the EC95 
concentration of levobupivacaine estimated (using probit logistic regression 
analysis) to provide ≥10 hours of analgesia from part A of this clinical trial and to 
determine if the peak plasma levobupivacaine concentrations are within safe 
limits. 
Methodology 
Part B: Femoral 3-in-1 nerve blocks will be performed pre-operatively 
using ultrasound to guide needle insertion with a catheter left in-situ.  A 
effective block will be defined as reduction in resting pain VAS of greater than 
or equal to 20/100 points with a pre block resting  pain VAS of greater than or 
equal to 50/100 with an associated sensory change.  To confirm an effective 
femoral 3-in-1 nerve block, the patient must also have <90% of initial sensory 
stimuli on testing with a blunted needle or altered sensation on testing with 
melting ice in the central area of distribution of femoral nerve in comparison to 
the contra lateral side at 30 minutes after the insertion of levobupivacaine. 
The primary end point, in effective femoral 3-in-1 nerve blocks will be the 
duration of analgesia (resting pain VAS ≤50/100 at rest); pain scores will be 
recorded hourly postoperatively from awake patients only.  Blood samples will 
be taken before the insertion of the levobupivacaine and at 10, 20, 30 and 60 
minutes post insertion of levobupivacaine from a cannula inserted to assess peak 
serum levels of levobupivacaine.  Blood samples will be taken for venous blood 
gases and liver function tests before the insertion of the levobupivacaine.  Once 
all the blood samples have been taken 60 minutes after the femoral 3-in-1 block 
all the blood samples will be taken to biochemistry at the Western infirmary 
liver function and venous blood gases will be analysed immediately.  The 
levobupivacaine samples will be centrifuged and frozen to minus 20 degrees 
Celsius for delayed analysis as a batch. 
Rescue analgesia 
Part B: If the ultrasound guided femoral 3-in-1 nerve block fails to reduce 
the resting pain VAS by <20/100 in 30 minutes (failed analgesia, ineffective 
nerve block) then 20mls of 0.25% levobupivacaine will be given via a femoral 
nerve catheter to achieve a resting pain VAS of <30/100 and if necessary 
intravenous morphine will be titrated to achieve a resting pain VAS of <30/100. 
Study design  
Part B: Observation prospective cohort study 
Femoral 3-in-1 nerve blocks will be performed with the levobupivacaine 
concentration estimated to be effective in 95% of patients from part A (EC95).  
The duration of analgesia will be the primary end point for this part of the study 
and 5 blood samples will be taken to determine the blood serum concentration 
of levobupivacaine.  It is estimated that the time taken to half the pain score in 
the patients recruited to part B of the study (see statistical considerations, Part 
B, 3.6 Secondary end points) 
Inclusion criteria 
Part B:  
 Emergency proximal fractured neck of femur 
Visual analogue pain score at rest of ≥50mm on a 100mm scale before 
recruitment. 
American Society of Anaesthesiology grading ≤4 
Able to give informed consent 
Patient is able to cooperate with sensory testing of lower limb function 
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Exclusion criteria 
Part B 
Acute mental test score of <7 at any time preoperatively 
Allergy to local anaesthetic 
Contra-indication to levobupivacaine 
Pre-existing neurological deficit (sensory or motor) affecting the lower 
limb 
Patient with lower limb amputations or other condition affecting 
sensation in lower limbs 
Patient with a history of chronic pain 
 
Number of patients needed 
Part B:  The primary outcome of this study will be the duration of 
analgesia. The standard deviation is approximately 4 hours (from clinical 
experience).  The standard error of the mean is the standard deviation divided 
by the square root of the sample size.  Hence a sample size of  approximately 16 
(range 5-30) will provide a standard error of 1 hour (assumed mean duration of 
approximately 10 hours). Therefore to estimate the mean duration of analgesia 
with a 95% confidence interval of ± 2 hours will require a sample size of 
approximately 16 patients (estimated range 5-30) with successful blocks, 
assuming an approximately normal distribution. 
 
Primary outcome 
Part B:  Duration of analgesia (resting pain VAS<50/100 at rest) provided by 
estimated EC95 concentration of levobupivacaine from part A. 
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1.0     Introduction 
1.1 Background 
Burden of disease caused by fractured neck of femur 
Fractured neck of femur or proximal femoral fracture is a significant cause of 
morbidity and mortality in the population of the developed world.  Johnell et al 
calculated that hip fracture was associated with 1.75 million disability adjusted 
life years (DALYS) which represents 1.4% of the total disease burden calculated 
in DALYS for women in established market economies in 1990 (Johnell and Kanis 
897-902).  Disability adjusted life years are a sum of years lost due to premature 
mortality and disability directly related to hip fracture for the number of years 
that the patient survives multiplied by a disability factor between 0 (no 
disability) to 1 (death).  The disability weight expressed as a fraction describes 
the range of disutility between death (=1) and perfect health (=0) and has been 
estimated for hip fracture by expert panels at 0.272 for each year of illness 
(Murray and Lopez 1347-52).  Fractured neck of femur represents a greater 
burden of disease in established market economies for women than cirrhosis of 
the liver (1.1%), stomach cancer (0.9%) or ovarian cancer (0.9%) (Johnell and 
Kanis 897-902).  Gullberg et al estimated that worldwide the total number of hip 
fractures in men and women in 1990 was 338,000 and 917,000 respectively, a 
total of 1.26 million(Gullberg, Johnell, and Kanis 407-13).  Gullberg also 
estimated that the number of hip fractures will double to 2.6 million by the year 
2025, and 4.5 million by the year 2050 with a 95% confidence interval of 
between 7.3 and 21.3 million if we assume no change in the age and sex specific 
incidence. 
Prognosis and historical perspective operative /non-operative management 
The prognosis for patients with a fractured neck of femur in the UK is poor.  The 
overall 1 year survival is approximately 25% (Heikkinen, Parker, and Jalovaara 
349-54) and a hospital mortality is 14.3% for those patients admitted from home 
(Bottle and Aylin 947-51).  The one year mortality has however improved 
significantly since Beals reported a 50%, 1 year mortality in a surgically managed 
cohort of patients recruited between 1956 and 1961(Beals 235-44).  Roberts et al 
retrospectively analysed the mortality rates for 32590 patients with a fractured 
neck of femur between 1968 and 1998(Roberts & Goldacre, 771-775).  Roberts 
concluded that the mortality reduction between 1968 and 1983 was associated 
with the introduction of surgical management.  No significant fall in mortality 
has been observed since 1983.  Non-operative management of fractured neck of 
femur is associated with significantly higher 30 day mortality (18%) than 
operative management(11%)(odds ratio 1.7, 95% confidence interval (CI) 1.6 - 
1.8), in a review of 50235 fractured neck of femur patients over 7 years in 
Ontario Canada (Jain, Basinski, and Kreder 11-17). 
Prognosis and delay in definitive surgical management 
Delay in definitive surgical fracture fixation is also associated with an increased 
risk of mortality.  Bottle et al examined a retrospective cohort of 129522 
patients from 151 Trusts in England and Wales between April 2001 and March 
2004 (Bottle and Aylin 947-51).  Bottle et al found an independent association 
between delayed operative treatment and an increased risk of death in hospital.  
For all deaths in hospital, the odds ratio for more than one day’s delay relative 
to one day or less was 1.27(95% confidence interval 1.23 to 1.32) after 
adjustment for co morbidity.  It is interesting to note that if the death rates in 
patients with at most one day’s delay had been repeated throughout all 151 
Trusts in this study, there would have been an average of 581 (478 to 683) fewer 
deaths per year.  The association between delay in surgical treatment and 
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increased mortality was also shown by Moran et al(Moran et al. 483-89).  Moran 
et al conducted a prospective observational study examining the mortality rates 
for 2660 patients in Nottingham, UK and he concluded that that if patients who 
were otherwise judged to be fit for surgery were delayed more than four days it 
was associated with a significant increase in mortality at 30 days (hazard ratio 
2.4; p>0.001) and 1year (hazard ratio 2.25; p>0.001).  Fox et al did not find that 
a delay of up to 48 hours had an affect on outcome in a relatively small cohort 
of 142 patients(Fox et al. 297-300;Perez et al. 237-40). 
Prognosis and aetiology for fractured neck of femur patients 
The aetiology of this poor prognosis is multifactorial; a review of multiple post 
mortem studies suggested that the principal cause of death was 
bronchopneumonia in 46% of patients, cardiac failure and myocardial infarction 
(23%) and pulmonary embolism (in 14%) (Perez et al. 237-40). Mortality from 
bronchopneumonia and pulmonary embolism was also significantly reduced in 
those patients who were operated on within 24hours (Perez et al. 237-40) but 
cardiac failure was not altered by surgery within 24 hours of admission. 
Safe serum levels of levobupivacaine 
Currently, there is no known serum level for levobupivacaine that can be 
considered toxic but levobupivacaine itself may be inherently safer than racemic 
bupivacaine and current practice to use a single dose of up to a 150mg in a 
volume of between 20mls and 40mls in fractured neck of femur patients.  
Kopacz and Allen reported an accidental intravenous injection of 142.5 mg of 
levobupivacaine into a patient during attempted epidural anaesthesia (Kopacz 
and Allen 1027).  Transient agitation was the only symptom of systemic toxicity 
and the patient recovered fully however, blood samples were taken after the 
injection and analysed retrospectively for serum levobupivacaine.  The 
levobupivacaine serum concentrations measured at 14 minutes and at 120 
minutes were 2.7µg/mL and 1.1µg/mL respectively.  Further evidence for 
reduced toxicity of levobupivacaine compared to the racemic bupivacaine can 
be found in a cross-over study of slow (10 mg/min) IV infusion of levobupivacaine 
in 12 healthy volunteers, central nervous system symptoms first appeared at a 
larger mean total dose (54.0 mg versus 45.6 mg), producing a higher resultant 
plasma level (2.38 µg/mL versus 1.87µg/mL) than for racemic bupivacaine 
(Gristwood et al. 1209 –12).  In contrast to the case described by Kopacz at al 
previous cases of accidental intravenous racemic bupivacaine injection in which 
seizures or severe cardiac arrhythmias occurred at serum levels as low as 1.8 
µg/mL (Rosenburg et al 95–8), 2.74 µg/mL (Moore et al 230–2), and 2.3 µg/mL 
(Ryan. 907–8) of racemic bupivacaine have been detected within 5 minutes of 
injecting patients having seizures.  It is possible that the toxicity of 
levobupivacaine may be dependant not only on the total concentration of 
levobupivacaine but on the amount of free levobupivacaine which is dependant 
on the acid base status of the patient.  It is known that acidosis increases the 
cardiotoxicity of intravenous local anaesthetics (Moore. 109 –21).  The incidence 
of systemic toxicity from local anaesthetics is very rare and a recent review 
estimated the incidence to be 1 in 10000 (Cox et al 111-36). 
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1.2 Current practice and results from previous clinical trials and 
studies 
 
Current practice: 
The hospital mortality for patients admitted to hospital from home in the UK 
with a fractured hip is 14.3% (Bottle and Aylin 947-51).  The current techniques 
for analgesia rely on parentral morphine, paracetamol and non-steroidal anti-
inflammatory (NSAIDS) drugs that frequently provide inadequate pain relief with 
multiple side effects despite this multimodal approach.  Studies have suggested 
a link with effective pain relief and a reduced risk of death.  Effective analgesia 
can be provided by ultrasound guided nerve blocks as this has been associated 
with an increased success rate, and shorter onset times than traditional regional 
anaesthesia techniques.  The aim of this project is to develop a safe method 
that will allow Accident and Emergency doctors to provide effective pain relief 
to those patients with a fractured hip. 
 
General Plan and background of PhD project: 
This clinical trial is part of an NRS career researcher award by the Chief 
Scientists office (CSO): 
 
7.1 Summary of results for clinical academic fellowship 
(PhD) CAF 05/07 
The results of the clinical academic fellowship clinical trial and clinical study are 
listed below with their associated research questions: 
  
7.1.1.1 Which method do we use to site the local anaesthetic from a femoral 
3-in-1 block? 
The success rates of methods of guiding insertion of a femoral 3-in-1 nerve block 
are as follows.  The exact percentage of successful blocks depended on the 
definition (*) of the primary end point used (sensory and motor changes) but the 
order and magnitude of the difference between each of the procedures is 
approximately the same which ever definition of the primary end point (sensory 
and motor changes) was used. 
Table 1: Success rate for 3 methods of guiding a femoral 3-in-1 nerve block 
Method used  Ultrasound  Nerve stimulator Loss of resistance 
Number of 
patients(Failed) 
16 12 15 
Number of 
patients(Successful) 
55 59 22 
Total analysed 71 71 37 
Percentage 
successful blocks 
77.5% 83.1% 59.4% 
*The definition of a successful block was sensory change <90/100 and/or a motor score decrease of <1 with a starting 
value of 4/4(starting values of <3/4 did not influence the outcome and success or failure was determined by the sensory 
change) 
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The use of ultrasound or a nerve stimulator resulted in an absolute increase in 
the effectiveness of the block by 17% or 23% respectively giving a number 
needed to treat to see a difference of approximately 5 (p=0.0159). 
 
 
7.1.1.2 What dose of levobupivacaine? 
The effective concentration of 30mls of levobupivacaine required to produce a 
reduction in pain verbal analogue score (VAS) of ≥20 points on a 100 point scale 
in 50% of patients (EC50) with a proximal traumatic fractured neck of femur using 
an ultrasound guided femoral 3-in-1 nerve block was EC50=0.0255% with 95% 
confidence interval of 0.0229% to 0.0284%.  The effective concentration of 
levobupivacaine in 95% of patients (EC95) was estimated using probit regression 
techniques as EC95=0.0357% with 95% confidence interval of 0.0332% to 0.0383%. 
 
7.1.1.3 What duration of analgesia from the dose of levobupivacaine? 
The median duration of analgesia from 30mls of 0.036% (the EC95 of 
levobupivacaine) is 166 minutes with an interquartile range of 110 to 210 
minutes.  
 
7.1.1.4 What is the pharmacokinetic profile of the dose of levobupivacaine 
used in the population of patients with a fractured neck of femur? 
The peak median total serum plasma concentration was reached at 30mins after 
the block and was 52ng/ml (‘safe range of <2000ng/ml’). 
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7.2 Current clinical trial 
7.3 To estimate the dose of levobupivacaine required to 
provide analgesia for greater than 10 hours 
The EC95 levobupivacaine concentration from the clinical trial ‘A dose finding 
study for pain relief of a broken hip’, ethics reference 09/S0703/87, EUDRACT 
number 2009-013462-25 did provide an estimate of the effective concentration 
to provide analgesia.  The effective concentration to provide analgesia was 
relatively low and therefore the duration of analgesia was too short to be 
clinically useful.  In order to provide a clinically useful duration of analgesia the 
EC95 and EC50 of levobupivacaine required to provide 10 hours of analgesia using 
a sequential Dixon up/down methodology needs to be determined. 
 
The review article by Pace et al provided a number of improvements to the 
original sequential Dixon’s up/down methodology.  Pace et al suggested using 
the bias coin method of patient allocation to target the EC95 instead of targeting 
the ED50 concentration of levobupivacaine.  This appears to be a very attractive 
option but as every failure will be accompanied by 19 successes, at the EC95 
concentration in order to estimate the EC95 with the same precision as the ED50 
20 times the number of patients will need to be recruited.  If the average dosing 
study needs 20 to 40 patients then 800 to 1600 patients would be required for 
the same precision as a traditional sequential Dixon’s up/down methodology 
targeting EC50.  This is not an efficient method of determining the EC95 and I 
propose to adapt the techniques used in the sequential Dixon’s up/ down 
methodology to estimate the effective levobupivacaine concentration ‘A dose 
finding study for pain relief of a broken hip’, ethics reference 09/S0703/87, 
EUDRACT number 2009-013462-25 in which the stepping value was altered on the 
basis of an interim probit logistic regression analysis. 
 
The sequential up/down Dixon’s method may be utilised to determine the 
concentration of levobupivacaine necessary to provide 10 hours of analgesia.  
The binary end point will be the successful provision of 10 hours of analgesia 
(with pain scores ≤50/100 on awake patients).  The number of patients required 
to obtain a precise estimate for EC95 and EC50 could be decreased by the use of 
iterative re-estimation of the optimal stepping value stepping value(δ). 
 
The protocol for ‘A dose finding study for pain relief of a broken hip’, ethics 
reference 09/S0703/87, EUDRACT number 2009-013462-25 started with a large 
stepping value (difference between the concentrations of levobupivacaine) 
which was decreased  after 16 patients had been recruited so that the stepping 
value (δ)  was between 2/3 and 3/2 of the estimated standard deviation (σ) 
using the probit logistic regression analysis techniques.  A better method would 
be to repeat this process on multiple occasions (iterative technique) during the 
trial to obtain progressively better estimations for the stepping value.  Iterative 
re-calculation of the mean and σ and adjustment of the δ will result in increased 
precision when creating a probability model to estimate levobupivacaine EC50 
and EC95  
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The iterative re-calculation of σ would have several other advantages: 
• The initial stepping value (δ) can be relatively large which will result in 
decease in the number of patients required to reach the first turning 
point 
• The number of patients will be less dependant on the starting 
concentration 
• Repeated measures of the standard deviation (σ) will give a measure of 
the stability of the model and therefore the precision of the final 
estimate of levobupivacaine EC50 and EC95. 
• Objective criteria for stopping the trial can be set at the beginning of the 
trial which will be dependant to the stability of the model created using 
probit logistic regression analysis. 
 
I have made the following assumptions when designing the protocol to use 
iterative re-calculation of the stepping value (δ). 
 
• The iterative calculation of (δ) will only yield a different result if the test 
result has reached a turning point(i.e. from failure to success or vice a 
versa) 
• If the turning point has been reached then if a further 2 patients are 
recruited then the results from these patients will allow determination of 
whether the turning point was above the mean, below the mean or at the 
mean. 
• Therefore an iterative re-calculation will take place 2 patients after a 
turning point.  The standard deviation(σ) and the estimated mean will be 
made and the stepping value(δ) adjusted to be within 3/2 and 2/3 of the 
σ  
• The new starting concentration after recalculation will be estimated using 
the equation (mean + the new stepping value (δ)). 
• The result of the iterative process should be rounded to achieve the most 
accurate result possible within the limits of error imposed by the 
pharmaceutical manufacturing process (with errors of approximately 
±5.1% according to previous work of chief investigator)  
• The iterative process will be repeated after recruiting two patients after 
each turning point until agreement is reached between three estimations 
of the mean and standard deviation within a predetermined precision 
(<10%).  This will imply that the probit logistic regression model is stable 
and that it will give a reliable estimation of levobupivacaine EC95 and 
EC50. 
• The application of these principles have allowed the development of the 
protocol for a clinical trial to determine the dose of levobupivacaine 
required for 10 hours analgesia and to ensure its safety. 
 
In summary the use of iterative re-calculation of the stepping value will 
decrease the number of patients needed to provide an accurate and precise 
answer to the levobupivacaine EC50 and EC95.  It will also provide objective 
criteria to stop the trial once it has achieved a stable endpoint. 
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Current clinical trial: Part-A and Part-B 
Part A 
The dosing of the femoral 3-in-1 nerve block required to produce 10 hours of 
analgesia will be determined in the fractured neck of femur population.  
Levobupivacaine dosing will be determined by a sequential Dixon’s up/down 
methodology.  Femoral 3-in-1 nerve blocks will be performed and the 
concentration of levobupivacaine will be increased or decreased for an 
unsuccessful or successful nerve block respectively until the concentration of 
levobupivacaine is effective in 50% of patients (EC50).  The data from part-A can 
then be used to estimate, using probit logistic regression analysis, the effective 
concentration in 95% (EC95) of patients. 
 
Part B 
Pharmacodynamics will be determined by monitoring pain scores to determine 
the actual duration of analgesia provided by the concentration calculated to 
provide ≥10 hours of analgesia in 95% (EC95) of fractured neck of femur patients. 
The plasma levels of levobupivacaine will also be measured in sequential blood 
samples to ensure that EC95 dose provides pharmacokinetics that are within the 
safe range. 
 
1.3       Research question 
Can we determine the effective dose of levobupivacaine to provide ≥10 hours of 
pain relief in patients with a broken hip using ultrasound to guide needle 
insertion? 
 
1.4    Major risk/benefits of trial to patients 
Risks- 
1 Ultrasound (US) is a relatively new technology for guiding needles to site 
local anaesthetic nerve blocks but a recent meta-analysis of 14 clinical trials 
(Abrahams et al, 408-17) found that nerve blocks performed using US guidance 
were:  
 
 1-more likely to be successful with a risk ratio (RR) for block failure of 
0.41, (95% confidence interval (CI) 0.26–0.66, P=0.001) 
 
 2-took less time to perform with a mean difference of approximately 1 
min less to perform with US, (95% CI 0.4–1.7 min, P=0.003) 
 
 3-had a 29% faster onset time, (95% CI 45–12%, P=0.001 
 
 4-had longer duration (mean difference 25% longer, (95% CI 12–38%, 
P=0.001) than those performed with PNS guidance. 
   
 5-US guidance also decreased the risk of vascular puncture during block 
performance (RR 0.16, 95% CI 0.05–0.47, P=0.001)   
 
 
 
 
 
2 Nerve damage is a risk with all types of nerve blocks but the risk is 
relatively small with femoral 3-in-1 nerve blocks.  The biggest single study to 
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estimate the level of risk of complications was a French study by Auroy et al 
which surveyed 158083 regional anaesthetic procedures performed by 487 
anaesthetists over a 10 month period (Auroy et al 1724-80).  10309 femoral 3-in-
1 nerve blocks were performed during this study; no deaths , no cardiac arrests, 
no episodes of respiratory failure and no seizures were reported and only 3 
peripheral neuropathies were reported all of which had completely recovered by 
3 weeks.  The study estimated that the true incidence of deaths, cardiac 
arrests, episodes of respiratory failure or seizures associated with the femoral 3-
in-1 nerve block using loss of resistance and nerve stimulation was 0-2.9/10000 
with a 95 % CI and the recorded incidence of transient neurological 
complications was 2.9/10000 with 95% CI of 0-7.8/10000. The incidence of 
adverse events using ultrasound guidance to guide a femoral 3-in-1 nerve block 
should be less than 2.9/10000 as the femoral nerve and vessels can be directly 
visualised and it should therefore be possible to avoid inadvertent intraneuronal 
or intravascular injection. 
  
3 Local anaesthetic toxicity may be a risk; however the femoral 3-in-1 
nerve block is currently used in standard clinical practice to provide 
preoperative analgesia to fractured neck of femur patients with the standard 
dose (40mls of 0.375% bupivacaine).  We will use levobupivacaine instead of 
racaemic bupivacaine as it is generally accepted to have a lower cardiac 
toxicity.  20% Intralipid is the current standard treatment for cardiac arrest or 
collapse as a result of local anaesthetic toxicity and is immediately available in 
all areas where local anaesthetic is administered including the emergency 
theatres at the Western Infirmary, Glasgow.  
 
Benefits- 
1 The clinical trial will provide analgesia (resting pain VAS<30/100) to a 
group of frail elderly patients who have suffered a traumatic fractured neck of 
femur with resting pain VAS scores of greater than 50/100. Morrison et al found 
that in 411 patients with surgically treated proximal femoral fractures that 
higher pain scores at rest were associated (Morrison et al 303-11): 
• with significantly longer hospital lengths of stay (P=0.03), 
• were significantly more likely to have physical therapy sessions missed or 
shortened (P=0.002), 
• were significantly less likely to be ambulating by post-operative day 3 
(P<0.001), 
• took significantly longer to ambulate past a bedside chair (P=0.01), and 
• had significantly lower locomotion scores at 6 months (P=0.02). 
 
Morrison et al concluded that untreated pain was also a significant risk factor for 
delirium in a further study of 541 surgically treated proximal fractured neck of 
femur patients (Morrison et al 76–81).  
 
2 Reduced opiate requirement postoperatively which will result in a 
reduction is opiates associated complications i.e. sedation, respiratory 
depression, delirium, nausea vomiting and constipation. 
 
3 Reduced volatile anaesthetic requirements intra operatively 
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2.0     Study Procedures 
2.1 Aim 
      Part A  
To determine the effective concentration of 30mls of levobupivacaine required 
to produce a reduction in resting pain VAS of ≤20/100 (effective block) and keep 
the pain scores ≤50/100 for ≥10 hours (successful block) in patients with a 
proximal traumatic fractured neck of femur (EC50) using an ultrasound guided 
needle placement below the facia iliacus membrane (femoral 3-in-1 nerve 
block). 
      Part B 
To determine the duration of analgesia provided by the EC95 of levobupivacaine 
and to study the pharmacokinetics of levobupivacaine to ensure peak serum 
levels are within safe limits. 
 
2.2 Study design 
Part A 
A prospective sequential Dixon’s up down dose finding study for ultrasound 
guided femoral 3-in-1 nerve block 
 
Part B 
Observation prospective cohort study of the duration of analgesia provided by an 
ultrasound guided femoral 3-in-1 nerve block 
 
2.3 Study Population 
Part A and Part B 
Competent patients with proximal traumatic fractured neck of femur  
 
2.4 Lay summary of trial 
Studies have suggested a link with effective pain relief and reduced illness and 
death in high risk patients.  Ultrasound guided nerve blocks have been 
associated with an increased success rate and allow visualisation of all the 
anatomical structures and the distribution of the local anaesthetic on injection.  
The hospital mortality for patients admitted to hospital from home in the UK in 
2006 with a fractured hip was 14.3% (Bottle and Aylin 947-51). 
The aim of this clinical trial is to determine the effective dose of local 
anaesthetic to provide pain relief to patients for ≥10 hours with a broken hip 
using ultrasound to guide needle insertion.  Patients with a broken hip will be 
recruited after admission to hospital and prior to surgical fixation.  All patients 
recruited to this study will receive appropriate standard anaesthesia, analgesia 
and surgical or non surgical management of their broken hip as dictated by their 
clinical condition. 
The trial can be divided into sequential two parts; the results of part A will 
provide an amount of local anaesthetic which will relieve pain of a broken hip in 
50% of all patients for ≥10 hours.  Part B will determine the actual duration of 
pain relief provided by the amount of local anaesthetic from part A and blood 
levels of local anaesthetic. 
In parts A and B a standard pain relieving nerve block to numb the nerves 
supplying the hip joint will be administered using ultrasound to guide the 
injection of local anaesthetic. The patient will then be observed for 30 minutes 
during which time the feeling in the upper leg and pain scores will be recorded.  
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Patients with ineffective and equivocal nerve blocks will be given immediate 
pain relief and withdrawn from further participation in the study. 
 
In part A the amount of levobupivacaine for the next patient will be increased or 
decreased if the nerve block is unsuccessful (≤10 hours analgesia) or successful 
(≥10 hours) respectively. 
 
In part B the dose required to provide successful pain relief for greater than 10 
hours in 95% of patients will be given to all patients.  Blood samples will be 
taken before the pain relieving nerve block and at 10, 20, 30 and 60 minutes 
afterwards.  In order to determine the duration of pain relief pain scores will be 
recorded in awake patients hourly for up to 24 hours. 
 
2.5 Inclusion criteria 
Part A and Part B 
Emergency hospital admission with proximal fractured neck of femur 
Visual analogue pain score at rest of ≥50/100 
American Society of Anaesthesiology grading ≤4 
Able to give informed consent 
A resting pain VAS of greater than 50mm on a 100mm scale before recruitment 
Patient is able to cooperate with sensory testing of lower limb function 
 
2.6 Exclusion criteria 
Part A and Part B 
Acute mental test score of ≤7 at any time preoperatively 
Allergy to local anaesthetic 
Contra-indication to levobupivacaine 
No pre-existing neurological deficit (sensory or motor) affecting the lower limb 
Patient with lower limb amputations or other condition affecting sensation in 
lower limbs 
Patient with a history of chronic pain 
 
2.7 Criteria for withdrawing a patient from the study 
Part A and Part B 
Patients who were administered regional anaesthesia or analgesia not specified 
in the protocol. 
Any patient may withdraw from the study at any time without giving any reason 
or justification. 
A significant protocol violation which would endanger the patient’s safety or 
invalidate the results from that patient will result in the patient being 
immediately withdrawn from the trial.  However we reserve the right to analyse 
all data collected prior to the patient’s withdrawal from the study. 
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2.8 Methodology  
Part A  
Patients consented for the study will be transferred to the operating theatre 
suite prior to their operation and initial sensory function testing will be 
performed (time 0).  Femoral 3-in-1 nerve blocks will be inserted preoperatively 
using ultrasound needle guidance with 30mls of levobupivacaine (IMP) the 
concentration of which will be determined by the response of the previous 
patient.  A femoral 3-in-1 nerve block will be undertaken using ultrasound to 
obtain images of the femoral artery, vein and nerve in the short axis and a 
100mm or 50mm 18G Contiplex® Tuohy needle (B-Braun) will be advanced in 
plane until the tip of the needle is under the fascia iliacus membrane 
immediately lateral to the femoral nerve.  30mls of levobupivacaine (IMP) will 
then be injected while imaging to ensure the correct spread of local anaesthetic 
(around the femoral nerve with ‘tenting’ of the fascia iliacus membrane).  A 
catheter will be advanced via the Contiplex® Tuohy needle and the needle 
removed to leave 4 to 5cm beyond the original site of the needle tip.  Full 
aseptic technique will be used during the injection of the levobupivacaine (IMP) 
and the insertion of the catheter.  The concentration of levobupivacaine (IMP) 
will be 0.20% for the first patient.  If the first patient has evidence of a sensory 
block and a ≥20/100 point reduction in resting pain score (an effective block), 
and the patient has analgesia for ≥10 hours (resting pain VAS ≤50/100)(a 
successful block) then the concentration of levobupivacaine will be decreased 
by 0.025% for the next patient recruited.  If the first patient has evidence of a 
sensory block and a ≥20/100 point reduction in resting pain VAS (an effective 
block), and the patient has analgesia for <10 hours (resting pain VAS ≤50/100) 
(an unsuccessful block) then the concentration of levobupivacaine will be 
increased by 0.025% for the next patient recruited.  Conversely, if no sensory 
block is present and the pain score does not increase (an ineffective block) then 
20mls of 0.25% levobupivacaine will be given via the catheter and the 
concentration will be repeated.  If the resting pain VAS is not <30/100 30minutes 
after the injection via the catheter the morphine will be titrated to reduce the 
resting pain VAS to <30/100.  Therefore the concentration of levobupivacaine for 
each patient will be dependent on the changes observed in the previous patient.  
A valid change in pain score must be accompanied by an associated change in 
sensation or the concentration will be repeated (equivocal block).  If the 
ultrasound guided femoral 3-in-1 nerve block fails to reduce the resting pain VAS 
to <30/100 in 30 minutes 20mls of 0.25% levobupivacaine will be given via a 
femoral nerve catheter to achieve a resting pain VAS of < 30/100 and if 
necessary intravenous morphine will be titrated according to local protocols to 
achieve a resting pain VAS of <30/100.  The duration of analgesia will be 
measured by recording hourly resting pain VAS scores for up to 24 hours post 
femoral 3-in-1 nerve block.  If the patient is sleeping the resting pain scores will 
be recorded as ‘S’ and the patient will not be woken to assess pain scores. 
Part-B 
Patients consented for the clinical trial will be transferred to the operating 
theatre suite prior to their operation and initial sensory function testing will be 
performed (time 0) and a single set of venous blood gases, baseline 
levobupivacaine levels and liver function tests will be taken.  A femoral 3-in-1 
nerve block will be undertaken using ultrasound to obtain images of the femoral 
artery, vein and nerve in the short axis and a 100mm or 50mm 18G Contiplex® 
Tuohy needle (B-Braun) will be advanced in plane until the tip of the needle is 
under the fascia iliacus membrane immediately lateral to the femoral nerve. 
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30mls of levobupivacaine (IMP) will then be injected while imaging to ensure the 
correct spread of local anaesthetic (around the femoral nerve with ‘tenting’ of 
the fascia iliacus membrane).  A catheter will be advanced via the Contiplex® 
Tuohy needle and the needle removed to leave 4 to 5cm beyond the original site 
of the needle tip.  Full aseptic technique will be used during the injection of the 
levobupivacaine (IMP) and the insertion of the catheter.  The EC95 of 
levobupivacaine for ≥10 hours of analgesia which will be determined by the 
patient’s response to part-A will be administered as the IMP.  A valid change in 
pain score must be accompanied by an associated change in sensation or the 
patient will be excluded from the study (ineffective block).  If the patient does 
not have a resting pain score of <30/100 then intravenous morphine will be 
administered according to local protocol to achieve a resting pain VAS of less 
than 30/100.  Patients with a valid change in pain score associated with a 
sensory change will have blood samples taken before the insertion of the local 
anaesthetic nerve block and at 10, 20, 30 and 60 minutes post insertion of local 
anaesthetic block, from a cannula inserted, to assess peak serum levels of 
levobupivacaine.  The primary end point, in successful blocks will be the 
duration of analgesia (resting pain VAS <30/100 at rest); acute pain scores will 
be recorded hourly postoperatively for up to 24 hours. If the block is ineffective 
or equivocal appropriate rescue analgesia will be given (20ml 0.25% 
levobupivacaine via a femoral nerve block catheter or intravenous morphine will 
be titrated according to local protocols to achieve a resting pain VAS of 
<30/100).  If the patient is sleeping the pain scores will be recorded as ‘S’ and 
the patient will not be woken to assess resting pain VAS.   
 
2.9   Anaesthesia and analgesia for hip replacement or fixation 
Part A and Part B 
Intra operative anaesthesia: No restriction but total bupivacaine and 
levobupivacaine given as part of spinal 
or general anaesthesia will always be 
less than 2mg/Kg 
 
Sedation:  May be used at the discretion of the 
attending anaesthetist using target 
controlled infusion (TCI) propofol 
  
Airway management:    As determined by attending 
anaesthetist. 
 
Intraoperative/post operative 
analgesia:      Paracetamol-1g IV, morphine IV as per 
local practice 
 
Rescue analgesia  
(resting pain VAS<30/100) 20mls of levobupivacaine via femoral 
nerve catheter or morphine IV by local 
protocol to achieve resting pain 
VAS<30/100 
  
Post operative analgesia:  Paracetamol 1g QID and Morphine IV by 
local protocol to achieve resting pain 
VAS<30/100 
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2.10  Assessment of sensory function for femoral 3-in-1 nerve block 
Part A and Part B 
The patient’s sensory function will be assessed by the intensity of a pin prick 
sensation and cold sensation produced by melting ice.  Pin prick sensation will 
be measured using a blunted 25G orange needle.  The patient will be asked to 
grade the intensity of the sensory response to a blunted 25G ‘orange’ needle by 
marking a line from 0 (no sensation) to 100.  100 will be defined as the same 
intensity of sensation as the contra lateral upper middle third of the thigh.  
Melting ice will also be used as a stimulus and a valid response will be taken as a 
reduced cold sensation on the side on which are nerve block was performed 
compared with the contra lateral (unblocked side) on the middle third of the 
upper thigh.  The area of skin to be assessed will be the middle third of the 
upper thigh which is thought to be supplied by the femoral nerve.  To fulfil the 
definition of effective analgesia as well as having a decrease in resting pain VAS 
of ≥20/100 the patient must also have <90% of initial sensory stimuli on testing 
with a blunted needle or altered sensation on testing with melting ice in central 
area of distribution of femoral nerve in comparison to the contra lateral side at 
30 minutes after the insertion of levobupivacaine (IMP). 
 
3.0  Statistical considerations 
Part A 
 
3.1 Primary end point  
Effective or ineffective analgesia 
Effective analgesia is defined by a 20/100 point or greater reduction in resting 
pain score (resting pain VAS) and an associated sensory change at 30 minutes 
post insertion of femoral 3-in-1 nerve block.  A change in resting pain score 
(resting pain VAS) must be accompanied by an associated change in sensation 
(please see ‘2.10 Assessment of sensory function for femoral 3-in-1 nerve 
block’ for a definition of an appropriate sensory change). Only effective femoral 
3-in-1 nerve blocks can be successful or unsuccessful.  Ineffective regional 
analgesia will be defined by a less than 20/100 point reduction in resting pain 
score (resting pain VAS) with no associated sensory changes and the 
levobupivacaine concentration will be recruited. 
 
Successful and unsuccessful block  
An effective femoral 3-in-1 nerve block may be successful or unsuccessful 
dependant on the duration of analgesia.  A successful block will provide 
analgesia for ≥10 hours with resting pain VAS less than or equal to 50/100.  An 
unsuccessful block will provide analgesia for ≤10 hours.  A successful or 
unsuccessful nerve block will result in a decrease or and an increase respectively 
in the concentration of the levobupivacaine for the next patient.  If the 
analgesia and sensory changes recorded conflict (equivocal) or 20mls of 0.25% 
levobupivacaine fails to provide analgesia (technical failure of femoral 3-in-1 
nerve block) the concentration will be repeated.  This will give an estimate of 
the EC50 concentration at which 50% of patients have successful (≥10 hours 
duration) and 50% have unsuccessful (≤10 hours duration) analgesia.  
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3.2 Secondary end points 
• Sensory function of the femoral nerves will be tested at 0mins (pre 
insertion of levobupivacaine) and at 10 and 20 minutes post insertion of 
30mls of levobupivacaine. 
• Time taken and number of attempts to insert femoral 3-in-1 nerve block 
• Blood pressure, oxygen saturation, pulse rate and respiratory rate before 
insertion of 30mls of levobupivacaine and at 10, 20 and 30minutes 
afterwards. 
 
3.3 Number of patients needed  
A single 30ml dose of levobupivacaine prepared by pharmacy production unit 
(PPU) at the Western Infirmary, Glasgow with the levobupivacaine concentration 
increased (by the stepping value δ) after an unsuccessful femoral 3-in-1 nerve 
block and decreased (by the stepping value δ) following a successful femoral 3-
in-1 nerve block and starting dose of 0.20%. The total number of patients 
required will be approximately 32 (estimated range 25-50) (Please see attached 
sample size justification in a letter for Dr Alex McConnachie senior statistician at 
the Robertson centre, Glasgow University).  Multiple interim analyses will be 
performed 2 patients after each turning to ensure that δ (the incremental 
change in the concentration which will initially be set at. 0.025%) is 
approximately 2/3 to 3/2 of the σ (the standard deviation of the normal 
distribution for the EC50) an δ will be altered if necessary to increase the 
accuracy of the estimate obtained for the EC50 concentration and hence the 
estimate of EC95. 
  
3.4 Statistical considerations 
Part B 
3.5 Primary end point 
The duration of analgesia following a successful femoral 3-in-1 block with the 
30ml of levobupivacaine at a concentration calculated to provide analgesia for 
≥10 hours to 95% of patients (EC95) with a fracture neck of femur (derived from 
the results of part A). 
3.6 Secondary end points 
• Sensory function of the femoral, obturator and lateral cutaneous nerves 
will be tested at 0 minutes (pre insertion of levobupivacaine) and at 10 
and 20 minutes post insertion of 30mls of levobupivacaine. 
• The resting pain VAS score will be recorded pre femoral 3-in-1 nerve block 
and at 10 minutes, 20 minutes and 30 minutes post block in order to 
estimate the time to half the resting pain VAS score.  This will be 
modelled using both linear and nonlinear statistics with fixed and random 
effects to achieve the best fit for the data and therefore the best 
estimate of half pain time. 
• Time taken and number of attempts to insert femoral 3-in-1 nerve block. 
• Blood pressure, oxygen saturation, pulse rate and respiratory rate pre and 
30 minutes after insertion of 30mls of levobupivacaine. 
• Serum concentrations of levobupivacaine from blood samples taken at 5, 
10, 20, 30 and 60 minutes after insertion of the local anaesthetic. 
• Venous blood gases and liver function tests. 
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3.7 Number of patients needed 
The primary outcome of this study is the duration of analgesia. The standard 
deviation is approximately 4 hours (from clinical experience). The standard error 
of the mean is the standard deviation divided by the square root of the sample 
size. Hence a sample size of 16 will provide a standard error of 1 hour (assumed 
mean duration of approximately 10 hours). Therefore to estimate the mean 
duration of analgesia with a 95% confidence interval of ±2 hours will require a 
sample size of approximately 16 (estimated range 5-30) patients, assuming an 
approximately Normal distribution. 
 
3.8 Statistical justification of sample size  
Part A 
8 Use of up down study design 
The Up-Down study design requires the specification of an initial dose x0, and δ, 
the difference between successive doses. Dose is usually measured on a log 
scale. The first experiment takes place at dose x0: if it is a success, the second 
experiment takes place at dose x0-δ; if it is a failure the second experiment 
takes place at x0+δ. The sequence of experiments continues in this way, with the 
dose reduced by δ whenever an experiment is successful or increased by δ 
whenever an experiment fails. 
 
Standard Estimation (Dixon & Massey) 
 
It is assumed that for a given (log) dose, x, the probability, P(x), that the dose 
will be effective is 
( ) 





σ
µΦ= -x xP  
where Φ is the cumulative density function of a standard Normal distribution. µ 
is the dose at which 50% of the population would achieve pain relief, or EC50, 
since P(µ) = Φ(0) = ½. 
 
If the numbers of successes is less than the number of failures, then 2-yˆ 1
δ
=µ , 
where 1y  is the mean dose over the successful experiments; otherwise 
2yˆ 0
δ+=µ , with 0y  being the mean dose over experiments that were failures. 
 
The standard error of µˆ  is estimated by 
( ) knGˆSE σ=µ  
with σ estimated by 






+
δ
δ=σ 0.029s1.620ˆ 2
2
k  
and k = 1 or 0 depending on whether µˆ  was estimated from the successful or 
unsuccessful experiments, 2ks  is the sample variance of the dose levels and nk is 
the number of experiments used in the estimation of µˆ . The constant G is an 
approximately linear function of 
σ
δ : for δ=σ, G≈1; for δ=2σ, G≈1.2. 
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Since nk is approximately ½N, where N is the total number of experiments 
conducted, the required sample size for a study can be calculated depending 
upon the desired width of the confidence interval for µ, relative to σ. Since the 
95% CI for µ will be approximately 2SEˆ ±µ , the required sample size will be 
2
8N ∆= , if δ≈σ, where ±∆ is the width of the 95% CI required for µ in units of σ, 
i.e. the 95% CI for µ is σ∆±µˆ . Thus for a 95% CI of ½σ each way, the required 
sample size will be about 32.  A sample size of 32 patients is the best estimate 
of the minimum number of patients needed to determine the EC50 and 95% 
confidence intervals.  The actual sample size needed may vary from the current 
estimate of 32 patients.  The estimated range of the population required will be 
35-50 patients using the information from the clinical trial data of the patients 
that have been recruited. 
Estimation of percentiles other than the 50
th, e.g. the dose at which 95% of 
patients would achieve pain relief, or EC95, is given by 
 
σ+µ ˆzˆ 0.95  
 
where z0.95=1.645 is the 95
th percentile point of a standard Normal distribution. 
The standard error of this estimate is 
( ) ( )220.952 ˆSEzˆSE σ+µ  
where ( ) knHˆSE σ=σ , with H following an approximately quadratic function of 
σ
δ , taking its smallest values over the range σ<δ<2σ, where H≈1.3-1.4. 
 
Comments 
The estimation method as described in Dixon & Massey is straightforward in the 
sense that it provides an estimate of µ based on a mean dose, and leads to a 
simple sample size calculation. However, many of the steps taken to reach 
parameter estimates and their standard errors are not transparent, and the 
estimates of standard errors involve multiplication by factors (G and H) that are 
not well defined. Furthermore, the standard error estimate for quartiles other 
than the EC50 does not take account of the correlation between estimates for µ 
and σ. 
 
Justification of interim analysis of part A 
The number of patients needed is affected by two variables: 
 
1- A suitable starting value for x0 
2- A value for the dose change between experiments (δ) which should 
ideally be in the region of σ-1.5σ.  
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Recommendations: 
 
The formula 24N ∆=  should be used as an initial estimate of the required 
sample size for a study. 
 
The appropriateness of the value used for δ should be modified throughout the 
study based on the accrued evidence, and modified if necessary. 
 
 
Statistical justification of sample size of part B 
Part B of the proposal seeks to estimate the mean duration of analgesia. Based 
on an assumption that the standard deviation of this outcome is 4 hours, then to 
estimate the mean duration of analgesia with a 95% confidence interval of ±2 
hours will require a sample size of approximately 16 patients with successful 
blocks, assuming an approximately Normal distribution. Assuming a mean 
duration of analgesia of approximately 12 hours, an estimate of ±2 hours will be 
adequately precise.  This sample size calculation depends on several factors 
which are impossible to estimate accurately prior to conducting the trial and the 
actual sample size needed may vary considerably from the current estimate of 
16 patients.  The estimated range of the population required will be 5-30 
patients using the information from the clinical trial data of the patients that 
have been recruited.’ 
 
3.9  Pharmacy 
Study medication 
The investigational medicinal product in this study is levobupivacaine.  All doses 
of levobupivacaine will be prepared, using levobupivacaine that is commercially 
available within the United Kingdom, by the Pharmacy Production Unit (PPU) at 
the Western Infirmary, Glasgow.  Each 30ml dose will be prepared aseptically in 
a 50ml capped syringe as a batch (n=1) using 0.9% sodium chloride as a diluent 
and will be subject to a QP batch release.  Prepared study supplies of levobupivacaine with a 
protective sleeve will be stored in a secure location in a temperature monitored refrigerator at 2-8°C and deviations of >2°C 
for greater than 50 minutes will be reported.  The expiry date from preparation will be a 
maximum of 28 days.   
• Supplies of levobupivacaine will be labelled with the following 
information as a minimum: 
• Information on sponsor and chief investigator  
• Drug, formulation, strength and quantity 
• Route of administration 
• Statement ‘for clinical trial use only’ 
• Storage and administration instructions 
• Batch number 
• Expiry date 
Part A:  
The initial concentration of levobupivacaine will be 0.20%. The levobupivacaine 
concentration will then be increased by the stepping value which will initially be 
Appendix 13 
Page 276 of 287 
 
0.025% after an unsuccessful femoral 3-in-1 nerve block and decreased by the 
stepping value which will initially be set at 0.025% following a successful femoral 
3-in-1 nerve block as outlined in section 2.8 above.  The maximum and minimum 
concentration of levobupivacaine to be used in the study will be 0.375% and 
0.005% respectively. The total volume of all levobupivacaine (IMP) doses will be 
30ml.   
 
Part B:  
PPU will prepare a fixed concentration of 30ml levobupivacaine for use in 
patients recruited to part B based on the outcome of part A.  The chief 
investigator will be responsible for informing sponsor and PPU in writing of the 
calculated EC95 dose prior to the dosing of any patients under part B.   
 
Storage and supply will be under the control of PPU.  Study drug will only be 
supplied from pharmacy once all the appropriate regulatory and governance 
approvals are in place.  Only those supplies intended for use in the study can be 
administered to study participants.   
 
A record of all study drug movements will be maintained for accountability 
purposes.  Drug accountability records for all used and unused supplies will 
include: 
o An inventory at the site 
o Use by each patient 
o Return and disposal 
The records should include dates, quantities, batch numbers and expiry dates.  
The study specific IMP destruction form must be completed prior to the 
destruction of any excess, expired or patient returns of study medication.  The 
inventories must be made available for inspection by the study sponsor or their 
designee and the regulatory authorities. All concomitant medications prior to 
and during the study period will be collected.   
 
4.0  Study site staff and responsibilities log 
See associated document ‘study site staff and responsibilities log’ version-1 
dated 20/04/12 
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5.0  Adverse events-Pharmacovigilance 
Definitions 
 
Adverse Event (AE)  
Any untoward medical occurrence in a subject to whom a medicinal product has 
been administered, including occurrences which are not necessarily caused by or 
related to that product.  
 
Adverse Reaction (AR)  
Any untoward and unintended response in a subject to an investigational 
medicinal product which is related to any dose administered to that subject.  
 
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) 
 
Any adverse event or adverse reaction that  
 a. results in death  
 b. is life threatening  
 c. requires hospitalisation or prolongation of existing hospitalisation  
 d. results in persistent or significant disability or incapacity  
 e. consists of a congenital anomaly or birth defect.  
f. is otherwise considered medically significant by the investigator  
Suspected Serious Adverse Reaction (SSAR)  
Any adverse reaction that is classed in nature as serious and which is consistent 
with the information about the medicinal product in question set out in the 
summary of product characteristics (SmPC) or the Investigator’s Brochure (IB) 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR)  
Any adverse reaction that is classed in nature as serious and which is not 
consistent with the information about the medicinal product in question set out 
in the summary of product characteristics (SmPC) or the Investigator’s Brochure 
(IB) 
 
Detection, Recording, and Reporting of Adverse Events 
 
5.1   Expected SAES     
 The adverse events expected during the study are those commonly 
associated with hip hemi-arthroplasty and hip fixation using dynamic hip screw, 
spinal anaesthesia, general anaesthesia, sedation and anterior psoas 
compartment nerve block.  
5.2  Femoral 3-in-1 nerve block 
Those associated with femoral nerve block include failure, either to develop a 
satisfactory block for the surgery to commence or for the duration of the block 
to be greater than 2 days. 
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5.3  Spinal anaesthesia 
Spinal anaesthesia may be very rarely associated with spinal cord damage; 
haematomas or abscesses around the site of nerve block; hypotension after 
onset of the block; adverse drug reactions including allergy, rash, headache.  
5.4  Surgical fixation of fractured neck of femur 
Adverse events commonly associated with surgical fixation of a proximal femoral 
fracture include: death, dislocation of hip, peri-prosthetic fracture, readmission 
to hospital, haemorrhage, deep venous thrombosis and pulmonary embolism; 
wound infection and wound haematoma, cardiac failure, cardiac arrhythmias, 
sepsis, respiratory failure, paralytic ileus of the gut, bleeding or perforated 
gastric or duodenal ulceration.  The patients often develop an acute confessional 
state or suffer the exacerbation of a chronic confessional state during there 
admission to hospital.  Patients also commonly require long term care or an 
increased level of input from nursing and social services after a hip fracture. 
5.5  Non surgical management of fractured neck of femur 
Adverse events commonly associated with non surgical management of a 
proximal femoral fracture include: death, pressure sores, readmission to 
hospital, haemorrhage, deep venous thrombosis, pulmonary embolism, cardiac 
failure, cardiac arrhythmias, myocardial ischaemia or infarction, sepsis, 
respiratory failure or infection, paralytic ileus of the gut or constipation, 
bleeding or perforated gastric or duodenal ulceration and cerebrovascular 
accident (intracranial haemorrhage or ischaemia).  The patients often develop 
an acute confessional state or suffer the exacerbation of a chronic confessional 
state during their admission to hospital.  Patients also commonly require long 
term care or an increased level of input from nursing and social services after a 
hip fracture and due to the high incidence of osteoporosis they often fracture 
other bones. 
5.6  Sedation and general anaesthesia 
Adverse events associated with sedation and general anaesthesia include post 
operative nausea and vomiting, post operative respiratory depression, 
respiratory infection, hypotension, aspiration and sedation. 
5.7  Recording, Assessment and Reporting of SAEs 
Part A 
Adverse events occurring after discharge from theatre recovery will only be 
reported and recorded if they are causally related to the anterior psoas 
compartment nerve block. 
Part B 
Adverse events occurring after the final pain scores are recorded (up to 24 hours 
later) will only be reported and recorded if they are causally related to the 
anterior psoas compartment nerve block. 
 
Full details of  all adverse events (including the nature of the event, start and 
stop dates, severity, relationship to study drug and outcome ) will  be recorded 
in the patient case notes and the study case report forms, signed and dated and 
Dr. Malcolm J. Watson will be informed  
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AEs will be monitored and followed up until satisfactory resolution or 
stabilisation.  
 
Serious Adverse Events other than those listed in Section 6.1 above must be 
reported to the sponsor as detailed below. 
 
NB: Any AE that is assessed as serious, is suspected of having a causal 
relationship to the trial medication and is unexpected is a SUSAR and will 
require expedited reporting to the MHRA/ Ethics Committee. 
 
5.8  Assessment of adverse events 
All adverse events must be assessed for seriousness, causality, expectedness and 
severity. This assessment is the responsibility of the Chief Investigator  
 
Assessment of Seriousness  
 
An adverse event is serious if it:  
a. results in death  
b. is life threatening  
c. requires hospitalisation or prolongation of existing hospitalisation  
d. results in persistent or significant disability or incapacity, or 
e. consists of a congenital anomaly or birth defect. 
f. is otherwise considered medically significant by the investigator  
 
Assessment of causality i.e. does it have a “reasonable causal relationship” 
with trial medication?  
Assessment for expectedness. (i.e. is the reaction a recognised adverse effect 
of the medication or is it unexpected?)  
 Expected: consistent with the toxicity of the (Investigational Medicinal Product 
(IMP) listed in the Summary of Product Characteristics (SmPC) or Investigator’s 
Brochure (IB) 
Unexpected: not consistent with the toxicity of the IMP listed in the SmPC or IB 
 
Assessment of severity  
This should be assessed and described using the following categories: 
Mild-awareness of event but easily tolerated 
Moderate-discomfort enough to cause some interference with usual activity 
Severe-inability to carry out usual activity 
 
5.9 Reporting of serious adverse events 
Once the Chief Investigator Dr Malcolm J Watson becomes aware that a SAE ( not 
listed in 5.1 above ) has occurred in a trial participant he is required to inform 
the sponsor (via the Glasgow Clinical Trials Unit Pharmacovigilance office) 
immediately (24-48 hours),  
 
For all such SAEs, a Serious Adverse Event form should be completed and 
forwarded to the GCTU Pharmacovigilance Office following the procedure 
detailed on the GCTU website http://glasgowctu.org/for-investigators.aspx  
 
All SUSARS must be reported in an expedited fashion to the MHRA and Ethics 
Committee as follows:  
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Fatal or life threatening SUSARs: not later than 7 days after the CI had 
information that the case fulfilled the criteria for a fatal or life threatening 
SUSAR, and any follow up information within a further 8 days.  
All other SUSARs: not later than 15 days after the CI had information that the 
case fulfilled the criteria for a SUSAR. 
5.10 Annual Safety Report 
An Annual Safety Report is required to be submitted to MHRA and REC on the 
anniversary of the issue of the Clinical Trials Authorisation. The Chief 
Investigator will submit this report on behalf of the sponsor as per GCTU SOP 
18.003. 
 
6.0  Data handling and record keeping 
All electronic data will be stored on hospital computers and any other electronic 
copies will have any identifiable patient details removed.  Unidentifiable patient 
data may be stored on NHS, university computer, web sites and personal 
computers with built in redundancy or back up procedures to prevent data loss 
and all such data will be password protected and encrypted.  The paper records 
containing the personal identifiable data of the patients and their unique 
sequential identifier will be stored on paper for 1 year after completion of the 
trial in a locked metal filing cabinet in the Ultrasound research office, F-block, 
Lower Ground Floor, Western Infirmary General, 38 Church Street, Glasgow, G11 
6NT.  Only the chief investigator will have access to this data. 
 
7.0  Indemnity and insurance  
 
This study is sponsored by NHS Greater Glasgow and Clyde Health Board and all 
the researchers named in this protocol are full time NHS employees therefore 
patients’ recruited to this clinical trial will be covered for negligent harm 
through the NHS CNORIS indemnity scheme. 
  
8.0  Definition of the start and end of the trial 
The trial will be terminated when the last patient is recruited and treated in the 
study. 
 
9.0  Publication Plan      
The data from this study will be published in peer review journals (i.e. British 
Journal of Anaesthesia, Anaesthesia or Regional Anaesthesia and Pain Medicine).  
Prior to publication it will be presented in poster and abstract form at the 
annual ESRA meeting. 
             
10.0  Data Monitoring 
10.1  Data monitoring committee 
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The data monitoring committee will comprise of Dr Michael Serpell and Dr Alex 
McConnachie of the Robertson centre, Glasgow University. They will meet every 
3 months to review the data gathered by the trial and adverse events recorded. 
11.0  Archiving of data 
Data will be archived in accordance with the NHS Greater Glasgow and Clyde 
Health Board policies 5 years after the end of the study. 
12.0  Updates to protocol or changes to paper work 
We will seek approval from the ‘The West Glasgow (1) Research Ethics 
Committee’, the MHRA and Research and Development at NHSGGC before any 
changes are made to the protocol, procedures, personnel or paperwork 
associated with this trial.   
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Appendix 1: Flowchart for Assessing and Reporting Adverse Events in 
IMPs 
 
Is event serious? 
 
No Yes 
This is an 
Adverse 
Event. (AE) 
Record in CRF 
and report as 
per protocol. 
 This is a 
Serious 
Adverse 
Event (SAE) 
Does the SAE have 
a “reasonable 
causal 
relationship” with 
Yes 
Record the SAE in 
CRF. 
Assess for severity. 
Complete SAE 
form. 
Report to 
CI/Sponsor within 
24 hours. 
 
This is a Serious 
Adverse Reaction 
(SAR) 
Record the SAE in 
CRF. 
Assess for severity. 
Complete SAE form. 
Report to 
CI/Sponsor within 
24 hours. 
(Will be reported in 
Is the event 
expected? 
(i.e. is it 
included in 
Yes 
No 
This is a  
Suspected 
Unexpected 
Serious 
Adverse 
Reaction 
(SUSAR) 
 
Record in CRF 
Assess for severity 
Complete 
SAE/SUSAR form. 
Report to 
CI/Sponsor within 
24 hrs. 
Is the SUSAR life 
threatening or 
fatal? 
Yes No 
To be reported to 
MHRA/REC within 
7 days with follow- 
up within 8 days 
 
To be reported to 
MHRA/REC within 
15days 
 
No 
Adverse Event reported to Trial Staff 
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Appendix 2: Flow chart summary of study 
 
-Part A- 
The first approximately 32 (35-50) patients to 
be recruited to study 
Time Patient pathway 
-12 to -9 hours Patient falls and fractures hip at home 
-9 to -8 hours Transferred to Accident and Emergency via 
ambulance 
-8 to-5 hours Admitted to Orthopaedic ward 
-5 to -4 hours Investigator called by ward medical or 
nursing staff 
-4 to -2 hours Attend ward to give verbal and written 
information about study 
-2 to -1 hours Written consent taken  
-1 hours Patient transferred to theatre suite 
continuous cardiorespiratory monitoring 
started 
-2minutes Baseline resting pain scores and sensory 
scores (25G needle and melting ice) 
0 hours Ultrasound guided femoral 3-in-1 block and 
catheter inserted by Malcolm Watson 
+10minutes 10 minutes resting pain scores and sensory 
scores (25G needle and melting ice) 
+20minutes 20 minutes resting pain scores and sensory 
scores (25G needle and melting ice) 
+30minutes 30 minutes resting pain scores and sensory 
scores (25G needle and melting ice) 
+35minutes If resting pain VAS >30/100, Patient given 
rescue analgesia , 20mls of 0.25% 
levobupivacaine via femoral nerve catheter 
+1 to +24 hours Returned to ward for standard cardio 
respiratory monitoring and hourly VAS pain 
scores 
+24hours Patient has induction of Anaesthesia 
(general or regional) and surgical fixation of 
hip or returned to ward for non surgical 
management of proximal femoral fracture 
 
 
After approximately 32 (35-50) patients have 
been recruited with effective femoral 3-in-1 
nerve blocks the levobupivacaine EC50 and 
EC95 will be estimated  
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-Part B- 
The next approximately 16 (5-30) patients 
with effective nerve blocks with the 
levobupivacaine EC95 will be recruited to part 
B 
Time Patient pathway 
-12 to -9 hours Patient falls and fractures hip at home 
-9 to -8 hours Transferred to Accident and Emergency via 
ambulance 
-8 to-5 hours Admitted to Orthopaedic ward 
-5 to -4 hours Investigator called by ward medical or nursing 
staff 
-4 to -2 hours Attend ward to give verbal and written 
information about study 
-2 to -1 hours Written consent taken on morning of scheduled 
hip fixation surgery 
-1 hours Patient transferred to theatre suite continuous 
cardiorespiratory monitoring started 
-2minutes Baseline resting pain scores and sensory scores 
(25G needle and melting ice).  Blood sample 
taken for levobupivacaine concentration 
0 hours Ultrasound guided femoral 3-in-1 block and 
catheter inserted by Investigator 
+10minutes 10 minutes resting pain scores and sensory 
scores (25G needle and melting ice).   
Blood sample taken for levobupivacaine 
concentration 
+20minutes 20 minutes resting pain scores and sensory 
scores (25G needle and melting ice).   
Blood sample taken for levobupivacaine 
concentration 
+30minutes 30 minutes resting pain scores and sensory 
scores (25G needle and melting ice).   
Blood sample taken for levobupivacaine 
concentration 
+35minutes If resting pain VAS >30/100, Patient given 
rescue analgesia , 20mls of 0.25% 
levobupivacaine via femoral nerve catheter 
+1 to +24 hours Returned to ward for standard cardio 
respiratory monitoring and hourly resting pain 
VAS  
+24hours Patient has induction of anaesthesia (general or 
regional) and surgical fixation of hip or returned 
to ward for non surgical management of 
proximal femoral fracture 
 
